Journals
Call For Papers: Join Our Article Collections
Article Collections present an excellent opportunity for your research to reach a wider audience. By consolidating the work of researchers from around the world, Collections serve as a centralized hub for the latest research on emerging and important topics. They enhance article discoverability and visibility and can boost article-level citations. All manuscripts undergo rigorous peer review, and if accepted, they benefit from rapid online publication, enabling quick sharing of your work.
- AI-driven Personalized Learning: Exploring how AI can tailor educational content to individual student needs, improving engagement and retention.
- Simulation and Virtual Reality: The role of AI in creating realistic, immersive environments for clinical training and skill development.
- AI in Assessment and Feedback: How AI can enhance formative and summative assessments, provide real-time feedback, and assist with competency tracking.
- Ethical and Practical Challenges: Examining issues such as data privacy, algorithmic bias, and the implications of AI on teaching roles.
- Future Trends and Innovations: Investigating upcoming AI technologies and their potential applications in evolving medical education paradigms.
- Assessment of knowledge, skills, and competencies in medicine and health sciences
- Quantitative and qualitative research on student and professional education in medical and health sciences
- The use and impact of educational technology and innovations on learning outcomes
- Applications of health sciences education in undergraduate, postgraduate, and continuing education, as well as clinical training
- The role of learning and working environments and institutional culture: investigating how curriculum design, assessment practices, student-teacher relationships, institutional or organizational culture and study or working conditions influence mental wellbeing.
- Help-seeking and barriers to support: examining barriers to seeking help and identifying strategies to overcome these barriers.
- Interventions to help students and trainees thrive: focusing on ways to build psychological resilience, self-care practices, self-compassion, peer support programs and other initiatives that can help foster long-term wellbeing.
- Mental health, attrition and workforce: addressing the impact of mental health issues on academic performance and drop-out as well as on building a sustainable workforce.
- Mental health and quality of care: examining the impact of mental health on patient safety and quality of care.
Advances in Medical Education and Practice
Artificial Intelligence (AI) in Medical Education
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Artificial Intelligence (AI) in Medical Education" in Advances in Medical Education and Practice.
Artificial Intelligence (AI) is rapidly transforming healthcare and educational systems worldwide. Within the domain of medical education, AI has emerged as a powerful tool with the potential to enhance learning, teaching, and assessment. The integration of AI technologies, such as machine learning, natural language processing, and intelligent tutoring systems, promises to reshape how medical students, clinicians, and educators interact with educational content and teaching strategies. AI has already shown promise in areas like personalized learning, simulation-based training, predictive analytics for performance evaluation, and administrative automation. As the future of medical practice becomes increasingly tech-driven, it is critical to explore how AI can both augment and redefine the landscape of medical education.
AI's integration into medical education is a timely and vital development. The global healthcare system is experiencing an urgent need for more skilled professionals, with a growing demand for more efficient, scalable, and personalized learning methods. AI offers an unprecedented opportunity to address these needs by facilitating adaptive learning environments that respond to individual learners' strengths and weaknesses. Furthermore, AI can help overcome challenges such as faculty shortages and time constraints, making high-quality medical education more accessible across diverse geographic regions. Additionally, AI can support more objective assessments, enhance the accuracy of feedback, and help educators make data-driven decisions that improve student outcomes. As AI continues to evolve, its potential to enrich medical education and improve healthcare delivery grows, making this an essential area of exploration for academic scholarship.
This Article Collection will focus on the application and potential of AI in medical education, with a particular emphasis on both theoretical and practical aspects. Subtopics include, but are not limited to:
All manuscripts submitted to this Article Collection will undergo full peer-review; Guest Advisors will not be handling submitted articles. Please review the journal’s aims and scope and author instructions prior to submission.
Please submit your manuscript through the Dovepress website. During submission, enter the promo code FEHJU for a 10% discount on the Article Processing Charge and to indicate that your article should be considered for this Collection.
The manuscript submission deadline is 31 October 2025.
Guest advisors
Dr. Rasha A. Alamoush, The University of Jordan
Dr. Rasha A. Alamoush is an Associate Professor in the Department of Fixed and Removable Prosthodontics at the University of Jordan. She holds a Doctor of Dental Surgery (DDS) and a Master of Science (MSc), along with a Clinical PhD in Fixed and Removable prosthodontics. Her research focuses on fixed and removable prosthodontics, dental materials, CAD/CAM technology, and implantology, with numerous publications in reputable journals. Dr. Alamoush is also a consultant in her field, dedicated to improving patient care and advancing dental education and science.
Dr. Haider Julfikar, Manchester Metropolitan University
Dr. Julfikar Haider is a Senior Lecturer in Mechanical Engineering at Manchester Metropolitan University, specializing in surface engineering and advanced materials processing. He holds a PhD from Dublin City University and has published extensively, contributing to over 100 peer-reviewed journal articles. His research interests include composite materials, tribology, and applications of artificial intelligence in manufacturing systems.
Dr. Basima Ahmad Elshqeirat, The University of Jordan
Dr. Marwa M. Alnsour, The University of Jordan
Future in Health Professions Education: Innovative Teaching Alternatives
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Future in Health Professions Education: Innovative Teaching Alternatives" in Advances in Medical Education and Practice.
The adoption of updated and innovative teaching methodologies, such as problem-based learning, 3D virtual simulations, augmented reality, and gamification, is increasingly recognized as essential for meeting the educational needs of today's students. These tools enable a pedagogical approach that supports the development of critical competencies - basic, transversal, and specific - required for the future careers of health professionals. In medicine and health sciences, the acquisition of these competencies spans knowledge, skills, values, and attitudes. These elements must be integrated and applied at various stages of medical education and practice to prepare students for the evolving demands of the healthcare field.
As higher education faces a rapidly changing world and a new generation of students with diverse learning preferences, health professions education must embrace innovative and adaptive approaches. The training of future healthcare professionals must move beyond traditional lecture-based methods, which, while valuable, may not fully equip students with the practical skills, critical thinking, and interpersonal competencies necessary for high-quality care. Novel pedagogical approaches, including gamification, game-based learning, simulations, and virtual reality, offer opportunities to foster active, collaborative learning environments that focus on comprehensive competency development.
This Article Collection aims to explore innovative teaching strategies in health professions education. Topics of interest include, but are not limited to:
All manuscripts submitted to this Article Collection will undergo full peer-review; Guest Advisors will not be handling submitted articles. Please review the journal’s aims and scope and author instructions prior to submission.
Please submit your manuscript through the Dovepress website. During submission, enter the promo code SMSJM for a 10% discount on the Article Processing Charge and to indicate that your article should be considered for this Collection.
The manuscript submission deadline is 31 October 2025.
Guest advisors
Dr. Ana Isabel Cisneros-Gimeno, University of Zaragoza
Professor of Human Anatomy and Embryology at the Faculty of Medicine of Zaragoza, teaching since 1996.
Researcher in several consolidated and multidisciplinary groups of university teaching innovation.
President of the Technical Committee for Teaching Assessment and member of the Quality Assurance Committee for the Degree in Medicine. Mentor of students and scholarship holders.
Dr. Alberto Garcia-Barrios, University of Zaragoza
Professor of Human Anatomy and Embryology at the Faculty of Medicine of Zaragoza, teaching since 2016.
Lead researcher in the consolidated group of university teaching innovation (INNO_MED).
Mentor of students and scholarship holders.
Innovations and Impact: The Role of Ultrasound in Undergraduate Medical Education
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Innovations and Impact: The Role of Ultrasound in Undergraduate Medical Education" in Advances in Medical Education and Practice.
Point-of-care ultrasound (POCUS) is transforming clinical practice across numerous medical specialties, and its integration into undergraduate medical education has gained increasing attention in recent years. Ultrasound offers a dynamic, visual, and interactive modality for teaching anatomy, physiology, clinical reasoning, and procedural skills. Medical schools worldwide are recognizing its pedagogical value and are piloting curricular innovations that bring ultrasound training to students early in their careers. This Article Collection aims to highlight current advances, practical implementations, and educational outcomes related to ultrasound-based teaching in undergraduate medical training.
Early exposure to ultrasound not only enhances the learning of foundational sciences but also supports competency-based education by fostering clinical decision-making, spatial reasoning, and diagnostic acumen. As educational institutions respond to technological advances and evolving healthcare demands, equipping students with ultrasound skills has become both feasible and essential. Moreover, the inclusion of ultrasound aligns with modern strategies for active, student-centered learning. Despite growing enthusiasm, challenges remain - including curricular integration, faculty training, resource availability, and assessment. Sharing successful strategies and rigorous evaluations is critical to advancing the field.
This Collection invites original research, systematic reviews, short reports, commentaries, and case studies that explore ultrasound in the context of undergraduate medical education. Potential subtopics include curriculum development, faculty development, interprofessional education, assessment strategies, student outcomes, and the role of simulation. Submissions may also address institutional frameworks, technology adoption, and longitudinal program evaluations. We especially welcome articles that demonstrate measurable educational impact, novel pedagogical models, or interdisciplinary collaboration. All contributions should be aligned with the journal’s mission to advance research and best practices in medical education.
All manuscripts submitted to this Article Collection will undergo full peer-review; Guest Advisors will not be handling submitted articles. Please review the journal’s aims and scope and author instructions prior to submission.
Please submit your manuscript through the Dovepress website. During submission, enter the promo code D7645 to indicate that your article should be considered for this Collection.
The manuscript submission deadline is 31 March 2026.
Guest advisor
Dr. Florian Recker, University Hospital Bonn
Dr. Florian Recker is a physician-scientist and medical educator based at the University Hospital Bonn, Germany. A specialist in obstetrics and prenatal medicine, he combines clinical expertise with a strong academic focus on medical education and ultrasound-based teaching. He holds a PhD, a Master of Medical Education from the University of Heidelberg, and completed his habilitation in the field of ultrasound education in obstetrics and gynecology.
Dr. Recker has received multiple national awards for excellence in university teaching and educational innovation, including the prestigious Ars Legendi Prize (2024) and multiple recognitions from the German Society for Medical Education (GMA). He is an active reviewer and editorial board member for several high-impact journals.
Internationally engaged in professional organizations such as DEGUM, ISUOG, and SUSME, he is committed to advancing clinical skills training and interprofessional learning. Dr. Recker also has played key roles in national and European committees on medical education and ultrasound.
Dr. Johannes Matthias Weimer, Gutenberg University Mainz
Dr. med. Johannes Weimer is a physician and medical educator at the University Medical Center Mainz. As coordinator of the student ultrasound training program, he oversees the development and implementation of innovative teaching approaches, including peer-assisted learning and simulator-based instruction. His academic work centers on advancing ultrasound education and improving sonographic ergonomics, with a particular emphasis on embedding ultrasound training into medical curricula. Beyond his educational responsibilities, Dr. Weimer is actively involved in the clinical application of sonography, with a strong focus on the integration of cutting-edge ultrasound technologies into routine patient care. He is a member of DEGUM, EFSUMB, GMA and the Editorial Board of BMC Medical Education.
Thriving in Training: Mental Health and Wellbeing of Health Professional Students and Trainees
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Thriving in Training: Mental Health and Wellbeing of Health Professional Students and Trainees" in Advances in Medical Education and Practice.
The mental health of medical students and postgraduate trainees is a growing area of concern and opportunity. As future healthcare providers, they are often exposed to intense academic demands, long working hours, severe competition, and high emotional stress - all of which can impact their wellbeing and mental health. In light of current workforce shortages and growing demands on healthcare systems, it is more important than ever to prepare medical students and trainees to become adaptable doctors who can sustain their wellbeing throughout their careers. By fostering supportive learning and working climates, institutions can help future doctors thrive in the face of professional challenges - ensuring they are not only clinically competent, but also mentally prepared for the realities of modern medical practice. These environment plays a crucial role in promoting mental wellbeing and reducing stigma around seeking help, empowering students and trainees to manage their mental health proactively.
Research into the mental health of medical students and postgraduate trainees is essential for understanding the unique challenges they face and developing effective strategies to support their wellbeing. Mental health issues can significantly impact students’ personal lives, leading to emotional distress, impaired relationships, and reduced academic performance. Left unaddressed, these challenges can also compromise clinical judgment, empathy, and communication skills - ultimately threatening the quality and safety of patient care. Furthermore, mental health issues can cause students and trainees to drop-out of their education and training, jeopardizing our already understaffed healthcare workforce even further. Institutions must therefore prioritize creating supportive learning environments alongside the design and implementation of evidence-based interventions that promote wellbeing, reduce stigma, encourage help-seeking, minimize attrition, and ultimately foster a healthier, more effective medical workforce capable of meeting growing healthcare demands.
This Article Collection will focus on understanding and improving medical students’ and trainees’ mental health. Theoretical as well as practical contributions are welcomed. Subtopics include, but are not limited to:
All manuscripts submitted to this Article Collection will undergo full peer-review; Guest Advisors will not be handling submitted articles. Please review the journal’s aims and scope and author instructions prior to submission.
Please submit your manuscript through the Dovepress website. During submission, enter the promo code DAD72 to indicate that your article should be considered for this Collection.
Please contact Sam Zhang at [email protected] with any queries and discount codes regarding this Article Collection.
The manuscript submission deadline is 31 May 2026.
Guest advisors
Dr. Milou Silkens, Erasmus University
Dr. Milou Silkens is an Assistant Professor in the Erasmus School of Health Policy & Management at the Erasmus University in the Netherlands. She holds a Master of Science (MSc) in Health Sciences and a PhD in Medical Education. Her work centres on workforce issues in healthcare, with a strong focus on the impact of digital transformation and how technological innovations can support healthcare delivery and improve doctors’ working conditions. She also examines the mental health of healthcare professionals and medical students, aiming to better understand how to achieve a resilient and future-ready workforce.
Dr. Asta Medisauskaite, University College London
Dr. Asta Medisauskaite is a Principal Research Fellow at UCL Medical School. She obtained her PhD in Organizational Psychology from Birkbeck, University of London, on understanding and improving the occupational health of medical doctors. Her research continues to explore the mental health and wellbeing of both medical students and doctors. She is particularly interested in how psychological and organizational factors shape their experiences, from training through to long-term career development. Through her work, she aims to create a healthier and more sustainable medical careers, through better understanding mental health and attrition in the healthcare workforce.
Dr. Renée Scheepers, Erasmus University
Dr. Renée Scheepers is an Assistant Professor in Health Workforce Well-being at the Erasmus School of Health Policy & Management. She is an occupational health psychologist focusing on clarifying and improving well-being of healthcare professionals (and medical) students. Specifically, she performs research on the effects of working conditions and healthcare provider well-being on patient care quality.
Transformative Learning: The Next Step in Medical Education
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Transformative Learning: The Next Step in Medical Education" in Advances in Medical Education and Practice.
Medical education finds itself at a crossroads. As healthcare systems grow increasingly complex, facing pressures from demographic shifts, rising costs, and enduring and increasing health disparities, educators are called to prepare future professionals not only to function within these systems, but to transform them. Traditional pedagogical models often fall short in equipping learners with the mindset, competencies, adaptability, and critical consciousness needed for a role as change agent. Transformative learning theory offers a compelling response. Rooted in fostering deep, structural shifts in perspective, this educational approach enables learners to question assumptions, engage in critical reflection, and develop the capacity to act ethically and innovatively in the face of uncertainty. As medical education seeks to remain relevant and future-oriented, the integration of transformative learning becomes increasingly vital.
Embracing transformative learning in medical education is not merely theoretical: it is a practical necessity. Healthcare professionals must be prepared to navigate moral complexity, collaborate across and beyond academic disciplines, and confront the hidden curriculum that shapes professional identity. Transformative learning encourages these capabilities by supporting learners in making meaning from experience, developing agency, and challenging existing power structures. When integrated into medical education, it fosters a culture of continuous learning, critical inquiry, and social responsibility. Such a shift can enhance professional resilience, promote equity in care, and ultimately contribute to the sustainability of healthcare systems. In doing so, transformative learning has the potential to empower healthcare workers not just to adapt to change, but to lead it.
This Article Collection invites contributions that explore the integration, theory, and practice of transformative learning in medical education. We welcome a range of article types, including empirical research (both qualitative and quantitative), conceptual papers, case studies, curriculum innovation reports, and commentaries. Submissions may address topics such as the design of transformative learning environments, critical reflection practices on transformative learning theory, inter- and trans-disciplinary education, the role of the hidden curriculum, embodied learning, and the development of change agency and change makers among learners. Contributions should align with the journal’s focus on advancing health professions education through scholarship and innovation. By gathering diverse perspectives and experiences, this collection aims to shape a new narrative in health professions education, one that places transformation at its core.
All manuscripts submitted to this Article Collection will undergo full peer-review; Guest Advisors will not be handling submitted articles. Please review the journal’s aims and scope and author instructions prior to submission.
Please submit your manuscript through the Dovepress website. During submission, enter the promo code F1E5A to indicate that your article should be considered for this Collection. The manuscript submission deadline is 31 July 2026.
Please contact Sam Zhang at [email protected] with any queries regarding this Article Collection.
Guest advisors
Dr. Efraim Hart, OLVG / VU University, Amsterdam, Netherlands
Dr. Efraim Hart is a medical doctor, a PhD-candidate, and education consultant from the Netherlands. His research is focused on health activism and transformative learning.
Dr. Frederique Demeijer, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
Dr. Frederique Demeijer is an assistant professor at the Athena Institute of the Vrije Universiteit Amsterdam. Her research and education are centred around complex societal issues, which she aims to address by working together with diverse groups in a transdisciplinary setting. Her current research focuses on transformative learning, inter- and transdisciplinary education and research, competency development, and community engaged learning.
Prof. Dr. Fedde Scheele, University of Amsterdam & Vrije Universiteit, Amsterdam, Netherlands
Prof. Dr. Fedde Scheele is Dean of ACTA (Faculty of Dentistry, Amsterdam), Professor of Health Systems Innovation and Education at VU University Amsterdam, and Chair of European Foundation for Women’s Health. His research focuses on designing socially relevant, future-oriented healthcare education, and his goal is to deliver respectful healthcare in an open culture where education, research, and societal responsibility flourish.
- Clinical studies into the use of biosimilars, biobetters and bioparallels.
- Bioequivalence studies.
- Pharmacoeconomic analyses
- Research relating to the regulation, pricing, re-imbursement and market uptake of biosimilars, biobetters and bioparallels.
- Biosimilar drug development
- Rare disease drug development
- Hybrid adaptive trial design
- Real-world data (RWD) and real-world-world evidence (RWE) or alternative and confirmatory data/evidence (ACD/ACE)
- Novel design and analysis for cancer research
- Model-informed drug development (MIDD)
- AI technology for biomarker development of imaging data
- Benefit- risk assessment
Biologics: Targets and Therapy
Biosimilars, Biobetters, and Bioparallels
Dove Medical Press is pleased to invite you to the upcoming Article Collection “Biosimilars, Biobetters, and Bioparallels” led by Professor Ivo Abraham, Ms. Ansam Beddor, Dr. Nimer Alkhatib, and Dr. Karen MacDonald in Biologics: Targets and Therapy.
Looking back on almost three decades of biosimilars and despite their difficult start in Europe in 2015, biosimilars are solidly embedded in patient care and have become a mainstay in human therapeutics – at least in high income countries. Being equivalent in efficacy/effectiveness, safety and (mainly) priced lower than the originators they reference, biosimilars enable savings, expanded patient access, and greater patient equity.
Furthermore, two recent developments have broadened the “later-in-class” biologics space beyond biosimilars. In October 2023, the United States Food and Drug Administration (FDA) approved Zymfentra, a subcutaneous (SC) formulation of Inflectra, an intravenous (IV) biosimilar referencing infliximab (Remicade). Rather peculiar but this SC formulation is approved in other jurisdictions as a biosimilar – along with its IV formulation – but in the US as a biological. Zymfentra is increasingly being referred to as a biobetter, in this case of a biosimilar (Inflectra) of originator infliximab (Remicade). Additional biobetters are on the horizon – as novel agents of biosimilar candidates that failed the upper bound of the equivalence margin.
That same month, the FDA also approved toripalimab (Loqtorzi), the first Chinese PD-1 inhibitor based exclusively on Chinese clinical trials: not a biosimilar and neither a biobetter, but a bioparallel. It is a new biological molecule without the ambition of being an early-in-class innovator but instead a “later-in-class” entry, analogous (but not similar) in efficacy and safety, competing on price. There are more are on the horizon as well.
While there can be clear benefits for adopting biosimilars, biobetters and bioparallels, many issues remain to be addressed: regulatory pathways; clinical evidence in support of regulatory approval; interchangeability; pricing and competition; commoditization of biological therapy; and the need for global access, especially in low, lower-middle and higher-middle income countries – among many others.
To help address these issues, Biologics: Targets and Therapy invites authors to submit Original Research, Reviews, and Commentaries on relating to biosimilars, biobetters and bioparallels. Potential topics include but are not limited to:
Keywords
Biosimilars, Biobetters, Bioparallels
All manuscripts submitted to this Article Collection will undergo desk assessment and a full peer-review. Please review the journal scope and author submission instructions prior to submitting a manuscript.
The deadline for submitting manuscripts is 31st December 2025. Please note normal Article Processing Charges apply.
Please submit your manuscript on our website, quoting the promo code DJZNQ for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
Please contact Ashley Ambros at [email protected] with any queries and discount codes regarding this Article Collection.
Regulatory (FDA) Critical Clinical Initiative in Drug Research and Development
Dove Medical Press is pleased to invite you to the upcoming Article Collection “Regulatory (FDA) Critical Clinical Initiative in Drug Research and Development” in Biologics: Targets and Therapy.
In recent years, the United States (US) Food and Drug Administration (FDA) has kicked off a number of critical clinical initiatives to assist the sponsors in pharmaceutical research and development. These critical clinical initiatives include, but are not limited to, (i) biosimilar drug development, (ii) cancer research, (iii) adaptive trial design, (iv) real-world data (RWD) and real-world evidence (RWE), (v) model-informed drug development (MIDD), (vi) AI for mobile individualized medicine, (vii) rare disease drug development, (viii) biomarker development, (ix) precision and personalized medicine, and (x) benefit-risk assessment. The purpose of these critical clinical initiatives is not only to provide regulatory flexibilities in drug development, but also to improve, shorten or speed up the review and approval process of drug development.
In the past decade, it is aware that increasing spending of biomedical research does not reflect an increase of the success rate of pharmaceutical development. Woodcock (2004) performed a diagnosis and found out the following problems (i) a diminished margin for improvement that escalates the level of difficulty in proving drug benefits. (ii) genomics and other new science have not yet reached their full potential, (iii) easy targets are the focus as chronic diseases are harder to study, (iv) failure rates have not improved, (v) rapidly escalating costs and complexity decrease willingness/ability to bring many candidates forward into the clinic. To fix the problems, FDA kicked off these critical clinical initiatives to bridge the gap between the quick pace of new biomedical discoveries and the slower pace at which those discoveries are currently developed into therapies. These critical clinical initiatives are important to provide the sponsors the flexibility for identifying any signal, possible trend/pattern, and ideally optimal benefit regarding safety/efficacy of the test treatment under investigation. In addition, these critical initiatives can help in speeding up the development process in a more efficient way without undermining the scientific validity of the development.
Potential topics include but are not limited to:
All manuscripts submitted to this Article Collection will undergo desk assessment and a full peer-review. Please review the journal scope and author submission instructions prior to submitting a manuscript.
The deadline for submitting manuscripts is 31st December 2025. Please note normal Article Processing Charges apply.
Please submit your manuscript on our website, quoting the promo code WZJNO for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
Please contact Ashley Ambros at [email protected] with any queries and discount codes regarding this Article Collection.
Breast Cancer: Targets and Therapy
Antibody-Drug Conjugates for Breast Cancer Treatment
Breast Cancer: Targets and Therapy is pleased to announce an upcoming Article Collection dedicated to the transformative role of antibody-drug conjugates in the treatment of breast cancer.
Antibody-drug conjugates (ADCs) consist of monoclonal antibodies linked to cytotoxic drugs, allowing for selective delivery of the therapeutic agent directly to cancer cells and minimizing damage to healthy tissues. Advances in ADC research have led to numerous approvals for clinical use, with significant impact on breast cancer therapy, as ADCs can effectively reduce tumor size and improve progression-free survival. With the ongoing identification of novel targets and indications, ADCs are poised to become a leader in the era of targeted therapies for breast cancer.
We welcome submissions of original research articles, reviews, and perspectives that contribute to the understanding and advancement of these therapies, including mechanisms of action, clinical efficacy, optimal combinations and ordering, and understanding and overcoming resistance.
This Article Collection will be included in a wider Game Changer Series focused on breakthrough therapies across medicine. Papers published within the Game Changer series will benefit from additional promotional activities across Taylor & Francis and Dove Medical Press, increasing the discoverability and visibility of your research.
The deadline for submissions is 1 April 2026. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.
Please submit your manuscript on our website. Submitting authors are eligible for a 20% discount on the Article Publishing Charge. To apply this discount, enter the code NRLJP when prompted during submission.
Please contact Commissioning Editor Cassie Houtz at [email protected] with any questions.
Nanoparticles for Breast Cancer Treatment
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Nanoparticles for Breast Cancer Treatment" in Breast Cancer: Targets and Therapy.
Nanotechnology is a driver of innovation in many different fields, including in the field of breast cancer treatment. Nanoparticles have shown potential to be innovative pharmaceutical products for the treatment of breast cancer. Because of their small size and high surface area, nanoparticles possess unique properties such as the ability to penetrate biofilms and influence intracellular mechanisms. Even so, nanoparticles for breast cancer treatment face many challenges including offsite accumulation, sufficient dosing, and toxicity concerns.
Breast cancer continues to be a significant worldwide health concern. The recent development of targeted treatments has transformed breast cancer therapy, providing more precise and successful strategies by tailoring interventions to the distinct genetic and molecular attributes of individual tumors. The application of nanoparticles for breast cancer treatment is similarly poised to bring about further breakthroughs in breast cancer treatments.
This Collection aims to bring together articles relating to the application of nanotechnology and nanoparticles for breast cancer treatment. This includes applications such as nanoparticles as a drug delivery vehicles for other therapeutics, nanoparticles for radiation and other treatments, and nanoparticles as a therapeutic. Nanoparticles could be of any material with a size on the nanometer scale including polymer nanoparticles, lipid nanoparticles, protein nanoparticles, metal nanoparticles, silica nanoparticles, or quantum dots. We invite submissions of original research articles, basic and translational research, clinical studies, detailed reviews, and expert opinions and commentaries that align with the journal's focus. This Collection will function as a resource for researchers, physicians, and healthcare professionals, advancing the future for the development of nanoparticles and nanotechnology for more effective, tailored treatment solutions for breast cancer.
The deadline for submissions is 13 October 2025. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.
Please submit your manuscript on our website, quoting the promo code CSQWV for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
Guest Advisor
Kathleen McEnnis, New Jersey Institute of Technology, NJ, United States
- Optimization of already-approved IEC to improve outcomes and minimize toxicities
- Novel investigational cell therapy platforms and technologies in development
- Combination treatment with other agents like checkpoint inhibitors
- Expanding applications of IEC in solid tumors
- Strategies to modulate immunosuppressive tumor microenvironment,
- Expanding access to IEC through on site manufacturing,
- Methods to foster national and international collaborations to develop therapies for rare diseases
- Developing robust quality and regulatory infrastructures to ensure the safety of such promising therapies
Cancer Management and Research
CAR-T Cell Therapy for Cancer: Past, Present and Future of a Game-Changing Treatment
Cancer Management and Research is pleased to announce an upcoming Article Collection dedicated to the transformative role of CAR-T therapy in the management of cancer.
Since the 2017 US FDA approval of the use of anti-CD19 CAR-T cell therapy for use against B-cell malignancies, CAR-T therapy has demonstrated significant clinical benefits in treating hematologic malignancies, showing clinical efficacy and durability even in patients who have been refractory to other treatments. Research is underway to develop and evaluate CAR-based therapies for application in solid tumors.
Despite the remarkable impact of CAR-T therapies, challenges remain, including antigen escape, limited persistence, and overcoming the immunosuppressive microenvironment. Further, life-threatening toxicities, the high costs of manufacturing, and the need for a well-trained workforce currently limit the widespread use of CAR-T for cancer treatment.
Given the impact and continued importance of CAR-T cell therapies in cancer treatment, Cancer Management & Research welcomes submissions of original research articles, reviews, and perspectives on CAR-T, including basic science, translational research, clinical efficacy, and real-world implementation.
This Article Collection is part of a wider Game Changer Series focused on breakthrough therapies across medicine. Papers published within the Game Changer series will benefit from additional promotional activities across Taylor & Francis and Dove Medical Press, increasing the discoverability and visibility of your research.
The deadline for submitting manuscripts is 1 April 2026. Please review the journal’s Aims and Scope and author submission instructions prior to submitting a manuscript.
Please submit your manuscript on our website. Submitting authors are eligible for a 20% discount on the Article Publishing Charge. To apply this discount, enter the code TFRFH when prompted during submission.
Please contact Commissioning Editor Cassie Houtz at [email protected] with any questions.
Immune Effector Cells for Cancer Therapy – CAR-T and beyond
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Immune Effector Cells for Cancer Therapy – CAR-T and beyond" in Cancer Management and Research.
Cellular therapies for both malignant and non-malignant disease have substantially grown in the past decade. Genetically engineered immune effector cells (IEC) have provided hope for patients with primary refractory malignancies and have received multiple regulatory approvals in B-cell lymphomas, acute lymphoblastic leukemia, and myelomas. Now the investigational portfolio of such promising treatment has grown substantially to include other cellular types (natural killer cells, and tumor infiltrating lymphocytes) and other malignancies including solid tumors.
IEC were shown to be able to overcome resistance of malignant cells to treatment and have shown durable remissions in otherwise advanced malignancies with poor outcomes. The explosion of novel technologies beyond chimeric antigen receptor T-cells (CAR-T) to include T-cell receptor (TCR) engineered cells as well as other non-T cell therapy platforms like natural killer cells and tumor infiltrating lymphocytes expanded the application of such curative therapies beyond B-cell lymphomas and leukemias to other disease indications.
This Article Collection welcomes submissions on topics including but not limited to:
The deadline for submitting manuscripts is 30 October 2025. Please review the journal’s Aims and Scope and author submission instructions prior to submitting a manuscript.
Please submit your manuscript on our website, quoting the promo code VBJGE for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection. Please contact commissioning editor Cassie Houtz at [email protected] with any inquiries.
Guest Advisor
Basem M. William, MD, MRCP(UK), FACP
Professor Basem William is an internationally recognized expert in lymphoma, blood and marrow transplant, cellular therapy, and drug development. He is the inaugural Clinical Director of OhioHealth Blood and Marrow Transplant Program, Medical Director of Immune Effector Cell Program and Cell Therapy Laboratory, and John P. McConnell Endowed Chair for Cancer Research.
- Laryngology: age-related voice disorders (presbylarynx), dysphagia (presbyphagia), laryngeal neuromuscular degeneration, and innovations in diagnosis and voice therapy or surgical interventions for older adults
- Head and Neck Surgery: surgical outcomes, risk stratification, reconstructive techniques, and perioperative management in geriatric patients undergoing procedures for benign or malignant conditions
- Oncology: epidemiology, tumor biology, and treatment responses of head and neck cancers in older adults
- Otology and Neuro-otology: presbycusis, balance disorders (presbystasis), cochlear implantation in the elderly, age-related central auditory processing, and vestibular rehabilitation strategies
- Rhinology: chronic rhinosinusitis, olfactory dysfunction, age-associated mucosal changes, and surgical or medical management tailored to geriatric physiology
- Osteoporosis and sarcopenia – HRT’s impact on bone density, fall prevention, and frailty
- Cardiovascular and metabolic effects – HRT’s role in heart disease, diabetes, and inflammation
- Cognitive and neurological effects– HRT’s potential in Alzheimer’s disease and cognitive aging
- Long-term risks and monitoring – HRT’s potential risks in cancer and thromboembolism
- Mental health and quality of life – HRT’s impact on mood, depression, sleep, and sexual health
- Efficacy and safety – considerations in late initiation of HRT in older adults
- Evidence-based virtual and hybrid care models that expand health care access for older adults in underserved areas
- Innovative digital health tools designed to address age-related health challenges
- Advanced technologies that facilitate data exchange across electronic health records, improving care coordination for older adults with complex needs
- Caregiver integration tools that enhance support for older adults, particularly those experiencing cognitive decline
Clinical Interventions in Aging
Aging in Otolaryngology – Head and Neck Surgery
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Aging in Otolaryngology – Head and Neck Surgery" in Clinical Interventions in Aging.
Demographic shifts toward an increasingly aged global population demand heightened attention to age-related pathophysiology within otorhinolaryngology–head and neck surgery. This Article Collection explores the multifaceted impact of senescence on audiovestibular, sinonasal, laryngopharyngeal, and head and neck surgical disciplines. Conditions such as presbycusis, presbystasis, presbylarynx, presbyphagia, and age-related immunosenescence present distinctive diagnostic and therapeutic challenges. Molecular mechanisms underlying age-related deterioration - including oxidative stress pathways, mitochondrial dysfunction, and altered inflammatory cascades - warrant particular consideration.
Moreover, geriatric frailty and polypharmacy significantly influence perioperative risk stratification and postoperative rehabilitation. The intersection of gerontology and otolaryngology–head and neck surgery requires innovation in clinical approaches, including targeted interventions that address the unique physiological, cognitive, and functional considerations of the older patient population within this surgical domain.
The significance of age-focused otolaryngology is multidimensional. Demographically, individuals over 65 years will constitute an increasing proportion of the global population in the coming decades, accompanied by a growing incidence of age-related otolaryngologic conditions. Clinically, senescent changes in head and neck structures directly affect speech, voice, swallowing, breathing, hearing, and balance - fundamental aspects of human function. Economically, appropriately tailored interventions can reduce healthcare expenditures through fewer complications and hospitalizations. Scientifically, advancing our understanding of the molecular basis of otolaryngologic aging contributes to broader gerontological paradigms. Ethically, addressing these age-related conditions supports dignity, autonomy, and quality of life, representing both a clinical priority and a moral imperative.
We invite systematic reviews, state-of-the-art reviews, and original research articles that examine the impact of aging across the full spectrum of otolaryngology–head and neck surgery. Submissions may address clinical, translational, or basic science aspects in the following areas, including but not limited to:
A focus will be done for innovation in medical and surgical fields of otolaryngology in older adults.
Please submit your manuscript on our website, quoting the promo code A944F to indicate that your submission is for consideration in this Article Collection.
Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript. The deadline for submissions is 31 July 2026.
Guest Advisors:
Jerome R. Lechien, University of Mons, Belgium
Jerome R. Lechien is professor and chair of surgery in University of Mons, Belgium. He is consultant in robotic and laryngeal surgery in Foch Hospital, Paris, France and member of several scientific societies, including American College of Surgery (ACS), ABEA, CEORL, UEP, and ELS.
Lise Sogalow, University of Mons, Belgium
Dr. Sogalow is medical doctor and PhD candidate in Artificial Intelligence in University of Mons, Belgium.
Antonino Maniaci, University of Enna
Prof. Dr. Antonino Maniaci, born in Messina in 1989, is an Associate Professor of Otolaryngology at the University of Enna Kore, Italy, specializing in rhinology, head and neck oncology, and sleep apnea disorders. He holds a Ph.D. in Biomedical Sciences and has completed advanced training and fellowships in prestigious institutions across Europe, including Marseille and Forlì. With over 287 scientific publications and an H-index of 27, his research focuses on inflammatory and oncological diseases, genetic alterations, and innovative treatments in otolaryngology. He serves as European Secretary of YoIFOS and is actively involved in coordinating international research projects, conferences, and fellowships. Prof. Maniaci has received numerous awards, is a member of editorial boards of high-impact journals, and frequently speaks at international conferences.
Hormone Replacement Therapy in Aging - Benefits, Risks, and Clinical Considerations for Older Adults
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Hormone Replacement Therapy in Aging - Benefits, Risks, and Clinical Considerations for Older Adults" in Clinical Interventions in Aging.
We are pleased to announce a new Article Collection in Clinical Interventions in Aging, dedicated to the game-changing role of hormone replacement therapy (HRT) in healthy aging and the management of age-related disorders.
For eligible patients, HRT has revolutionized aging-related healthcare, offering significant benefits in restoring hormonal balance, alleviating menopause and andropause symptoms, reducing osteoporosis and cardiovascular risks, and ultimately enhancing health span and quality of life for older adults.
Given the importance of HRT in aging medicine, Clinical Interventions in Aging invites submissions of original research articles, reviews, and perspectives exploring the mechanisms of action, clinical efficacy, safety, and real-world application of these transformative therapies.
The collection, edited by the Editor-In-Chief Prof. Nandu Goswami, is part of the new Game Changer series of Article Collections, focusing on breakthrough therapies, drugs, or technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes.
While the call is open to receive manuscripts across the broad spectrum of HRT in aging medicine, the Editors are particularly interested in manuscripts highlighting the role of HRT for older adults in the following area, including but not limited to:
Please submit your manuscript on our website. Submitting authors will be eligible for a 20% discount of the Article Publishing Charge by applying the following code at the point of submission RFPTL. If you have any queries regarding the Article Collection or would like to discuss a submission, then please email the Commissioning Editor Sam Zhang at [email protected].
Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.
Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript. The deadline for submissions is 1 April 2026.
Innovative Care Models for Older Adults: The Role of Telehealth and Emerging Technologies
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Innovative Care Models for Older Adults: The Role of Telehealth and Emerging Technologies" in Clinical Interventions in Aging.
The rapid growth in the older adult population is driving health care systems to adopt a wide range of technology-enabled solutions to deliver care to this segment of the population. This approach has transformed how older adults receive care by offering diverse benefits, including greater accessibility, improved chronic disease management, and enhanced satisfaction for both patients and caregivers. Timely interventions and reduced travel demands are especially valuable for individuals with mobility limitations or those residing in rural areas. However, despite these benefits, widespread adoption of digital solutions remains challenging. Overcoming hurdles and tailoring interventions to meet the unique needs of older adults are crucial. This Article Collection will highlight evidence-based research and innovative strategies that advance person-centered and high-quality care for older adults.
Older adults are increasingly using digital health technologies, such as telehealth, mobile health, patient portals, and wearable devices.1 However, some older adults still face barriers in adopting technology-enabled care that can lead to inequities. Barriers include challenges in learning or accessing new technologies, age-related biases, and difficulty using technologies that are not designed to support patients with age-related issues such as cognitive decline or sensory impairments.2
To address these gaps, health care providers and health systems must ensure that technology-enabled care meets the needs of older adults and addresses the barriers they face. The Principles and Guidelines for Telehealth and Aging offer a roadmap for delivering telehealth in ways that are person-centered, equitable, accessible, integrated, and coordinated.3 Beyond telehealth, the same principles can guide broader technology-enabled care strategies to ensure solutions are tailored to the unique needs of older adults, leading to improved care delivery and outcomes.
This Article Collection for Clinical Interventions in Aging seeks submissions that explore how technology-enabled care can be delivered to older adults in ways that meet their needs and that are person-centered, equitable, accessible, integrated, and coordinated. We welcome evidence-based research, interventions, and insights highlighting solutions that overcome barriers to technology adoption and improve clinical outcomes in aging populations. Potential topics include:
The goal of this Article Collection is to provide actionable insights that advance effective, equitable care practices to improve health and quality of life for older adults.
Sources
1. James CA, Basu T, Nallamothu BK, Kullgren JT. Use of digital health technologies by older US adults. JAMA Network Open. 2025;8(1).
2. Leff B, Ritchie CS, Rising KL, Cannon K, Wardlow L. Addressing barriers to equitable telehealth for older adults. Frontiers in Medicine. 2025;12.
3. Wardlow L, Leff B, Biese K, et al. Development of telehealth principles and guidelines for older adults: A modified Delphi Approach. Journal of the American Geriatrics Society. 2022;71(2):371-382.
All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisors for this Collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript. The deadline for submitting manuscripts is 30 November 2025.
Please submit your manuscript on our website, quoting the promo code ENBIV for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
Please contact Sam Zhang at [email protected] with any queries.
Guest Advisors
Dr. Liane Wardlow, PhD, West Health Institute
Liane Wardlow, PhD, is the Senior Director of Clinical Research and Telehealth at the West Health Institute. With 20 years of experience in research across various disciplines, industries, and organizations, Dr. Wardlow has contributed to initiatives at the U.S. Department of Education’s Institute of Education Sciences, the University of California, San Diego’s Alzheimer’s Disease Research Center, Pearson Education, and now the West Health Institute. Her current research focuses on improving health service delivery to enhance the lives of older adults. This includes optimizing care-in-place models, such as telehealth, home-based primary care, home-based palliative care, and Programs of All-Inclusive Care for the Elderly (PACE). These healthcare delivery models aim to improve health outcomes, quality of life, and care experiences while reducing costs and enabling older adults to age in place with dignity.
Dr. Laurie Archbald-Pannone, MD, MPH, University of Virginia
Laurie Archbald-Pannone, MD, MPH, serves as the Claude Moore Associate Professor of Geriatrics, as well as in Infectious Diseases, at the University of Virginia School Of Medicine. As a geriatrician and infectious disease specialist with extensive experience in geriatric medicine and facility-based infection control and prevention, Dr. Archbald-Pannone has over 15 years of clinical and research expertise in the post-acute and long-term care setting (PALTC). She serves as an invited member of the Virginia Department of Health's Long-Term Care Advisory Task Force and, with funding support from VDH, serves as the medical director of the Virginia IMPACT. She is actively involved in medical education, currently serving as College Dean for Student Affairs at the University Of Virginia School Of Medicine.
Dr Suzanne M. Gillespie, MD, University of Rochester School of Medicine and Dentistry
Suzanne Gillespie, MD, is a geriatrician and Certified Medical Director. She is an Associate Professor of Medicine in the Division of Geriatrics and Aging at the University of Rochester School of Medicine and Dentistry and the past president of the Society for Post-Acute and Long-Term Care Medicine.
Perioperative Management and Integrated Surgical Care for Older Adults
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Perioperative Management and Integrated Surgical Care for Older Adults" in Clinical Interventions in Aging.
Global populations are aging. With this, comes increasing incidence of neoplastic and degenerative disease, as well as traumatic injuries sustained because of falls from standing height. Surgical management is the mainstay of management for these conditions. However, this is complicated by such multimorbidity and frailty in older populations. This can contribute to high complications rates and adverse outcomes, including mortality. Frailty has been shown to be associated with such outcomes across a whole host of surgical specialties and settings. However, interventions to influence adverse outcomes in frail older surgical patients have not been widely studied. Evidence is needed to inform best practice, permit guideline development, and improve health and social outcomes for older people with surgical pathologies.
Health economies globally are facing substantial financial crises in the current climate; there is therefore an absolute need to deliver efficient and cost-effective care, that minimizes bed occupancy and healthcare consumption. There is insufficient research to currently guide best practice in several surgical specialties and pathologies. Although examples have been set in the field of orthopedics, there is a clear need to research whether similar models of care and interventions have efficacy in other surgical arenas.
The sustainability of healthcare in the context of an aging population is absolutely dependent on maximizing safety and efficiency, minimizing harm, whilst still providing equal access for older people, who should not be discriminated against on the basis of age alone. This Article Collection calls for papers that contribute to global knowledge in this field. We welcome any submissions relating to the perioperative and surgical care of older people, which show clinical or socioeconomic benefit over conventional practice.
All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisors for this Collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript. The deadline for submitting manuscripts is 30 November 2025.
Please submit your manuscript on our website, quoting the promo code LAJJN for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
Guest Advisors
Dr. Frances Rickard, Southmead Hospital, North Bristol NHS, Bristol, United Kingdom
Dr. Rickard is a Consultant Physician and Perioperative Geriatrician at Southmead Hospital in Bristol
Dr. David Shipway, Southmead Hospital, North Bristol NHS, Bristol, United Kingdom
Dr. Shipway is a Consultant Physician and Perioperative Geriatrician at Southmead Hospital in Bristol. He is also a Senior Clinical Lecturer with the University of Bristol.
Dr. Margot Lodge, Alfred Health/Monash University
Dr. Lodge is a consultant geriatrician at Alfred Health. She is an adjunct research fellow at Monash University.
Understanding Physical Functioning in Older Adults – New Approaches and Novel Interventions
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Understanding Physical Functioning in Older Adults – New Approaches and Novel Interventions" in Clinical Interventions in Aging.
As older adults age, physical function declines. However, age-related decline happens at different rates for different individuals. Understanding risk factors for physical decline and mechanisms underlying this age-related decline is critical so that targeted interventions can be developed to prevent mobility disability. There is interest in understanding the biologic factors related to mobility decline, and how those relate to other functional capacities, especially cognitive. The contribution of sensory information to mobility function is increasingly appreciated. Multimorbidity and frailty are also significant factors influencing physical function in older adults. Systems-level factors, such as social determinants of health, can also impact risk for mobility disability.
Maintaining physical function is an important component of healthy aging that impacts older adults’ quality of life, their ability to remain independent, and their overall health. New approaches are needed to examine the multifactorial mechanisms influencing age-related physical decline on both an individual and systems-level. Novel interventions to prevent mobility disability or improve physical functioning can make a significant impact on not only physical health but overall well-being.
This Collection will accept original research, review articles, short reports, expert opinion, and clinical trial reports that cover a range of topics on physical function in older adults. Articles can discuss individual level and systems-level factors that increase risk for physical dysfunction or mobility disability, explore the geroscience hypothesis as it relates to mobility decline, and identify biochemical pathways and novel targets to prevent sarcopenia. The connection of mobility with other systems, such as sensory or cognitive, in older adults is of interest. In addition, both clinical trials and small pilots that test new interventions are welcome.
All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisors for this Collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript. The deadline for submitting manuscripts is 31 January 2026.
Please submit your manuscript on our website, quoting the promo code XSMQJ for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
Please contact Sam Zhang at [email protected] with any queries.
Guest Advisor
Dr. Atalie C. Thompson, MD, MPH, Wake Forest Baptist University School of Medicine
Atalie C. Thompson, MD, MPH is a clinician scientist and board certified ophthalmologist with fellowship training in glaucoma whose research focuses on the relationship of the visual system to aging and novel methods for early detection of age-related eye diseases. She completed her undergraduate studies at Harvard College, received a fellowship to complete a masters degree in public health from University of California, Berkeley, and received her medical degree from Stanford Medical School. She finished her residency, clinical fellowship in glaucoma and a research fellowship at Duke University Eye Center. She has received funding from the National Insitutes of Health, American Glaucoma Society, the Doris Duke Charitable Foundation and the OAIC Pepper Center. She currently serves as the Vice Chair of Research for the Department of Ophthalmology at Atrium Health Wake Forest Baptist and has a co-appointment in Gerontology and Geriatric Medicine.
- Outcomes of newer IOLs, focusing on secondary endpoints such as defocus curves, contrast sensitivity, and patient-reported outcomes
- Advanced IOLs, including trifocal IOLs, EDOF IOLs, monofocal-plus IOLs, LAL, toric IOLs, and any emerging options
- Design features related to IOL construction and fixation sites; materials used for optics, filters, and haptics
- Outcomes of supplementary (piggyback) IOLs, customized IOLs, and secondary IOLs
- Considerations for IOLs used in the pediatric population
- Advancements in IOL power calculation
- Innovations in the field of refractive cataract surgery and IOLs
- Surgical approaches for eyes with weak zonules, coexisting corneal pathology, or previous ocular surgeries
- Management of cataracts in uveitis, glaucoma, or high myopia
- IOL selection and fixation techniques
- Perioperative medical management
- Rehabilitation strategies
- The use of telemedicine and virtual consultations in ophthalmology.
- The engagement of ophthalmologists in social media content creation.
- Ethical considerations regarding patient privacy and professional conduct in digital spaces.
- The influence of social media on medical education.
- The adoption of new digital technologies within the field of ophthalmology.
- Approaches to the different types of femtosecond laser (fs) pulse energy pattern (low or high) reporting their similarities and differences in all kinds of outcomes.
- Reviews (preferably systematic) and/or meta-analyses on the subject with well-defined references to the studied fs platform(s).
- Emphasis on the refractive outcomes of femtosecond laser-assisted lens surgery, either in the context of cataract or, preferably, refractive lens exchange.
- New incomes to premium lens surgery, in the context of femtosecond laser lens surgery, such as Artificial Intelligence (AI).
- Further developments on fs technology as to permit “zero” phaco, i. e., the feasibility of femtosecond machine’s full autonomy.
- Improvements on fs platforms (portability) and cost-effectiveness strategies.
- The birth of new premium IOLs, as thrusted by fs technology.
- Infectious and non-infectious uveitis
- Anterior to posterior disease
- Pediatric uveitis
- Multimodal imaging
- Systemic workup strategies
- Biologics and small molecules
- Long-term monitoring tools
Clinical Ophthalmology
Advances in Intraocular Lenses
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Advances in Intraocular Lenses" in Clinical Ophthalmology.
We recently celebrated 75 years of intraocular lenses (IOLs), which were first implanted by Sir Harold Ridley in 1949. Refractive cataract surgery continues to evolve rapidly, with new surgical technologies constantly emerging. The advanced optics of premium IOLs not only enhance the patient's quality of vision but also their overall quality of life and independence from glasses.
Artificial intelligence has introduced a new generation of formulas that provide exceptionally accurate IOL power calculations. By understanding the design philosophies and clinical performances of newer IOLs, we can better guide patients toward achieving optimal visual outcomes tailored to their specific vision needs.
Recent advancements have led to significant improvements in intermediate vision through the use of trifocal IOLs, extended depth of focus (EDOF) IOLs, monofocal-plus IOLs, light adjustable lenses (LAL), and toric IOLs. These options have improved visual acuity for many patients and resulted in a high level of satisfaction.
Despite the many articles published on IOLs, important challenges remain in synthesizing clinical evidence. Common issues include meta-analyses comparing lens categories with only one or a few lenses per category, inconsistent publication of results, a lack of secondary analyses segmented by biometric data that could enhance selection criteria, and insufficient long-term results. Moreover, new IOLs and variations of existing IOLs are launched each year, which require clinical evidence to develop evidence-based recommendations for their use.
This Article Collection aims to provide readers with the latest advancements and current knowledge in IOLs. We welcome original research and review articles (including meta-analyses and systematic reviews) related to the suggested topics, though submissions are not limited to these areas:
All manuscripts submitted to this Article Collection will undergo full peer-review; Guest Advisors will not be handling submitted articles. Please review the journal’s aims and scope and author instructions prior to submission.
Please submit your manuscript through the Dovepress website. During submission, enter the promo code DXQSW for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
The manuscript submission deadline is 1 February 2026. If you have any questions about this Article Collection, please contact Krista Thom at [email protected].
Guest adviser
Dr. Mithun Thulasidas, Trinity Eye Hospital, Kerala, India
Comprehensive Management of Complex Cataracts: Surgical Innovations and Postoperative Strategies
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Comprehensive Management of Complex Cataracts: Surgical Innovations and Postoperative Strategies" in Clinical Ophthalmology.
Complex cataracts represent a diverse group of challenging cases that require advanced surgical skills, tailored techniques, and meticulous perioperative care. These cases may involve coexisting ocular comorbidities, traumatic cataracts, zonular instability, small pupils, corneal opacities, pseudoexfoliation, uveitis-related lens changes, or high myopia. The variability in presentation demands that surgeons not only master technical adaptations but also integrate multidisciplinary management approaches to optimize patient outcomes.
As global cataract surgery volumes rise, the proportion of cases with added complexity is increasing. Inadequate planning or inappropriate intraoperative decision-making in such cases can lead to sight-threatening complications and poor visual rehabilitation. At the same time, recent innovations - from femtosecond laser-assisted cataract surgery and capsular tension devices to advanced intraocular lens (IOL) technologies and enhanced imaging - offer unprecedented opportunities to improve safety and outcomes. By systematically addressing complex cataracts through both surgical and post-surgical lenses, clinicians can reduce complication rates, enhance visual quality, and improve patients’ quality of life.
This Article Collection seeks to explore all aspects of complex cataract management, including preoperative evaluation, surgical decision-making, intraoperative innovations, complication prevention, and comprehensive postoperative care.
Subtopics may include:
We welcome original research articles (including surgical technique papers), review articles, perspectives, and commentaries.
All manuscripts submitted to this Article Collection will undergo full peer-review; Guest Advisors will not be handling submitted articles. Please review the journal’s aims and scope and author instructions prior to submission.
Please submit your manuscript through the Dovepress website. During submission, enter the promo code 9B736 to indicate that your submission is for consideration in this Article Collection. Please note that normal Article Processing Charges will apply.
The manuscript submission deadline is 31 May 2026. If you have any questions about this Article Collection, please contact Krista Thom at [email protected].
Guest advisers
Dr. Bharat Gurnani, Gomabai Netralaya and Research Centre, Neemuch, Madhya Pradesh, India
Dr. Kirandeep Kaur, Gomabai Netralaya and Research Centre, Neemuch, Madhya Pradesh, India
Emerging Trends in Digital Ophthalmology and Social Media
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Emerging Trends in Digital Ophthalmology and Social Media" in Clinical Ophthalmology.
The prevalence of social media use globally has resulted in a profound shift in how patients access and interact with health information. Studies show that 75% of patients turn to social media as their first resource for health-related inquiries. This trend has led many to use online information as a substitute for professional consultations.
New digital and AI-based technologies have also broadened patients' understanding of and access to eye health screening and treatment modalities. Increased digital access to health information can have a significant influence on patients' health-related behaviors, whether positively or negatively. All of this underscores a concerning gap in the professional oversight of health-related content obtained via these platforms.
More research is needed to evaluate digital platforms and the type of ophthalmology content trending online (including the prevalence of misinformation) in order to optimize patient education and encourage practices that promote eye health.
Misinformation amongst ophthalmology-related content on social media is rampant. The medical community has been slow to leverage social media as a tool for health education. Although 70% of physicians are active on social media, only a small fraction—around 10%—are involved in content creation. This disparity highlights a missed opportunity for clinicians to provide evidence-based, reliable health information to a vast audience, especially in the face of widespread misinformation online.
Given these dynamics, it is important for ophthalmologists to better understand emerging digital technologies, social media usage, and trending online topics in the eyecare space to improve patient education and guide patients toward more informed decision-making.
This Article Collection will explore the intersection between digital platforms and eye care. Key areas include the impact of social media on public awareness of eye health, the role of online communities in supporting patients with ocular diseases, and the effectiveness of social media campaigns in promoting preventive eye care.
This Article Collection will also focus on the accuracy of health information shared online, as well as misinformation and its effects on patient behavior and treatment outcomes.
Subtopics may include, but are not limited to:
Both original research and review articles are welcome.
All manuscripts submitted to this Article Collection will undergo full peer-review; Guest Advisors will not be handling submitted articles. Please review the journal’s aims and scope and author instructions prior to submission.
Please submit your manuscript through the Dovepress website. During submission, enter the promo code EOQPN for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
The manuscript submission deadline is 1 November 2025. If you have any questions about this Article Collection, please contact Krista Thom at [email protected].
Guest adviser
Dagny Zhu, MD, NVISION Eye Centers, Rowland Heights, California, USA
Femtosecond Laser in Lens Surgery: Contribution to Emmetropia
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Femtosecond Laser in Lens Surgery: Contribution to Emmetropia" in Clinical Ophthalmology.
The achievement of emmetropia has been one of the oldest dreams in ophthalmology. This goal involves the correction of any refractive error, and by extension, age-related presbyopia. It is also presently established that lens surgery holds the title of the best available and definitive technique to address presbyopia correction, whether in the presence of a cataract or a transparent crystalline lens. In this quest, femtosecond laser technology arose, enabling competing indexes of reproducibility, precision, efficacy, and customization regarding the several steps involved in lens surgery. The present Article Collection will serve the purpose of providing further illumination on the role of femtosecond laser in lens surgery and stimulating new developments of this technology.
The advent of premium IOLs in the context of refractive lens exchange has triggered demands for a higher standard of surgical procedure; hence the concept of premium lens surgery. Cataract surgery itself has shifted goals in the direction of the best refractive correction. Independency of spectacles by means of surgical intervention has become the desire of an increasingly significant part of the population. The high levels of reproducibility and customization of femtosecond laser-assisted technology are liable to open new horizons in the domain of refractive lens surgery.
Topics of interest include:
We welcome original research articles, reviews, editorials, commentaries, clinical trial reports, and protocols. Please note that all meta-analyses require a pre-submission check. Complete the pre-submission check form before submitting.
All manuscripts submitted to this Article Collection will undergo full peer-review; Guest Advisors will not be handling submitted articles. Please review the journal’s aims and scope and author instructions prior to submission.
Please submit your manuscript through the Dovepress website. During submission, enter the promo code PCKXI for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
The manuscript submission deadline is 1 November 2025. If you have any questions about this Article Collection, please contact Krista Thom at [email protected].
Guest advisers
Dr. Ramiro Salgado, NewClinics, Porto, Portugal
Prof. Antonio A. P. Marinho, Hospital Luz Arrabida, Portugal
Prof. Dr. Alireza Mirshahi, Dardenne Eye Hospital, Bonn, Germany
Translating Science to Practice in Uveitis: A Step-by-Step Clinical Guide Across the Disease
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Translating Science to Practice in Uveitis: A Step-by-Step Clinical Guide Across the Disease" in Clinical Ophthalmology.
Uveitis represents a diverse group of intraocular inflammatory diseases affecting both children and adults. It remains a leading cause of preventable vision loss worldwide, with varied presentations, etiologies, and systemic associations that pose significant clinical challenges. This Article Collection aims to serve as a comprehensive, step-by-step guide for clinicians managing uveitis across its full spectrum—from diagnosis to long-term care. As diagnostic technologies and therapeutic options evolve, there is a growing need for practical, evidence-based frameworks that support real-world clinical decision-making. The increasing use of multimodal imaging, laboratory investigations, systemic screening, and artificial intelligence (AI) tools has transformed the approach to uveitis. Pediatric uveitis, in particular, demands special attention due to its unique disease patterns, treatment challenges, and impact on long-term visual outcomes. This Collection seeks to translate emerging science into accessible clinical practice, enabling better patient care across various healthcare settings.
This Article Collection is developed in partnership with Clinical Ophthalmology and the PROTON (Program for Ocular Inflammation and Infection Translational Research) Group, a global network dedicated to advancing ocular inflammation research and implementation. PROTON connects clinician-scientists and researchers to promote multidisciplinary, translational approaches. We invite submissions including original research, clinical reviews, diagnostic and treatment algorithms, expert consensus guidelines, pediatric-focused studies, and innovations in digital health and AI. Contributions spanning infectious and non-infectious uveitis, anterior to posterior involvement, systemic associations, imaging, therapeutics, and multidisciplinary care models are encouraged.
Topics may include, but are not limited to:
Contributions from ophthalmologists, rheumatologists, immunologists, pediatric specialists, and data scientists are especially welcome. Together, we aim to curate a pragmatic, high-impact, and forward-looking resource that enhances clinical practice and patient care in uveitis across all age groups and disease severities.
All manuscripts submitted to this Article Collection will undergo full peer-review; Guest Advisors will not be handling submitted articles. Please review the journal’s aims and scope and author instructions prior to submission.
Please submit your manuscript through the Dovepress website. During submission, enter the promo code 790D1 to indicate that your submission is for consideration in this Article Collection. Please note that normal Article Processing Charges will apply.
The manuscript submission deadline is 15 February 2026. If you have any questions about this Article Collection, please contact Krista Thom at [email protected].
Guest advisers
Prof. Rupesh Agrawal, Tan Tock Seng Hospital, Singapore
Prof. Vishali Gupta, Post Graduate Institution for Medical Education and Research, Chandigarh, India
Prof. Alejandra de-la-Torre, School of Medicine and Health Sciences Universidad Del Rosario, Bogota, Colombia
- Metabolic Syndrome
- Cardiovascular Disease
- Therapeutic interventions
- Atherosclerosis
- Cardiovascular Risk factors
Clinical Pharmacology: Advances and Applications
Metabolic Syndrome and Cardiovascular Disease
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Metabolic Syndrome and Cardiovascular Disease", organized by Guest Advisors Dr. Constantine E. Kosmas and Dr. Christina Kostara in Clinical Pharmacology: Advances and Applications.
Metabolic syndrome (MetS) is characterized by a constellation of metabolic abnormalities, including obesity (especially central obesity), insulin resistance, hypertension, hypertriglyceridemia, and low levels of high-density lipoprotein cholesterol (HDL-C). Each of these metabolic abnormalities represents an independent risk factor for cardiovascular disease (CVD), and their combination significantly increases the risk of a spectrum of cardiovascular conditions, including microvascular dysfunction, coronary atherosclerosis and calcification, cardiac dysfunction, myocardial infarction, and heart failure.
MetS is strongly associated with cardiovascular morbidity and mortality. Patients with MetS have a higher risk of developing CVD compared with those without MetS in the next 5–10 years, and the long-term CVD risk is even higher. While advances in understanding the etiology and consequences of MetS have been made, the underlying pathophysiologic mechanisms that conspire into the full spectrum of the observed MetS-associated cardiovascular pathologies remain insufficiently explained.
This Article Collection aims to highlight current knowledge pertaining to the pathophysiological mechanisms underlying MetS-associated cardiovascular entities and the clinical phenotyping of metabolic syndrome, as well as the advanced research in drug development based on experimental or clinical research studies and the therapeutic interventions to reduce the cardiovascular burden of metabolic syndrome. We welcome submissions (original articles, reviews, or short communications) from clinical, translational, and basic research.
All manuscripts submitted to this Article Collection will undergo desk assessment and peer review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are existing members of the Editorial Board. Please review the journal's Aims and Scope and author submission instructions prior to submitting a manuscript.
Keywords
All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.
The deadline for submitting manuscripts is 31 December 2025.
Please submit your manuscript on our website, quoting the promo code WPKNP for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
Guest Advisors
Dr. Constantine E. Kosmas, 2nd Department of Cardiology, National & Kapodistrian University of Athens, Greece
Constantine E. Kosmas, M.D., Ph.D., FACC, FACP is a Clinical/Academic/Non-Invasive Cardiologist and Clinical Lipidologist, currently serving as a Scientific Associate of the Lipid Clinic at the 2nd Department of Cardiology of the National and Kapodistrian University of Athens at the University General Hospital “ATTIKON”.
He has served for a long time (2014-2023) as Director of Nuclear Cardiology and Lipid Clinic at a large private practice in New York (Cardiology Unlimited, P.C.). He has also served as Assistant Professor of Medicine at Icahn School of Medicine at Mount Sinai and Medical Director of Mount Sinai Advanced Cardiovascular Group, as well as Clinical Assistant Professor of Medicine at the Medical School of the University of Pennsylvania and at the Weill Medical College of Cornell University. Dr. Kosmas has also served as Director of Clinical Services and Associate Director of Nuclear Cardiology at Episcopal Hospital, Philadelphia, PA, as well as Acting Director of Coronary Care Unit at New York Hospital Queens, Flushing, New York.
Dr. Kosmas holds Board Certifications in Internal Medicine and Cardiovascular Disease in the USA and Greece, as well as Board Certifications in Nuclear Cardiology and Clinical Lipidology in the United States. He has been extensively involved in teaching mid-level providers, students, medical residents, and cardiology fellows at several academic institutions in New York and Pennsylvania. He has also been extensively involved in cardiovascular clinical research with several publications in the medical literature and numerous lectures in academic institutions and national conferences, especially on lipid-related subjects. Dr. Kosmas has also served as a member of the American Board of Internal Medicine (ABIM)’s Cardiovascular Disease Item-Writing Task Force. In addition, he has served as a member of many Speaker Bureaus and Advisory Boards of several large international pharmaceutical companies. Dr. Kosmas is an active member of the Editorial Board as well as a Reviewer in several prestigious peer-reviewed medical journals.
Dr. Christina Kostara, Laboratory of Clinical Chemistry, Faculty of Medicine, School of Health Sciences, University of Ioannina, Greece
Christina Kostara is a Post-Doctoral Researcher in the Faculty of Medicine at the University of Ioannina, Greece.
Dr. Kostara’s main research interest focuses on the investigation of lipid profiling (Lipidomics) as a novel approach for the analysis of biological matrixes using high resolution nuclear magnetic resonance spectroscopy (NMR) combined with high throughput “omics” technologies.
Clinical, Cosmetic and Investigational Dermatology
Laser Treatment of Benign Pigmented Lesions and Facial Rejuvenation
Dove Medical Press is pleased to invite you to submit your research to the upcoming Article Collection on “Laser Treatment of Benign Pigmented Lesions and Facial Rejuvenation” in Clinical, Cosmetic and Investigational Dermatology.
Benign pigmented lesions and facial rejuvenation are among the highest growing demands of patients in the field of cosmetic and aesthetic dermatology. Laser treatment uses light energy to improve facial flaws, including melasma, uneven pigmentation, and blemishes by stimulating collagen production. Although there are numerous options for treatment of both benign pigmented lesions as well as facial rejuvenation, the outcome is not always satisfactory for patients.
Differentiating between the laser procedures that are backed by science from those derived by marketing is a very important mission to ensure patients have the best outcome. Collecting evidence-based materials from key opinion leaders and presenting it to practitioners is one way that we can complete this mission.
Through this Collection of publications focusing on the available literature about laser treatment of benign pigmented lesions and facial rejuvenation, we aim to provide practitioners with an open access volume of work that will aid patient care and satisfaction.
Review articles, clinical studies, and randomized control studies covering any topic related to laser treatment of benign pigmented lesions or laser assisted facial rejuvenation are welcomed to this Collection.
Please review the journal scope and author submission instructions prior to submitting a manuscript. The deadline for submitting manuscripts is 01 December 2025.
Please submit your manuscript on our website, quoting the promo code 73CB8 to indicate that your submission is for consideration in this Article Collection. Please note that normal Article Processing Charges will apply.
- Global incidence
- Technology-based management
- Treatment to prolong beta cell survival
- Cell-based treatments
- Obesity
- Diabetes complications, particularly cardiovascular disease, nephropathy, diabetic bone disease
- The brain (reduction in cognitive decline, addition) in diabetes
- Pediatric obesity and diabetes or type 1 diabetes
Diabetes, Metabolic Syndrome and Obesity
Co-occurring Obesity and Eating Disorders: Challenges, Mechanisms, and Intervention Strategies
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Co-occurring Obesity and Eating Disorders: Challenges, Mechanisms, and Intervention Strategies" in Diabetes, Metabolic Syndrome and Obesity.
Obesity and eating disorders often occur together, creating complex clinical profiles that challenge conventional treatment approaches. While obesity is most frequently associated with binge-eating disorder, it may also coexist - albeit less commonly - with bulimia nervosa, night eating syndrome, and atypical anorexia nervosa. In some cases, obesity develops before the eating disorder, functioning as a potential risk factor; in others, it emerges as a consequence of eating disorders. A striking aspect of this comorbidity is the marked gender disparity, with women disproportionately affected compared to men. The coexistence of these conditions is linked to heightened medical complications, greater psychological distress, and diminished quality of life. Shared biological, psychological, and sociocultural mechanisms likely play a role in their onset and persistence, while stigma, diagnostic overshadowing, and fragmented healthcare pathways often delay recognition and impede effective, integrated treatment.
Despite its significant clinical and public health implications, the coexistence of obesity and eating disorders remains under-recognized and under-researched. Many patients present with overlapping symptoms that do not fit neatly into traditional diagnostic categories, leading to misdiagnosis or delayed intervention. This gap in recognition can exacerbate both physical and mental health outcomes, increasing the risk of type 2 diabetes, cardiovascular disease, and severe psychiatric comorbidities. The lack of integrated treatment models means that obesity and eating disorders are often addressed separately, resulting in fragmented care that fails to address the interplay between them. Increased awareness and targeted research are essential to understand shared risk factors better, develop practical screening tools, and design multidisciplinary treatment strategies. Addressing this comorbidity could significantly improve long-term health outcomes, reduce stigma, and promote more effective prevention and intervention efforts in both obesity and eating disorder care.
This Collection invites submissions that explore the intersection of obesity and eating disorders within the context of metabolic health, psychological well-being, and clinical care. Relevant topics include epidemiological studies on prevalence and risk factors; research on shared biological pathways; the influence of sociocultural and environmental determinants; and the role of stigma and weight bias in clinical outcomes. It also welcomes studies evaluating screening tools, diagnostic criteria, and integrated treatment models, particularly those that address both physical and psychological aspects. Articles examining the impact of comorbidity on diabetes risk, glycaemic control, and other obesity-related complications are especially encouraged. The Collection will consider a range of formats, including original research articles, systematic reviews, meta-analyses, clinical case studies, and perspectives from multidisciplinary teams. By fostering cross-disciplinary dialogue, this initiative aims to advance understanding and improve prevention, early detection, and treatment strategies for individuals affected by both obesity and eating disorders.
All manuscripts submitted to this Article Collection will undergo desk assessment and a full peer-review. Please review the journal scope and author submission instructions prior to submitting a manuscript as it will be rejected if it does not fall within the scope of the journal.
Please submit your manuscript on our website, entering the promo code 190D6 to indicate that the paper is for consideration in this Article Collection. The deadline for submitting manuscripts is 31 May 2026.
Guest Advisor
Dr. Riccardo Dalle Grave, Villa Garda Hospital, Italy
From Type 1 to Type 2 Diabetes and Obesity: The Impact of Continuous Glucose Monitoring (CGM) and Emerging Diabetes Management Technologies on Metabolic Health
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "From Type 1 to Type 2 Diabetes and Obesity: The Impact of Continuous Glucose Monitoring (CGM) and Emerging Diabetes Management Technologies on Metabolic Health" in Diabetes, Metabolic Syndrome and Obesity.
Continuous glucose monitoring (CGM) is widely used in type 1 diabetes (T1D) to improve management and prevent dangerous fluctuations in blood glucose levels. While CGMs have long been a cornerstone of T1D care, their use is rapidly expanding beyond T1D into Type 2 diabetes (T2D) and obesity management, offering exciting possibilities for the future of diabetes care. In T2D, CGMs provide critical real-time insights into glucose fluctuations, helping patients make informed decisions about their diet, physical activity, and medication. This allows for more personalized, data-driven management, which has been shown to improve overall glycemic control and reduce the risk of complications. The true promise of CGMs, however, lies in their potential to reshape the way patients approach their health, particularly in T2D and obesity care. By offering continuous glucose feedback, CGMs help individuals better understand how their lifestyle choices - such as food intake, exercise, and stress—impact their glucose levels. This increased awareness encourages patients to make more mindful decisions and adapt their behaviors, fostering long-term, sustainable changes in their lifestyle. As individuals begin to see the direct impact of their habits on their metabolic health, they are empowered to take greater control over their condition, leading to better weight management and improved overall health outcomes.
Looking ahead, CGMs and other emerging technologies hold the potential to revolutionize diabetes and obesity care. By providing real-time, actionable data, these technologies enable a more integrated and personalized approach to managing these conditions. This Article Collection gathers articles that explore the evolving role of CGMs and emerging diabetes management technologies in shaping the future of care for diabetes and obesity, highlighting their ability to improve patient outcomes through personalized, lifestyle-driven, and pharmacology-based interventions.
All manuscripts submitted to this Article Collection will undergo desk assessment and a full peer-review. Please review the journal scope and author submission instructions prior to submitting a manuscript as it will be rejected if it does not fall within the scope of the journal.
Please submit your manuscript on our website. Submitting authors will be eligible for a 10% discount on the Article Publishing charge by entering the code B91B1.
The deadline for submitting manuscripts is 31 January 2026.
Guest Advisors
Dr. Emir Muzurovic, University of Montenegro, Montenegro
Emir Muzurovic (MD,PhD), a physician and researcher at the Department of Internal Medicine, Endocrinology Section, Clinical Centre of Montenegro, and the Faculty of Medicine, University of Montenegro, Podgorica, Montenegro. He works on advancing the management of diabetes and metabolic health, with a focus on integrating innovative medical technologies into clinical practice. His expertise spans endocrinology, metabolic disorders, and personalized patient care.
Prof. Manfredi Rizzo, University of Palermo, Italy
Prof. Manfredi Rizzo, MD, PhD, a physician and researcher specializing in internal medicine, diabetes, and cardiovascular prevention. He is Associate Professor at the University of Palermo and Head of both the Unit of Diabetes and Cardiovascular Prevention and the Cardiometabolic Research Laboratory. He is an active member of various scientific societies and has authored over 250 peer-reviewed publications, with a notable H-Index of 47.
Global Trends and Innovations in Type 1 Diabetes: Incidence, Management, and Beta-Cell Preservation
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Global Trends and Innovations in Type 1 Diabetes: Incidence, Management, and Beta-Cell Preservation" in Diabetes, Metabolic Syndrome and Obesity.
Concerns about the ongoing rise in Type 1 Diabetes (T1D) have been buoyed recently by exciting developments in approaches to easier, more effective management through automated insulin delivery and smart devices, as well as medication to delay T1D progression and use cell-based treatments—culminating in a true shift in the disease horizon.
Given the importance of these shifts for the trajectory of the field of T1D and future management, Diabetes and Metabolic Syndrome invites submissions of original research articles, reviews, and perspectives exploring global shifts in epidemiology, pathophysiology, and transformative technology and cell-based management.
This Collection focuses on breakthrough therapies, drugs, or technologies that have significantly altered the standard of care, leading improvements in patient outcomes.
While the call is open to receive manuscripts across the broad spectrum of changes in T1D incidence and treatment, we are particularly interested in manuscripts relating to the following areas:
All manuscripts submitted to this Article Collection will undergo desk assessment and a full peer-review. Please review the journal scope and author submission instructions prior to submitting a manuscript as it will be rejected if it does not fall within the scope of the journal.
Please submit your manuscript on our website, entering the promo code 2A26C to indicate that the paper is for consideration in this Article Collection. The deadline for submitting manuscripts is 28 February 2026.
Guest Advisor
Prof. Mark D. DeBoer, University of Virginia, USA
GLP-1 Agonists: The Game-Changers in Type 2 Diabetes and Obesity Care
We are pleased to announce a new hot-topic Article Collection in Diabetes, Metabolic Syndrome and Obesity dedicated to the game-changing role of GLP-1 receptor agonists in type 2 diabetes and obesity. Since their clinical introduction, GLP-1 receptor agonists have revolutionized patient care, offering significant benefits in glycemic control, weight loss and management, and cardiovascular and renal diseases for eligible patients.
Given the recognized importance of GLP-1 agonists in managing type 2 diabetes and obesity, and the accumulating new evidence showing several pleiotropic effects, Diabetes, Metabolic Syndrome and Obesity invites submissions of original research articles, reviews, and perspectives exploring the clinical efficacy, safety, mechanisms of action, and real-world application of these transformative therapies.
The Collection, edited by the Editor-In-Chief Professor Rebecca Conway and the Section Editor Professor Ernesto Maddaloni, is part of the new Game Changer series of Article Collections, focusing on breakthrough therapies, drugs, or technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes.
While the call is open to receive manuscripts across the broad spectrum of GLP-1 agonists in managing type 2 diabetes and obesity, the Editors are particularly interested in manuscripts relating to the following areas:
Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.
All manuscripts submitted to this Article Collection will undergo desk assessment and a full peer-review. Please review the journal scope and author submission instructions prior to submitting a manuscript as it will be rejected if it does not fall within the scope of the journal.
Please submit your manuscript on our website. Submitting authors will be eligible for a 20% discount on the Article Publishing charge by entering the code BOUZT.
The deadline for submitting manuscripts is 1 April 2026.
- Structural and Molecular Biology of p53 Elucidating its Therapeutic Value
- Small Molecule Modulators of Targets Involved in p53 Signalling and Regulation
- Rescue of Loss-of-function Mutant p53 or Restraint of Gain-of-function Mutant p53
- p53-targeted Gene / Immune Therapies
- Clinical Translation of p53-based Therapies
- Challenges and Future Directions
- Advancements in Fragment Screening Techniques
- Specialized Fragment-Libraries and Library Design
- Structural Biology and Fragment-Based Design
- Chemical Biology and Fragment Evolution
- Case Studies and Success Stories
- Challenges and Future Directions
Drug Design, Development and Therapy
Advances in p53 Drug Discovery
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in Drug Design, Development and Therapy on "Advances in p53 Drug Discovery", organized by Dr. Andreas Joerger (Goethe University, Germany), Dr. Alexander Dömling (Palacky University in Olomouc, Czech Republic) and Editor-In-Chief Dr. Frank M. Böckler (Eberhard Karls University Tübingen, Germany).
Often referred to as the "guardian of the genome", p53 plays an important role in maintaining cellular homeostasis by regulating and orchestrating cell cycle arrest, DNA repair, apoptosis, and senescence. Mutations in the TP53 gene which encodes p53, are found in a broad range of human cancers, leading to loss of its tumor-suppressive functions and contributing to cancer progression and metastasis. In addition, some gain-of-function (GOF) p53 mutants can acquire new oncogenic activities affecting genomic instability, metabolic reprogramming, and the tumor microenvironment, while promoting invasion, metastasis, and cancer cell proliferation. The complexity of p53's structure and function, particularly its role as a transcription factor and its interactions with a large number of cellular signaling pathways, has made it a challenging target for drug discovery. However, recent advances in structural biology, computational methods, and medicinal chemistry have opened new avenues for the development of drugs that can restore or enhance p53 function, offering hope for more effective cancer therapies. Furthermore, additional targets, such as MDM2/X, HAUSP, Cop-1, Pirh-2, Wip-1, PTEN, AKT, and Siah-1, could become points of therapeutic intervention, influencing p53 and its signaling and regulation network.
Playing a core role in tumor suppression, the ability to modulate p53 activity holds the potential to transform cancer treatment. The development of drugs that can restore the function of mutant p53 or enhance the activity of wild-type p53 is a critical area of research with significant implications for improving patient outcomes and survival rates in cancer.
To help raise the profile of this important area of research, Drug Design, Development and Therapy is publishing a timely Article Collection on p53 drug discovery. The Collection is led by Dr. Andreas Joerger, Prof. Dr. Alexander Dömling, and the Editor in Chief, Prof. Dr. Frank Böckler.
Potential topics include, but are not limited to, the following:
Please submit your manuscript on our website, using the promo code XITLT for 20% off the advertised article processing charge and to indicate that your manuscript will be considered for the “Advances in p53 Drug Discovery” Collection. We will be welcoming relevant papers up until the 31st of March 2026. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.
Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.
Guest Advisors
Dr. Andreas Joerger, Goethe University
Andreas C. Joerger obtained his doctoral degree from the University of Freiburg, Germany in 2000. He then assumed a postdoc position in the group of Prof. Sir Alan Fersht at the Medical Research Council (MRC) Centre for Protein Engineering in Cambridge, United Kingdom, initially working on protein design. He stayed on as a senior scientist in structural biology until 2010, before moving to the MRC Laboratory of Molecular Biology in Cambridge (2010-2015). During his long spell at the MRC, he made key contributions towards unraveling the complex structural biology of the tumor suppressor p53 and related proteins. He determined the first crystal structures of p53 cancer mutants, which led to the Y220C mutant being used as a paradigm for the development of mutant p53 rescue drugs based on protein stabilization. In 2016, Dr. Joerger joined the group of Prof. Stefan Knapp at the Institute of Pharmaceutical Chemistry at Goethe University, Frankfurt am Main. Since 2018, he is Principal Investigator on p53 drug discovery and transcriptional regulation at the Structural Genomics Consortium (SGC) Frankfurt. His other research interests include the evolutionary history of the p53 pathway, protein design, epigenetic targets and E3 ubiquitin ligases.
Dr. Alexander Dömling, Palacky University in Olomouc
Alex Dömling studied Chemistry & Biology at the Technische Universitat Munchen (TUM). He performed his Ph.D. with Ivar Ugi and his postdoc – funded by a Feodor Lynen stipend from the Alexander von Humboldt Foundation – with double Nobel Laureate Barry Sharpless. After his habilitation at TUM, he became a professor at the University of Pittsburgh, then chair of the Department of Drug Design at the University of Groningen, and most recently ERA Chair at Palacky University. He also started several biotech companies. He is the author of over 300 publications and over 70 patent applications. His current lab works according to the mantra ‘Automation + Miniaturization = Acceleration’ on the ERC-funded project of engineering an autonomous drug discovery platform called AMADEUS.
Alexander Dömling is a world-renowned researcher in the area of miniaturization, automation of synthetic chemistry, and multicomponent reaction chemistry. Professor Dömling applies multicomponent reaction chemistry to solve problems in drug discovery and related areas. Notably, he introduced the Acoustic Droplet Ejection technology platform to perform precise high throughput synthetic chemistry and demonstrated its applicability to multiple different chemistries and chemical biology projects.
Dr. Frank M. Böckler, Eberhard Karls University Tübingen
At the Institute of Pharmaceutical Sciences, Frank Böckler heads the laboratory of Molecular Design & Pharmaceutical Biophysics, which combines Chemical Biology, Molecular and Structural Biology and Biophysics, as well as Computational Chemistry, Machine Learning and Molecular Design. In addition, he is a member of the Institute for Bioinformatics and Medical Informatics (IBMI). In 2004, he received his Ph.D. in Medicinal Chemistry with summa cum laude at Friedrich-Alexander University in Erlangen (Germany). Joining Prof. Sir Alan R. Fersht as a postdoc at the MRC Center for Protein Engineering in Cambridge/UK, he discovered p53 mutant stabilizers as potential new cancer therapeutics. In 2008, he was appointed Professor (W2tt) for Bioanalytics at Ludwig-Maximilians University (LMU) Munich, before moving to Tübingen in 2010 as a full professor. His work is dedicated to understanding molecular interactions, such as halogen and chalcogen bonds, as the foundation for chemical biology and drug discovery and to apply theoretical, fragment-based, biophysical, and structural methods to cancer research, particularly involving the human kinome and the network of the tumor suppressor p53.
Exploring Fragment-Based Approaches in Drug Discovery
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in Drug Design, Development and Therapy on "Exploring Fragment-Based Approaches in Drug Discovery", organized by Prof. Anna K. H. Hirsch (Saarland University, Germany), Dr. Walid A. M. Elgaher (Saarland University, Germany), Prof. Oliver Koch (Universität Münster, Germany) and Editor-In-Chief, Prof. Frank M. Böckler (Eberhard Karls University Tübingen, Germany).
With the emergence of fragment-based drug discovery (FBDD), the field of drug discovery has undergone significant changes. Unlike traditional high-throughput screening techniques, FBDD is based on identifying low molecular weight compounds (fragments) with a low affinity to the biological target. These initial fragment hits are then developed into drug-like molecules through a range of techniques, including fragment merging, growing, and linking, to produce a lead with a higher affinity.
FBDD has the capacity to streamline the drug discovery process by initiating a bottom-up process of combining fragments with high ligand efficiencies. Structural insights from X-ray crystallography have fostered hopes that fragments with strong local interaction networks could be extended to target a wider binding site, often boosting the affinity substantially. The method not only increases the probability of identifying active compounds compared to random screening but also allows an in-depth exploration of the chemical and biological space surrounding these fragments. In 2024, 52 fragment-derived candidates had made it to different phases of clinical studies (phase 1–3), while seven drugs (Asciminib, Capivasertib, Erdafitinib, Pexidartinib, Sotorasib, Vemurafenib, and Venetoclax) have already been approved. This highlights the great relevance and potential of this approach for drug discovery.
To help raise the profile of this important area of research, Drug Design, Development and Therapy is publishing a timely Article Collection on fragment-based drug discovery. The Collection is led by Prof. Anna K. H. Hirsch, Dr. Walid A. M. Elgaher, Prof. Oliver Koch, and Editor in Chief, Prof. Frank M. Boeckler.
Potential topics include, but are not limited to, the following:
Please submit your manuscript on our website, using the promo code SODHO for 20% off the advertised article processing charge and to indicate that your manuscript will be considered for the “Advances in p53 Drug Discovery” Collection. We will be welcoming relevant papers up until the 30th of April 2026. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.
Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.
Guest Advisors
Prof. Dr. Anna K. H. Hirsch, Saarland University, Germany
Anna Hirsch read Natural Sciences with a focus on Chemistry at the University of Cambridge and spent her third year at the Massachusetts Institute of Technology, doing a research project with Prof. Timothy Jamison. She carried out her Master’s research project in the group of Prof. Steven V. Ley at the University of Cambridge. She received her Ph.D. from the ETH Zurich in 2008 and worked on the de novo structure-based design and synthesis of inhibitors for an anti-infective target enzyme in the group of Prof. François Diederich. Subsequently, she joined the group of Prof. Jean-Marie Lehn at the Institut de Science et d’Ingénierie Supramoléculaires (ISIS) in Strasbourg as an HFSP postdoctoral fellow, before taking up a position as assistant professor at the Stratingh Institute for Chemistry at the University of Groningen in 2010 where she was promoted to associate professor in 2015. In 2017, she moved to the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), where she heads the department for drug design and optimization. Her work focuses on anti-infective drug design by adopting rational approaches such as structure- and fragment-based drug design in combination with the target-guided strategies dynamic combinatorial chemistry and kinetic target-guided synthesis.
Dr. Walid A. M. Elgaher, Saarland University, Germany
Dr. Walid A. M. Elgaher studied Pharmacy at Assiut University (Egypt). He was awarded a scholarship from the German academic exchange service (DAAD) for doctorate study in Germany. In 2016, he got his Ph.D. in Medicinal Chemistry under the supervision of Prof. Rolf W. Hartmann, Saarland University. He then returned to Egypt and was appointed as a Lecturer of Pharmaceutical Organic Chemistry at the Faculty of Pharmacy, Assiut University. In 2017, he joined the group of Prof. Anna K. H. Hirsch as a postdoctoral fellow at HIPS, and since 2024 has been a habilitand at Saarland University. His work focuses on the application of modern drug design approaches tackling un(der)exploited therapeutic targets and the use of biophysical and computational techniques for drug discovery and optimization.
Prof. Dr. Oliver Koch, Universität Münster, Germany
Oliver Koch is Heisenberg-Professor of Computational Drug Discovery at the Institute of Pharmaceutical and Medicinal Chemistry, University of Münster. His interests lie in the development and application of computational methods in rational drug design with focus on ‘big data’ driven decisions and artificial intelligence combined with fragment- and structure-based design. The methods are applied to develop bioactive molecules and to understand selectivity, promiscuity and polypharmacology of protein-ligand interactions. In an interdisciplinary way, the in-silico work is combined with biochemical evaluation, x-ray crystallography and preparative organic synthesis. He received his Ph.D. in Pharmaceutical Chemistry in 2007 at Philipps-University Marburg in the group of Gerhard Klebe and also completed a postgraduate program computer science with focus on machine learning and data science. He worked as a postdoc at CCDC in Cambridge/UK and afterwards for MSD Animal Health Innovation GmbH, Schwabenheim, Germany. In 2012, he became an Independent Junior Group Leader of „In-silico Medicinal Chemistry“ at Technical University Dortmund, Germany. From 2019-22 he was Independent Group Leader for “Computational Medicinal Chemistry and Molecular Design” at University of Münster, where he became a Heisenberg-Professor for Computational Drug Discovery in 2022.
Prof. Dr. Frank M. Böckler, Eberhard Karls University Tübingen
At the Institute of Pharmaceutical Sciences, Frank Böckler heads the laboratory of Molecular Design & Pharmaceutical Biophysics, which combines Chemical Biology, Molecular and Structural Biology and Biophysics, as well as Computational Chemistry, Machine Learning and Molecular Design. In addition, he is a member of the Institute for Bioinformatics and Medical Informatics (IBMI). In 2004, he received his Ph.D. in Medicinal Chemistry with summa cum laude at Friedrich-Alexander University in Erlangen (Germany). Joining Prof. Sir Alan R. Fersht as a postdoc at the MRC Center for Protein Engineering in Cambridge/UK, he discovered p53 mutant stabilizers as potential new cancer therapeutics. In 2008, he was appointed Professor (W2tt) for Bioanalytics at Ludwig-Maximilians University (LMU) Munich, before moving to Tübingen in 2010 as a full professor. His work is dedicated to understanding molecular interactions, such as halogen and chalcogen bonds, as the foundation for chemical biology and drug discovery and to apply theoretical, fragment-based, biophysical, and structural methods to cancer research, particularly involving the human kinome and the network of the tumor suppressor p53.
Modern Computational Approaches for Drug Design and Discovery
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in Drug Design, Development and Therapy on "Modern Computational Approaches for Drug Design and Discovery", organized by Dr. Tamer M Ibrahim Abdelrehim (Kafrelsheikh University, Egypt), Dr. Muzammal Hussain (New York University, USA), Dr. Ahmed Elkerdawy (University of Lincoln, UK) and Editor-In-Chief Dr. Frank M. Böckler (Eberhard Karls University Tübingen, Germany).
Computer-aided drug design (CADD) is a fundamental component of contemporary drug discovery. CADD methods are generally divided into two main categories: Structure-Based Drug Design (SBDD) and Ligand-Based Drug Design (LBDD). The swift advancements in crystallography and homology modeling have greatly improved structure-based virtual screening, facilitating the effective identification of potential drug candidates in the initial stages of drug discovery. Furthermore, the rise in accessible computational power has enhanced the implementation of traditional in silico drug design and discovery methods, allowing for the rapid screening of extensive chemical libraries. CADD methods have garnered significant attention due to their ability to expedite drug discovery while reducing time, labor, and costs. They have emerged as a crucial driving force in drug discovery across both academic and industrial sectors.
Recently, this field has experienced remarkable advancements, largely fueled by the progress of artificial intelligence (AI) including both machine learning and/or deep learning in drug discovery initiatives. The increasing availability of experimental data has facilitated the creation of highly precise AI models, which have a wide range of applications, including predicting the pharmacological activities of molecules, conducting ADME/T profiling, and forecasting molecular properties.
This Collection seeks to gather the most recent advancements in the development and application of computational methods for drug design and discovery, along with their application in preclinical research. We invite submissions from all relevant fields of study, including but not limited to:
• de novo drug design
• lead optimization
• virtual screening methodologies
• AI models to predict molecular activities/properties
• ADME/T property prediction
The collection is primarily open to original research articles, as well as reviews and perspectives.
The deadline for submissions is 31 October 2025. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.
Please submit your manuscript on our website, quoting the promo code EPTVR for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection. Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.
Guest advisors
Dr. Tamer M Ibrahim Abdelrehim, Kafrelsheikh University
Tamer M. Ibrahim Abdelrehim is an Associate Professor of Pharmaceutical Chemistry in the Faculty of Pharmacy, Kafrelsheikh University, Egypt. Prof. Abdelrehim’s research interest includes enhancing the performance of Structure-Based Virtual Screening workflows and fighting infectious diseases using Computer-Aided Drug Design (CADD) methodologies, and Medicinal Chemistry synthesis approaches.
Dr. Muzammal Hussain, New York University
Muzammal Hussain is currently a Postdoctoral Fellow at the New York University Grossman School of Medicine, where his research focuses on targeted protein degradation and drug discovery aimed at addressing challenging disease targets. His interests include structure-based drug design, modeling and analysis of ligand-protein interactions, phenotypic and virtual drug screening, and investigating drug mechanisms and signaling pathways.
Dr. Ahmed Elkerdawy, University of Lincoln
Dr. Ahmed Elkerdawy earned his doctoral degree from the University of Erlangen–Nuremberg - Germany with a specialization in Computer-aided Drug Design (CADD) in the Computer-Chemistry-Centre (CCC) research group. Dr. Elkerdawy has a unique blend of experiences in synthetic chemistry and CADD. He published more than 70 papers dealing with using computer-aided drug design approaches for lead discovery and lead optimization for new targets in the treatment of serious health problems like cancer, Alzheimer’s, and inflammation.
Dr. Frank M. Böckler, Eberhard Karls University Tübingen
At the Institute of Pharmaceutical Sciences, Frank Böckler heads the laboratory of Molecular Design & Pharmaceutical Biophysics, which combines Chemical Biology, Molecular and Structural Biology and Biophysics, as well as Computational Chemistry, Machine Learning and Molecular Design. In addition, he is a member of the Institute for Bioinformatics and Medical Informatics (IBMI). His work is dedicated to understanding molecular interactions, such as halogen and chalcogen bonds, as the foundation for chemical biology and drug discovery and to apply theoretical, fragment-based, biophysical and structural methods to cancer research, particularly involving the human kinome and the network of the tumor suppressor p53.
Nanotechnology in Drug Delivery for Neurodegenerative Diseases
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in Drug Design, Development and Therapy on "Nanotechnology in Drug Delivery for Neurodegenerative Diseases", organized by Dr. Pravin Hivare (University of Utah, US).
Neurodegenerative diseases (NDs), including Alzheimer’s disease (AD), Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis (ALS), and Huntington’s disease (HD), are marked by progressive neuronal loss, resulting in severe cognitive and motor impairments. According to the World Health Organization, AD alone affects over 50 million people globally, with projections suggesting this number could triple by 2050. Current treatments are limited in efficacy, primarily due to the blood-brain barrier (BBB), which restricts the entry of most therapeutic agents into the brain. Furthermore, the complex pathophysiology of NDs necessitates innovative approaches for developing effective disease-modifying therapies.
Nanotechnology offers a promising solution to overcome the challenges posed by the BBB. Nanoparticles (1–100 nm), nanomaterials, and DNA-based devices with specific properties such as size, shape, and surface modifications can facilitate targeted drug delivery to the brain. Nanocarriers like liposomes, polymeric nanoparticles, and dendrimers enhance drug solubility and stability, enabling controlled release, minimizing side effects. Recent advances demonstrate nanotechnology’s potential to deliver diverse therapeutics, including small molecules and gene therapies, revolutionizing treatment for neurodegenerative diseases.
This Article Collection aims to showcase cutting-edge research and promote interdisciplinary collaboration in nanotechnology for drug delivery in NDs. We invite submissions on a variety of topics, including but not limited to: novel nanocarrier design and synthesis, strategies to enhance BBB penetration, in vitro and in vivo evaluation of nanotech-based therapies, clinical translation and trials, safety and toxicity assessments, and emerging fields such as theranostics and personalized nanomedicine. We welcome original research articles, systematic reviews, meta-analyses, clinical trial reports, and perspective pieces that detail the development process of nanotech-based drug delivery systems, from initial design to clinical application. By consolidating the latest research, this collection seeks to accelerate the translation of innovative therapies into clinical practice, ultimately improving outcomes for patients with neurodegenerative diseases.
Please submit your manuscript on our website, using the promo code 975F1 to indicate that your manuscript will be considered for this Collection. We will be welcoming relevant papers up until the 30th of April 2026. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.
Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.
Guest advisor
Dr. Pravin Hivare, University of Utah, US
Dr. Pravin Hivare is a Postdoctoral Fellow in the Department of Neurology at the University of Utah, where he investigates the molecular mechanisms of neurodegenerative diseases using advanced techniques like RNA sequencing, rodent models, and microscopy. His expertise in bionanomaterials, including DNA-based nanodevices, nanomaterials, and hydrogels, supports innovative therapeutic strategies. Dr. Hivare has published extensively in high-impact journals, contributing to neuroscience and drug delivery advancements.
New Trends in Formulations for Oral Inhalation
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in Drug Design, Development and Therapy on "New Trends in Formulations for Oral Inhalation", organized by Prof. Eleonore Fröhlich (Medical University of Graz, Austria) and Dr. Sarah Zellnitz-Neugebauer (Research Center Pharmaceutical Engineering GmbH, Austria).
Inhalation is a promising, noninvasive method of delivering active pharmaceutical ingredients to the lungs. It can achieve high local and systemic concentrations in a short amount of time. However, oral inhalation poses problems as well. Formulating some drugs in high enough amounts, delivering large molecules as stable aerosols, and generating particles of the optimal size (1-5 µm) are challenges. Additionally, inconsistent absorption due to differences in patient anatomy and physiology can lead to less predictable topical and systemic drug levels. The potential of systemic treatment by oral inhalation has not been fully realized. The thin air-blood barrier poses a risk of lung damage, and biocompatibility may be an issue.
The prevalence of chronic pulmonary diseases is increasing worldwide due to an aging population, delayed diagnosis, and air pollution. The prevalence of communicable pulmonary diseases remains a significant global health challenge. The incidence of tuberculosis has peaked due to the outbreak of the novel coronavirus, and pneumonia continues to cause high mortality rates. Engineered dry powders, co-formulations, improved targeting methods (e.g., mucoadhesion), innovative carrier systems (e.g., exosomes), and new therapeutic agents (e.g., biologics) offer opportunities for improved pulmonary treatment. It is also important to understand which anatomical or physiological patient properties may influence drug efficacy and toxicity.
This Collection is interested in tools that may improve the success of orally inhaled formulations in clinics, including new drug particles, targeted delivery approaches, fixed dose combinations, and innovative carriers or drug delivery techniques. This also includes in silico tools that can identify promising drug formulations or predict efficacy and toxicity in patients. Additionally, studies that can explain interpatient differences in pulmonary formulations, and any methods that increase the efficiency of pulmonary delivery are welcome. Further, there is room for a more precise assessment of the biocompatibility and long-term effects of pulmonary formulations.
Please submit your manuscript on our website, using the promo code 0EB1F to indicate that your manuscript will be considered for this Collection. We will be welcoming relevant papers up until the 31st of May 2026. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.
Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.
Guest advisors
Prof. Eleonore Fröhlich, Medical University of Graz
Eleonore Fröhlich is a biochemist and medical doctor with specialization in anatomy, histology, and embryology. She is affiliated with the Medical University of Graz (Director of the Core Facility Imaging, 2007–2024), the Eberhard-Karls University Tübingen (Extraordinary Professor since 2007), and the Research Center Pharmaceutical Engineering (Key Researcher since 2013). Her research activities started with studies on the retina, skin cancer, and thyroid disease at the University of Tübingen. Since the 2010s, her research has focused on the toxicological effects of nano- and microparticles, particularly those inhaled, at the Center for Medical Research in Graz.
Dr. Sarah Zellnitz-Neugebauer, Research Center Pharmaceutical Engineering GmbH
Sarah Zellnitz-Neugebauer is a pharmacist by training. During her PhD at the Graz Technical University (AT) she focused on glass beads as new model carries in dry powder inhalers (DPIs) and gained expertise in particle engineering via surface modification and detailed material characterization. She currently holds the position of Senior Scientist at the Research Center Pharmaceutical Engineering (RCPE) in Graz (AT). Meanwhile, her work centers on tailoring DPI formulations via mechanistic understanding of the interplay of material properties, formulation properties, adhesive-cohesive force balance and drug detachment. Recently, she also took up the field of co-processing of API combinations for inhalation therapy.
Next-Generation Treatments for Depression: From Novel Compounds to Optimized Use of Available Drugs
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in Drug Design, Development and Therapy on "Next-Generation Treatments for Depression: From Novel Compounds to Optimized Use of Available Drugs", organized by Dr. Vassilis Martiadis (Local Health Authority Napoli 1 Centro, Italy) and Dr. Domenico De Berardis (Local Health Authority Teramo, Italy).
Depression is one of the most prevalent and debilitating mental health conditions worldwide. It encompasses a range of clinical presentations, from unipolar major depression to bipolar depression. Furthermore, despite the wide availability of pharmacological treatments, many patients fail to achieve remission. In recent years, there has been a surge in research into novel pharmacological agents, ranging from rapid-acting antidepressants to drugs that target previously unexplored neurobiological mechanisms. At the same time, repurposing established compounds or optimizing existing treatment strategies has opened up new avenues of therapy, particularly for patients with treatment-resistant forms of depression. This article collection aims to explore the full range of emerging pharmacological treatments for depressive disorders.
The need for more effective, individualized pharmacological treatments for depression is greater than ever before. The expansion of pharmacotherapeutic options, including NMDA receptor modulators, multimodal antidepressants and novel mood stabilizers, has introduced promising alternatives to conventional monoaminergic approaches. Additionally, combining therapies or re-evaluating established medications through novel dosing regimens or indications has demonstrated initial efficacy in challenging patient groups. This collection invites studies that critically evaluate the efficacy, safety, mechanisms of action and clinical application of these emerging treatments for unipolar and bipolar depression, including treatment-resistant forms.
We welcome submissions covering a wide range of topics related to the pharmacological treatment of depression. These topics include, but are not limited to, novel antidepressants, glutamatergic agents, fast-acting compounds, polypharmacy strategies, pharmacogenetics and augmentation or combination therapies. We encourage submissions that address both clinical and translational research, as well as systematic reviews, meta-analyses and real-world evidence studies. Particular emphasis will be placed on research related to treatment-resistant and bipolar depression, and on the repositioning of known compounds in new therapeutic contexts. Accepted article types include original research articles, review articles, brief reports and case series.
Please submit your manuscript on our website, using the promo code B3D62 to indicate that your manuscript will be considered for this Collection. We will be welcoming relevant papers up until the 31st of May 2026. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.
Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.
Guest advisors
Dr. Vassilis Martiadis, Local Health Authority Napoli 1 Centro
Dr. Vassilis Martiadis is a psychiatrist and researcher with a strong focus on treatment-resistant depression, psychopharmacology, and personalized mental health care. He collaborates on various national and international projects exploring novel therapeutic strategies for mood disorders. He has authored over 50 peer-reviewed publications (h-index: 23).
Dr. Domenico De Berardis, Local Health Authority Teramo
Dr. Domenico De Berardis is a psychiatrist with extensive clinical and academic experience in mood disorders and psychopharmacology. He collaborates with the University of Chieti-Pescara and L'Aquila, and is Visiting Professor at Samara State Medical University. He has authored over 220 peer-reviewed publications (h-index: 47). His expertise focuses on innovative pharmacological approaches to depression.
Drug, Healthcare and Patient Safety
Medication Safety in Geriatric Populations
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in Drug, Healthcare and Patient Safety on "Medication Safety in Geriatric Populations". The Collection is led by the Editor-in-Chief, Professor Rajender Aparasu.
With the increase in older adults globally, there is a greater need to understand medication safety issues, as older adults are often excluded in randomized trials. In addition, the complexity of chronic care for older adults often leads to polypharmacy and potentially inappropriate medication use, which can result in drug-induced diseases, adverse drug reactions, drug interactions, cognitive impairment, falls, hospitalization, and mortality. This Article Collection aims to address these challenges by bringing together the latest research and clinical insights to improve medication safety in geriatric populations.
Medication safety is crucial in geriatric populations due to the increased susceptibility of older adults to adverse drug reactions and the potential for drug interactions. The aging process can alter pharmacokinetics and pharmacodynamics, making older adults more prone to medication-related problems. Ensuring medication safety in this vulnerable population is essential to prevent medication-related morbidity and mortality and associated healthcare burden such as hospitalization, healthcare costs, and health-related quality of life for older adults.
To help raise the profile of this important area of research, Drug Healthcare and Patient Safety is publishing a timely Article Collection on medication safety in geriatric populations.
Potential topics include, but are not limited to, the following:
1. Medicated-related problems in older adults
2. Polypharmacy and Medication Management
3. Inappropriate Medication Use
4. Drug-drug and Drug-disease Interactions
5. Prescribing Cascade and Deprescribin
All manuscripts submitted to this Article Collection will undergo desk assessment and peer review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are existing members of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.
The deadline for submissions is 31 December 2025.
Please submit your manuscript on our website, quoting the promo code IXNYV for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
- Agents in PrEP strategy
- Delivery models
- Target populations
- Barriers and support
- Education, acceptability, adoption, adherence and retention
HIV/AIDS - Research and Palliative Care
Pre-Exposure Prophylaxis for HIV
We are pleased to announce a new Article Collection in HIV/AIDS - Research and Palliative Care, dedicated to the transformative role of pre-exposure prophylaxis (PrEP) in HIV prevention. Since its clinical introduction, PrEP has revolutionized HIV care, providing significant benefits in preventing transmission, enhancing prevention confidence, and reducing anxiety for at-risk populations.
Given the global importance of PrEP, HIV/AIDS - Research and Palliative Care invites submissions of original research articles, reviews, and perspectives exploring the clinical efficacy, safety, mechanisms of action, and real-world application of this transformative strategy.
The collection, edited by Editor-In-Chief Professor Olubunmi Akindele Ogunrin, will be included in Taylor & Francis’ Game Changer Series. This series features Article Collections focused on breakthrough therapies, drugs, or technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes.
Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.
While the call is open to receive manuscripts across the broad spectrum of PrEP in HIV prevention, the Editors are particularly interested in manuscripts relating to the following areas:
All manuscripts submitted to this Article Collection will undergo a full peer-review. Please review the journal scope and author submission instructions prior to submitting a manuscript. The deadline for submitting manuscripts is 1 April 2026.
Please submit your manuscript on our website. Submitting authors are eligible for a 20% discount on the Article Publishing charge by applying the following code at the point of submission F4375.
If you have any queries regarding the Article Collection or would like to discuss a submission, then please email the Commissioning Editor at [email protected].
Guest Advisors
Olubunmi Akindele Ogunrin, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, United Kingdom
Stigma and discrimination in HIV prevention and care
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Stigma and discrimination in HIV prevention and care" in HIV/AIDS - Research and Palliative Care.
Despite the biomedical advancements in HIV prevention and treatment, and evolving public discourse on sexuality, HIV-related stigma persists, posing a significant challenge to the quality of life and mental health of people living with HIV (PLHIV). In the current context, marked by new prevention methods, innovative treatments, and a complex interplay with conservative political landscapes, novel forms of stigma and discrimination emerge, impacting both prevention and treatment efforts.
This Article Collection aims to examine the complex effects of HIV-related stigma, encompassing a myriad of forms, on the treatment and care of PLHIV. This Collection invites contributions from a variety of perspectives, including but not limited to, examinations of the effects of stigma and discrimination on PLHIV, particularly in terms of health outcomes, barriers to treatment, and strategies to overcome them. We welcome studies exploring how gender identity, sexual orientation, ethnicity, socioeconomic status, and other socioeconomic variables, modulate HIV-stigma experience and both mental and physical health outcomes among different populations and contexts. We are also interested in research on interventions and policies that aim to reduce HIV-related stigma and discrimination, and improve the mental health and well-being of PLHIV through capacity building and social inclusion. Additionally, we welcome articles that develop instruments to assess HIV-related variables, including stigma, adherence to treatment, knowledge, and attitudes.
In line with this publication's commitment to high standards and a global approach, we will seek to ensure that published articles represent diversity in international contexts, disciplinary approaches, and contributors, with particular focus on the Global South and underrepresented populations. Our objective is to promote a worldwide discussion regarding the effects of stigmatization of individuals living with HIV, enabling readers to understand the intricacies of health inequalities that emerge in diverse settings and populations.
All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisors for this collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.
The deadline for submitting manuscripts is 31 January 2026.
Please submit your manuscript on our website, quoting the promo code WKFVI for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
Please contact Zhiyuan Zhang at [email protected] with any queries regarding this Article Collection.
Guest Advisors
Angelo Brandelli Costa, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Brazil; John Cabot University, Italy
Psychologist. Professor at the Pontifical Catholic University of Rio Grande do Sul (PUCRS), Brazil and John Cabot University, Rome. Researches and publishes extensively on social psychology, particularly in areas like prejudice, discrimination, and LGBTQ+ psychology. Has a strong academic presence and is recognized for his work in these fields.
Guilherme W Wendt, Faculty of Medicine, Western Paraná State University, Brazil
Psychologist. Professor at the Faculty of Medicine, Western Paraná State University, Brazil. Researches and publishes in the areas of clinical psychology, psychoanalysis, and gender studies. Has a strong academic background, and is known for his work related to gender and sexuality.
Henrique Pereira, University of Beira Interior, Portugal
Clinical Psychologist, specialist in Clinical and Health Psychology and Sexology, and Full Professor of Clinical Psychology and Sexuality at the University of Beira Interior - UBI, Covilhã (Portugal), Department of Psychology and Education. Holds a doctorate in Clinical Psychology, and a Master’s degree in Health Psychology. Develops work and research in the fields of Psychology, Sexuality, Health, Human Development and Aging.
Felipe Alckmin-Carvalho, University of Beira Interior, Portugal
Clinical Psychologist. Holds a Doctorate in Clinical Psychology (University of São Paulo, Brazil). Currently a Visiting Assistant Professor in the Department of Psychology and Education at the University of Beira Interior, Covilhã, Portugal, where he is also a post-doctoral researcher. Develops work and research in the fields of Health Psychology, HIV/AIDS, Stigma and Sexuality.
- Natural Autoantibodies
- Autoimmune disorders: New epidemiological data
- Pathophysiology of autoimmune diseases
- Novel diagnostic and therapeutic approaches for autoimmune disorders
- Therapeutic targeting of autoantibodies
- Clinical utilization of autoantibodies
- Regulatory immune cells for the treatment of autoimmune diseases
- Autoantigenomics
- AI in autoimmunity
- Autoimmune- and inflammatory- related epilepsy including new-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES).
- Multiple sclerosis (MS).
- Myelin oligodendrocytes antibodies associated disease (MOGAD).
- Neuromyelitis optica spectrum disorder (NMOSD).
- Autoimmune encephalitides (AE).
- Acute disseminated encephalomyelitis (ADEM).
- Primary angiitis of the CNS.
- Secondary CNS vasculitis.
- Limbic encephalitis.
- Cerebellar ataxia.
- Progressive multifocal leukoencephalopathy.
- Acute necrotizing encephalopathy,
- Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids(CLIPPERS).
ImmunoTargets and Therapy
Autoimmune Disease
Immunotargets and Therapy is pleased to invite you to submit your research to its latest Article Collection on "Autoimmune Disease.” The Collection, led by Editor-In-Chief Professor Michael Shurin, welcomes relevant Reviews, Original Research and Editorials up until the 1st January 2026. The Collection promises to be a valuable resource for years to come, with articles published alongside some of our finest hot-topic reviews.
Please submit your manuscript on our website, using the promo code ZFWRR for 20% off the advertised article processing charge and to indicate that your manuscript will be considered for the “Autoimmune Diseases” Collection.
Please contact Ashley Ambros at [email protected] with any queries and discount codes regarding this Article Collection.
While the call is open to receive manuscripts across the broad spectrum of autoimmune diseases, the Editors are particularly interested in manuscripts relating to these key areas:
CombImmunoTherapy: Personalizing Oncology Treatment
ImmunoTargets and Therapy is pleased to announce a new Article Collection dedicated to examining CombImmunoTherapy (CIT) as a game-changing oncology treatment strategy.
This Collection, edited by the Editor-In-Chief Prof. Michael R. Shurin, is part of the new Game Changer series of Article Collections, focusing on breakthrough therapies, drugs, and technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes.
In 2011, the first immunotherapy for cancer was approved. Since then, the FDA has approved at least 11 immune checkpoint inhibitors and other types of immunotherapies, including CAR T-cell therapies. Currently, there are more than 1,000 immunotherapy clinical trials underway across the United States alone, with 15-20% of patients experiencing robust results. While immunotherapy has significant promise, traditional methods of cancer treatment, such as chemotherapy and radiation therapy, still prevail as the first line of treatment. As we learn more about factors such as the tumor microenvironment that influence treatment efficacy, one thing remains clear – there is a great need for personalized combination therapy. CIT provides a more tailored approach, allowing oncologists flexibility to effectively treat each individual patient.
While this call is open to receive manuscripts highlighting all aspects of CIT, the Editors are particularly interested in manuscripts relating to the following areas:
• Preclinical models investigating combinatorial immunotherapy strategies
• Promising combinatorial approaches currently in trial
• Interaction, safety, and contraindication data
• Current therapeutic drugs/antibodies in the pipeline
• Mechanistic action, targets, and immune effects of CIT
• Immunotherapy in combination with traditional chemotherapy and/or radiation therapy
• Cancer vaccines for CIT
• Combinational immunotherapy of patients with cancer and comorbid immune-mediated diseases
Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.
Submitting authors are eligible for a 20% discount on the Article Publishing charge by applying the following code at the point of submission: 0A8F9. All manuscripts submitted to this Article Collection will undergo desk assessment and a full peer review. Please review the journal scope and author submission instructions prior to submitting a manuscript as it will be rejected if it does not fall within the scope of the journal.
Please submit your paper on our website. The deadline for submitting manuscripts is 1 June 2026.
If you have any queries regarding the Article Collection or would like to discuss a submission, please email the Commissioning Editor, Ashley Ambros at [email protected].
Pathogenesis and Therapy of CNS Immune-Mediated Diseases
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Pathogenesis and Therapy of CNS Immune-Mediated Diseases" in ImmunoTargets and Therapy.
Central nervous system (CNS) immune-related diseases include a broad range of conditions whereby the immune system abnormally targets the brain, spinal cord, or other neuronal tissues. The origin of these diseases can be autoimmune, inflammatory, infectious, or paraneoplastic. Autoimmune conditions include epilepsy, multiple sclerosis (MS), myelin oligodendrocytes antibodies associated disease (MOGAD), neuromyelitis optica spectrum disorder (NMOSD), autoimmune encephalitides, and acute disseminated encephalomyelitis (ADEM). Inflammatory conditions can include epilepsy, primary angiitis of the CNS and secondary CNS vasculitis. Paraneoplastic neurological syndromes comprise of limbic encephalitis and cerebellar ataxia. Infectious or post-infectious diseases consist of cerebellitis and progressive multifocal leukoencephalopathy The underlying mechanisms of the these conditions include T-cell-mediated damage, antibody-mediated injury, microglial activation and blood-brain barrier (BBB) disruption Therapies for these conditions include immunosuppressants (steroids, rituximab, cyclophosphamide), plasma exchange, intravenous immunoglobulin as well as disease-modifying therapies such as ocrelizumab, tociluzumab and natalizumab.
Studying CNS immune-related diseases is critically important for several reasons. These diseases have high disease burden and poor outcomes; they cause severe disability, chronic pain, cognitive decline and even death. They affect children, young and middle-aged adults mostly, leading to significant socioeconomic impacts due to loss of work force and long-term dependency. These conditions have complex and poorly understood mechanisms. Understanding the underlying mechanisms can reveal new therapeutic targets. There is a limited treatment options and the available ones are expensive. Most of the available therapies such as steroids, immunosuppressants and monoclonal antibodies have serious side effects. Of concern, some patients are treatment-resistant, underscoring the need for exploring precision medicine approaches. Exploring CNS immunity can reveal how the brain interacts with peripheral immune cells, which can be applied to other conditions. In a nutshell, this topic is essential to pave the way for the development of the safer therapies and uncover fundamental brain-immune interactions that could transform treatment for neurological diseases.
Although the Collection is open to receiving manuscripts across the broad spectrum of central nervous system (CNS) immune-related diseases, the Editors are principally interested in manuscripts relating to the mechanisms and/or treatment of these conditions:
This Collection, led by Prof Lifen Yang, welcomes relevant original research papers, reviews (critical reviews and systematic reviews), and case series until the 31st January 2026. The Collection promises to be a valuable resource for years to come, with articles published alongside some of our finest hot-topic reviews.
Please submit your manuscript via our website. Upon submission, please use the promo code CDCFE to indicate that your manuscript will be considered for the “Molecular and Cellular Mechanisms of Hypersensitivity” Collection. Please note that normal Article Processing Charges will apply.
Guest advisers
Prof. Lifen Yang, Xiangya Hospital, Central South University
Dr. Miriam Kessi, Xiangya Hospital, Central South University
Treating Comorbid Immune-Mediated Diseases with Immunotherapy
ImmunoTargets and Therapy is pleased to announce a new Article Collection dedicated to examining immunotherapy strategies to treat comorbid immune-mediated diseases.
Patients with comorbid immune-mediated diseases have at least two or more autoimmune, allergic, infectious or inflammatory diseases that significantly impact their quality of life. Some conditions typically co-occur together, such as Sjogren’s Syndrome and Systemic Lupus Erythematosus. Other diseases may be a result of shared inflammatory signaling pathways or caused by the primary immune-mediated disease. Treating patients with comorbid immune-mediated diseases presents a unique challenge, as treatment may require a multidrug regimen with multiple opportunities for drug interaction.
In this Article Collection, we seek to explore the mechanistic underpinnings of immune-mediated disease comorbidities and potential opportunities for immunotherapeutic treatment. While this call is open to receive manuscripts highlighting all aspects of comorbid immune-mediated disease therapy, the Editors are particularly interested in manuscripts relating to the following areas:
• Cell-based therapeutics such as stem cell and CAR-T cell-mediated therapies
• Novel preclinical models, shared disease pathway targets, and mechanism of action studies
• Emerging immunotherapeutic treatment options and strategies
• Clinical management strategies such as combination therapy and therapeutic resistance
• Special patient populations, including immune disorders involving multiple systems
• Immune-related adverse events while treating comorbid diseases
• New use cases for already-approved immunotherapy to target multiple disease pathways
• Regulation of immunological balance in treating comorbid diseases
All manuscripts submitted to this Article Collection will undergo desk assessment and a full peer review. Please review the journal scope and author submission instructions prior to submitting a manuscript as it will be rejected if it does not fall within the scope of the journal.
Please submit your paper on our website, quoting the promo code 86788 to indicate that the paper is intended for the Article C0llection. The deadline for submitting manuscripts is 1 June 2026.
If you have any queries regarding the Article Collection or would like to discuss a submission, please email the Commissioning Editor, Ashley Ambros at [email protected].
- Multidrug Resistance
- Antibiotic Stewardship
- Infection Control
- Novel Therapies
- Epidemiology
- Molecular diagnostics
- Microbiome analysis
- Resistance profiling
- Clinical implementation & therapeutic drug monitoring
- Personalized therapy in specific populations, including pregnancy.
- Economics and cost-effectiveness
- Ethical and regulatory considerations
- Patient education and engagement
- The performance of AI/machine learning techniques in combating antimicrobial resistance
- Studies relating to emerging resistance patterns and potential hotspots
- Design and evaluation of user-friendly machine learning decision support systems
- Challenges and opportunities for practical implementation
- Topics relating to ethics, data privacy, and algorithmic bias
Infection and Drug Resistance
Emerging Trends in Multidrug-Resistant Infections
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Emerging Trends in Multidrug-Resistant Infections" in Infection and Drug Resistance.
Multidrug-resistant infections represent a critical global health crisis, posing significant threats to public health, economics, and patient safety. As resistance to antibiotics increases, healthcare providers face a diminishing arsenal of effective treatments, complicating the management of infections and leading to higher morbidity and mortality rates. This situation results in longer hospital stays and increased medical costs, imposing a substantial economic burden on healthcare systems. Vulnerable populations, such as the elderly and immunocompromised individuals, are particularly at risk, underscoring the urgency to confront this challenge. Moreover, the global nature of infectious diseases means that resistance can lead to widespread outbreaks that transcend national borders, necessitating coordinated global responses and enhanced surveillance efforts.
Addressing multidrug resistance is essential to protect public health, preserve modern medical achievements, and ensure that effective treatment options remain available for future generations. It becomes imperative to understand the epidemiology, mechanisms, and clinical implications of these infections.
This Article Collection aims to unite innovative research that examines the numerous facets of multidrug resistance, including the mechanisms of antibiotic resistance, the epidemiology of multidrug resistance pathogens, outbreaks by multidrug resistance, the role of novel therapeutic strategies such as phage therapy and antimicrobial peptides, public health implications, and effects on patient outcomes. Additionally, contributions addressing the socioeconomic impact of drug resistance, public health interventions, and strategies for infection prevention and control are welcome. Articles on the development of rapid diagnostics and stewardship programs that promote responsible antibiotic use will also be prioritized.
Preferred article types for this Collection are original research, reviews, guidelines, expert opinions, commentary and clinical studies in all areas of infection and drug resistance that provide insights into emerging trends and innovative solutions in the fight against multidrug-resistant infections.
By featuring groundbreaking studies from various disciplines, we aim to provide a thorough overview that enriches future research and clinical practice. We invite researchers worldwide to submit their manuscripts that explore new trends, emerging patterns, and potential solutions for combating multidrug-resistant infections. This is a vital opportunity to contribute to a critical dialogue aimed at improving global health outcomes in an era where resistance threatens to outpace available treatments. Join us in this essential conversation and share your findings with the broader scientific community.
Keywords
All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.
The deadline for submissions is 31 December 2025.
Please submit your manuscript on our website, quoting the promo code KTNFZ for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
Please contact Zhiyuan Zhang at [email protected] with any queries regarding this Article Collection.
Guest advisor
Muhammad A. Halwani, Al Baha University, Faculty of Medicine, Saudi Arabia
Dr. Muhammad A Halwani a distinguished professor and consultant specializing in infection control, boasting over 21 years of extensive experience in this vital field. His expertise spans infection control, hospital epidemiology, and clinical microbiology, making him a leading figure in advancing research and practice. As the editor of this special issue, Dr. Halwani warmly invites researchers to contribute their innovative findings and insights, fostering a collaborative environment for sharing knowledge and advancing the field.
Personalized Antimicrobial Strategies: A Path to Precision Therapy
Dove Medical Press is pleased to announce a new Article Collection in Infection and Drug Resistance, dedicated to the game-changing role of personalised antimicrobial strategies in managing infectious disease.
In contrast to the standard “one-size-fits-all" approach to prescribing antibiotics, personalized antimicrobial strategies involve using advanced diagnostics and data-driven approaches to determine the best course of treatment for an individual patient. Bringing a precision medicine approach to infectious disease management improves patient outcomes and promotes antimicrobial stewardship.
In light of the growing importance of personalized antimicrobial techniques, Infection and Drug Resistance invites submissions of original research articles, reviews, and perspectives that advance our understanding and use of these strategies.
The Collection, Edited by Editor-In-Chief Professor Oliver Planz, will be included in Taylor & Francis’ Game Changer Series. This series features Article Collections focused on breakthrough therapies, drugs, or technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes.
While the call is open to receive manuscripts across the broad spectrum of personalized antimicrobial strategies, the Editors are particularly interested in manuscripts relating to the following areas:
Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.
All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.
The deadline for submissions is 1 January 2026.
Please submit your manuscript on our website, quoting the promo code LTMAV for a 20% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
Please contact Zhiyuan Zhang at [email protected] with any queries and discount codes regarding this Article Collection.
Guest Advisor
Oliver Planz, University of Tübingen, Germany
Respiratory Syncytial Virus (RSV): progress, challenges and outcomes
Respiratory Syncytial Virus (RSV) can lead to symptoms akin to the common cold or winter flu, runny nose, cough, fever and so on. While the body can conquer the infection by itself, there are serious implications to being infected with RSV, as it is a common cause of pneumonia or bronchitis in infants aged under one year of age. Vulnerable patients, including the elderly and immunocompromised, may also be put at risk of further harm from an RSV infection.
During the COVID-19 pandemic, a dip in RSV infections was noted in the United States, meaning the pandemic could have influenced the transmission of RSV during this period. This Thematic Series will consider how infection rates prior to the pandemic differ from to those from 2020 onwards. Questions we’ll be asking include the factors leading to these changes, how does COVID-19 infection affect RSV, or mortality rates. The body’s immunity response will also have a vital role in this Thematic Series, to provide further understanding on where the dangers of RSV lie.
Considering these topics, we hope the submissions will culminate into a fount of knowledge about RSV. This includes efforts to find successful treatments and preventions for RSV, such as antiviral drugs and vaccinations. What sort of treatment should drug developers be looking for? Do we need to take consideration of special populations? These facets of a complicated infection – such as RSV – will be accounted for in this crucial Thematic Series.
The journal is seeking original submissions and review articles on the following topics related to RSV:
• Infection rates before and since the COVID-19 pandemic
• Driving factors behind the infection changes
• Immunity cell responses to RSV and the role of antiviral inhibitors
• RSV interactions with cell receptors
• Infant mortality rates from RSV
• Pneumonia deaths originating from RSV infection
• Interaction between COVID-19 and RSV infections
• Different vaccination types currently in development (e.g., Live attenuated, mRNA, polyvalent etc.)
The deadline for submissions is 31 May 2025.
Please submit your manuscript on our website, quoting the promo code PUYAG to indicate that your submission is for consideration in this Article Collection.
Unlocking Drug Resistance Prediction with AI
Dove Medical Press is pleased to announce a new Article Collection in Infection and Drug Resistance, dedicated to the role of artificial intelligence (AI) in the prediction of drug resistance.
AI has the potential to revolutionize patient care, offering significant benefits in predicting drug response and resistance and improving antibiotic stewardship. Given the importance of AI in this setting, we are pleased to invite submissions of original research articles, reviews, and perspectives on the topic.
The Collection, edited by Editor-In-Chief Professor Oliver Planz, will be included in Taylor & Francis’ Game Changer Series. This series features Article Collections focused on breakthrough therapies, drugs, or technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes. Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.
While the call is open to receive manuscripts across the broad spectrum of AI in predicting drug resistance, the Editors are particularly interested in manuscripts relating to the following areas:
All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.
The deadline for submissions is 1 January 2026.
Please submit your manuscript on our website, quoting the promo code AOWGL for a 20% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
Please contact Zhiyuan Zhang at [email protected] with any queries and discount codes regarding this Article Collection.
Guest Advisor
Oliver Planz, University of Tübingen, Germany
- Clinical Effectiveness Evaluation: Investigate the efficacy and safety of telepharmacy services compared to traditional pharmaceutical care in a variety of medical conditions. This could include collecting data on clinical outcomes, compliance rates, and patient satisfaction.
- Technology Integration: Study how the incorporation of emerging technologies, such as artificial intelligence and machine learning, can improve pharmaceutical decision making, drug-drug interaction identification, and treatment personalization.
- Data Security and Patient Privacy: Investigate advanced data security methods to protect patient privacy and ensure the integrity of health information transmitted through telepharmacy platforms.
- Reimbursement Models and Economic Sustainability: Explore sustainable reimbursement models for telepharmacy that incentivize the delivery of high-quality services and encourage pharmacist involvement in healthcare.
- Pharmacist Education and Training: Investigate how effective training can be provided to pharmacists to acquire the skills needed in the telepharmacy environment and keep up with technological advances.
- Access and Equity: Examine how telepharmacy can address disparities in access to pharmaceutical care, especially in rural and underserved areas.
- Multidisciplinary Integration: Investigate how more effective collaboration between pharmacists and other healthcare professionals can be achieved through telepharmacy for comprehensive patient care.
- Patient Experience: Study patient satisfaction and preferences in the use of telepharmacy and how to improve the overall patient experience.
- Regulation and Standards: Investigate how regulations and standards are evolving in response to the growth of telepharmacy and how they can be adapted to ensure patient safety and quality of care.
- Cost and Societal Benefit Assessment: Conduct cost-benefit analyses to determine the financial and societal impact of telepharmacy on the healthcare system as a whole.
Integrated Pharmacy Research and Practice
Telepharmacy Innovations: The Great Opportunity for Advancing Healthcare in the Digital Age
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Telepharmacy Innovations: The Great Opportunity for Advancing Healthcare in the Digital Age" in Integrated Pharmacy Research and Practice.
Telepharmacy, an innovative branch of pharmacy that uses technology to provide services remotely, has emerged as a crucial response to changing healthcare needs in the digital age. Its importance lies in its ability to overcome geographic barriers and increase patient access to quality pharmaceutical services. As the world faces challenges such as the COVID-19 pandemic, telepharmacy has become a valuable resource for ensuring continuity of care and reducing the risk of exposure to the virus in healthcare settings.
However, despite its growth and acceptance, telepharmacy remains an evolving field that requires continued research. Research is critical to better understand how to maximize its effectiveness, ensure patient safety, and address ethical and legal issues. In the future, potential lines of research could focus on improving communication technologies, integrating effectively with other healthcare professionals, identifying appropriate reimbursement models, and exploring how telepharmacy can be used in primary and specialty care settings.
The new concept and model of pharmaceutical care presents telepharmacy as a great opportunity for permanent and real-time contact with the patient.
Potential subtopics:
All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisor for this collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.
The deadline for submitting manuscripts is December 31 2025.
Please submit your manuscript on our website, quoting the promo code KAIKS to indicate that your submission is for consideration in this Article Collection.
Guest Advisor
Ramón Alejandro Morillo Verdugo, Associate Professor, Hospital Pharmacy, University of Seville, AGS Sevilla Sur, Hospital de Valme
Dr. Ramón Alejandro Morillo Verdugo has worked at Hospital Pharmacy Seville since 2006. He has been an Associate Professor at University of Seville since 2011. He is also the Spanish national coordinator of the “MAPEX Project” from SEFH since 2014.
- Balance and falls
- Gait and locomotion
- Physical therapy and pulmonary rehabilitation
- Muscle fatigue and weakness
- Extra-pulmonary function including exercise capacity
- Assessment of COPD comorbidities by HRCT
- Lung cancer as fatal COPD comorbidity
- Overlap syndrome: COPD and sleep apnea
- Impact of diabetes on COPD
- Management of heart failure in COPD
- Risk of atherosclerosis in chronic respiratory diseases
- Link between COPD and autoimmune diseases
- New phenotype IPF plus emphysema
- COPD
- Comorbidities
- Obstruction
- Non-pharmacological interventions
- Physiological
- Physical
- Psychological
- Outcomes
International Journal of Chronic Obstructive Pulmonary Disease
Biomechanical Advancements in COPD
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Biomechanical Advancements in COPD" in the International Journal of Chronic Obstructive Pulmonary Disease.
Extra-pulmonary functional decline is common in patients with chronic obstructive pulmonary disease (COPD). These include but are not limited to muscle fatigue, muscle weakness, falls, slower gait speed, and decreased physical activity. Biomechanics, the study of forces and how they act upon a body, can contribute greatly to our understanding of mechanisms leading to dysfunction. Biomechanical studies have provided insight into changes in balance, gait, muscle mechanics, and breathing mechanics to name a few. The use of biomechanical tools such as motion capture has been used to develop optoelectronic plethysmography allowing for study of lung volume contributions to breathing mechanics. Despite the uses of biomechanics in studying COPD, there remains a need to investigate functional outcomes, rehabilitation strategies, and preventative interventions.
Major extra-pulmonary patient concerns include increased fear of falling, increased falls, muscle fatigue, and/or muscle weakness, to name a few. Physiological mechanisms to these functional outcomes has been studied in considerable detail, and these studies have provided advancements in treatment. Extra-pulmonary functional decline that progresses with disease severity may be independent of a decline in lung function. It is important to intervene early and precisely to slow the progression of extra-pulmonary functional decline. Rehabilitation strategies are needed to restore or maintain levels of function. Further, there may be functional outcomes that decline in patients with COPD that have been considered part of the aging process, yet are tied to the pathophysiology of the disease. Biomechanical studies may complement mechanistic physiological investigations. Further, biomechanical assessments in clinic may provide an additional dimension of disease severity.
This Collection will bring together articles focused on extra-pulmonary functional outcomes associated with COPD, with special emphasis on biomechanics-based approaches. Articles may include investigations into mechanisms, both physiological and psychological, driving functional decline; advances in rehabilitation and treatment strategies to restore or maintain function; advancements in early identification of functional decline; precision medicine and treatments to slow the progression of functional decline; and similarly related topics. Preferred article types include original research, reviews, short report, and methodology. Other article types may be considered.
Keywords
All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisors for this collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.
The deadline for submitting manuscripts is 31 January 2026.
Please submit your manuscript on our website, quoting the promo code XEVGI for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
Please contact Zhiyuan Zhang at [email protected] with any queries regarding this Article Collection.
Guest Advisors
Stephan I Rennard, University of Nebraska Medical Center, USA
Professor Rennard trained in pulmonary medicine at the NIH, joined University of Nebraska Medical Center as Chief, Pulmonary Medicine in 1984 where he remains Professor of Medicine. He has conducted basic and clinical investigations focusing on chronic obstructive pulmonary disease. He was a member of the original GOLD guidelines committee and has served on the Board of Directors of the American Thoracic Society, the American Lung Association, the COPD Foundation and the Alpha 1 Foundation. Currently he serves as the Medical Director for the Alpha 1 Foundation Therapeutic Development Network.
Jennifer Yentes, Texas A&M University, USA
Dr. Yentes' research focuses on functional resiliency and reserve in older adults, and in patients with COPD. Dr. Yentes’ group highlighted biomechanical changes in gait in persons with chronic obstructive pulmonary disease. She has also explored the clinical utility of locomotor respiratory coupling in this population. Her research has shown that non-varying coupling is related to energy expenditure.
Impact of comorbidities on COPD
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Impact of comorbidities on COPD" in the International Journal of Chronic Obstructive Pulmonary Disease.
Chronic obstructive pulmonary disease is a leading cause of morbidity and mortality worldwide with an economic and social burden that is both substantial and increasing. A number of meta-analyses and systematic reviews provide evidence that prevalence of COPD is appreciable higher in smokers compared to non-smokers, in those >40 years of age compared to those <40, and in men compared to women. COPD is a progressive respiratory condition often accompanied by various comorbidities that significantly affect patient outcomes. It is estimated that 80% of COPD patients are likely to have at least one comorbidity. An increasing number of people in any aging population will suffer from multi-morbidity, defined as the presence of two or more chronic conditions, and COPD is present in most multi-morbid patients. The systemic involvement in patients with COPD, as well as the interactions between COPD and its comorbidities, justify the description of chronic systemic inflammatory syndrome.
The pathogenesis of COPD is closely linked with aging, as well as with cardiovascular, endocrine, musculoskeletal, renal, and gastrointestinal pathologies. These complex interactions are based on chronic low-grade systemic inflammation, chronic hypoxia, and multiple common predisposing factors, and are currently under intense research. The incidence of comorbidities increases later in life, decreasing the quality of life of patients with COPD, as well as complicating the management of the disease.
We welcome reviews and original articles. Potential topics of this Article Collection include but are not limited to:
Keywords
All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisors for this collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.
The deadline for submitting manuscripts is 30 June 2026.
Please submit your manuscript on our website, quoting the promo code 5293F to indicate that your submission is for consideration in this Article Collection.
Please contact Zhiyuan Zhang at [email protected] with any queries regarding this Article Collection.
Guest Advisors
Alexandru Corlateanu, Nicolae Testemitanu State University of Medicine and Pharmacy, Moldova
Dr. Alexandru Corlateanu is the Professor and chief of Department of Respiratory medicine at State University of Medicine and Pharmacy "Nicolae Testemitanu", Chisinau, Moldova. He is National Leader for Moldova at The Global Initiative for Chronic Obstructive Lung Disease (GOLD) and member of the The Global Initiative for Asthma (GINA) Assembly for Moldova. He has written over 50 peer-reviewed articles and several book chapters. He is a reviewer for multiple reputed journals in the field of respiratory diseases.
Alexandr Ceasovschih, Grigore T. Popa University of Medicine and Pharmacy, Romania
MD, PhD, Assistant Professor in Grigore T. Popa University of Medicine and Pharmacy, Internal Medicine and Cardiology Consultant in Clinical Emergency Hospital Sfântul Spiridon, Iași, România. His Clarivate Web of Science h-index and consistent publication record reflect meaningful academic involvement, with a focus on areas of Internal Medicine. He is young fellow of European Society of Atherosclerosis and deputy editor in the European Journal of Preventive Cardiology, as well as reviewer in many Clarivate Web of Science journals.
Pradeesh Sivapalan, Herlev & Gentofte University Hospital, Denmark
Pradeesh Sivapalan is a respiratory physician and clinical researcher based in Denmark. His research focuses on acute and chronic respiratory infections, COPD, and the use of biomarkers and randomized trials to guide treatment strategies. He has authored several high-impact publications and leads or co-leads multiple national and international research projects, including large pragmatic trials and registry-based studies. Pradeesh is also involved in medical education and mentoring of early-career researchers.
Non-Pharmacological Interventions for Improving Physiological, Physical, and Psychological Health Outcomes in Individuals with COPD
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Non-Pharmacological Interventions for Improving Physiological, Physical, and Psychological Health Outcomes in Individuals with COPD" in the International Journal of Chronic Obstructive Pulmonary Disease.
Optimal management of COPD includes non-pharmacological interventions including pulmonary rehabilitation, smoking cessation, disease self-management, medication adherence, routine vaccinations, oxygen therapy and ventilatory support, and physical activity promotion. This Article Collection highlights new and innovative non-pharmacological interventions for improving physiological, physical, and psychological outcomes in individuals with COPD.
COPD is a leading cause of morbidity, disability, and mortality worldwide. The disease affects the whole person impacting physiological (e.g., lung function), physical (e.g., physical activity, exercise capacity), and psychological (i.e., depression) outcomes. Non-pharmacological interventions are part of guideline-based care for COPD. Yet, gaps in the management of COPD exist. Many non-pharmacological interventions are underutilized and/or benefits dwindle over time. For example, while pulmonary rehabilitation remains the gold-standard for improving an array of health outcomes, it remains severely underused and benefits begin to wane after 12 months. New and novel non-pharmacological intervention can supplement existing non-pharmacological interventions for individuals with COPD with the potential to improve physiological, physical, and psychological outcomes.
This Article Collection seeks articles focused on intervention development and testing (from preliminary/pilot to effectiveness, implementation and dissemination studies) of interventions targeting improvement in physiological, physical, and/or psychological outcomes. We welcome original research articles, short reports, and systematic reviews. Study protocols of highly innovative non-pharmacological interventions will also be considered. Interventions may include a single component (e.g., balance training) or multiple components (e.g., complex behavioral interventions). Interventions that include chronic pain management, treatment of sleep disturbances, integrative therapies such as mind-body interventions, and psychotherapies (i.e., cognitive behavioral therapy) are salient to this Article Collection. Outcomes should broadly fall within the categories of: physiological, physical, and psychological domains and may include primary and/or secondary outcomes, as well as secondary analysis of completed trials. Moderator and/or mediation analyses of completed trials asking how and for whom interventions work are also welcomed.
Keywords
All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisors for this collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.
The deadline for submitting manuscripts is 2 April 2026.
Please submit your manuscript on our website, quoting the promo code 15402 for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
Please contact Zhiyuan Zhang at [email protected] with any queries regarding this Article Collection.
Guest Advisors
Patricia M. Bamonti, VA Boston Healthcare System, Harvard Medical School, USA
Patricia M. Bamonti, PhD, ABPP, Assistant Professor of Psychology, Department of Psychiatry, Harvard Medical School, is a Staff Psychologist at VA Boston Healthcare System. Dr. Bamonti studies the impact of depression and anxiety symptoms on health outcomes in the context of pulmonary rehabilitation and physical activity interventions. She is currently developing and testing an integrated physical activity intervention with cognitive behavioural therapy for individuals with COPD and comorbid depression and/or anxiety.
Marilyn L. Moy, VA Boston Healthcare System, Harvard Medical School, Boston University Chobanian & Avedisian School of Medicine, USA
Marilyn L. Moy, M.D., M.Sc., Associate Professor of Medicine, Harvard Medical School, is a Staff Pulmonary Physician at VA Boston Healthcare System. She is Medical Director of the Pulmonary Rehabilitation Program, accredited by the American Association of Cardiovascular and Pulmonary Rehabilitation. Dr. Moy studies the role of physical activity in the risk stratification of COPD, technology-based interventions to promote PA, and the biological mechanisms underlying the beneficial effects of PA on COPD outcomes.
- Chronic obstructive pulmonary disease (COPD)
- Pulmonary hypertension
- Pulmonary fibrosis
- Genetic factors of pulmonary health
- Environmental and lifestyle factors affecting pulmonary health
International Journal of General Medicine
Today in Pulmonary Medicine from the Bench to Bedside and Beyond
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Today in Pulmonary Medicine from the Bench to Bedside and Beyond" in the International Journal of General Medicine.
The International Journal of General Medicine seeks to publish innovations in clinical, translational, and basic science that improve our knowledge and management of pulmonary diseases. Although the scope of pulmonary medicine is vast, we seek impactful contributions that use state-of-the-art approaches to promote lung health in the areas of obstructive airways disease, fibrosis, pulmonary hypertension, sleep, neural control of breathing, environmental medicine, and population health. Topics may also include new therapeutics, biomarkers, diagnostics, devices, and new research methodology.
Lung diseases represent one of the most widespread and severe categories of medical conditions globally. In the United States alone, tens of millions of people are affected by various forms of lung disease, ranging from mild respiratory issues to life-threatening conditions. These diseases include chronic obstructive pulmonary disease (COPD), asthma, pulmonary fibrosis, and lung cancer, among others. The primary causes of lung disease are well established: tobacco smoke—both firsthand and secondhand exposure—remains the leading risk factor. In addition, respiratory infections such as pneumonia and influenza can significantly damage lung function, particularly in vulnerable populations. Genetic factors also play a critical role, with inherited conditions like cystic fibrosis contributing to chronic respiratory problems. Environmental pollutants, occupational exposures, and lifestyle factors further compound the risk, making lung health a critical area of public health concern.
Article types such as Original Research, Reviews and Commentaries are welcomed. Case reports/series are not sought; any submitted to the International Journal of General Medicine will be diverted to the International Medical Case Reports Journal.
Topics of interest include but are not limited to:
Innovative pulmonary therapeutics
Keywords
1 Respiratory
2. Lung
3. Airways
4. Fibrosis
5. Population health
All manuscripts submitted to the Article Collection will undergo a full peer-review; the Guest Advisor for this collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.
Please submit your manuscript on our website, quoting the promo code 5E564 to indicate that your submission is for consideration in this Article Collection. The deadline for submitting manuscripts is March 16 2026.
Guest Advisor
Professor Reynold A. Panettieri, Jr., MD, Rutgers University, New Brunswick, NJ USA
- Design and synthesis of novel polymeric carriers with nanoscale precision for enhanced oral drug delivery.
- Mechanistic studies on drug-polymer interactions and release kinetics within the gastrointestinal environment.
- Advances in bioadhesive, mucoadhesive, and stimuli-responsive polymer systems designed for oral drug administration.
- The application of computational and machine learning approaches in the realm of polymer-mediated oral drug delivery, particularly in predicting nanoparticle behavior, optimizing formulations, and identifying potential candidates for further development in nanomedicine.
- In vitro and in vivo evaluation of polymeric carriers for oral therapeutics.
- Novel lipid nanoparticle formulations and characterization
- Optimization of mRNA delivery systems and targeting strategies
- Scalable manufacturing processes & stability optimization
- mRNA-based vaccines for infectious disease
- mRNA-based therapies for genetic diseases including metabolic disorders, hemophilia, and neurological conditions
- Cancer vaccines and immunotherapies
International Journal of Nanomedicine
Advances in Polymeric Carriers for Oral Drug Delivery
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Advances in Polymeric Carriers for Oral Drug Delivery", organized by Dr. Wing-Fu Lai (University of Leeds, UK) in the International Journal of Nanomedicine.
Nanomedicine has emerged as a transformative field, revolutionizing various aspects of drug delivery, particularly in the realm of oral administration. Oral drug delivery continues to be the most preferred route due to its convenience, patient compliance, and cost-effectiveness. Nonetheless, numerous therapeutic agents face significant challenges such as poor solubility, stability, and bioavailability, which severely restrict their clinical efficacy when administered orally.
In recent years, nanomedicine-based approaches, especially the use of polymeric carriers, have gained considerable attention as promising solutions. These polymeric carriers, often operating at the nanoscale level, can effectively protect drugs from the harsh gastrointestinal conditions encountered during oral delivery. Moreover, they possess tunable physicochemical properties that can be precisely engineered to enhance mucosal adhesion and drug absorption, which are crucial for improving the overall bioavailability and therapeutic outcome.
The integration of computational modeling and advanced characterization techniques has further propelled the rational design of polymer-based nanosystems for oral drug delivery. These cutting-edge tools enable researchers to predict and optimize the behavior of polymeric carriers in complex biological environments, ensuring improved efficacy and safety profiles.
This Article Collection aims to provide a comprehensive platform for showcasing the latest research findings and critical reviews on the development, characterization, and application of polymeric carriers within the context of nanomedicine-driven oral drug delivery. We welcome original research articles and review papers covering, but not limited to:
By gathering contributions from experts across materials science, pharmaceutical technology, and nanomedicine, this Article Collection aims to highlight the current progress and future directions in the field of nanomedicine-based oral drug delivery. It seeks to foster interdisciplinary collaboration and innovation, driving the development of more effective and safe oral drug delivery systems that can overcome the existing challenges and unlock new therapeutic possibilities.
All manuscripts submitted to this Article Collection will undergo full peer-review; Guest Advisors will not be handling submitted articles. Please review the journal’s aims and scope and author submission instructions prior to submission.
Please submit your manuscript through the Dovepress website. During submission, enter the promo code JBKQL for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
The manuscript submission deadline is 31 December 2025.
Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.
Guest advisor
Dr. Wing-Fu Lai, University of Leeds
Dr. Wing-Fu Lai obtained his MSc degree in Materials Engineering and Nanotechnology from the City University of Hong Kong, and earned his PhD in Chemistry from the University of Hong Kong. He is currently an Associate Professor in School of Food Science and Nutrition at the University of Leeds. His research focus lies in the development and engineering of polymeric materials for food and pharmaceutical applications. He has been ranked among the world's top 2% of scientists by Stanford University.
Gamechanger Series: Transformative Applications of Lipid Nanoparticles in mRNA Therapeutics
We are pleased to announce a new Article Collection in the International Journal of Nanomedicine, dedicated to the game-changing role of lipid nanoparticles (LNP) in the area of mRNA Therapeutics. Since their clinical introduction, mRNA-LNP therapeutics have revolutionized patient care, offering significant benefits in speed of development, therapeutic efficacy, and targeted delivery for eligible patients.
Given the global importance of mRNA-LNP vaccines in COVID-19, and their potential for use in other infectious diseases, cancer, and genetic disorders, the International Journal of Nanomedicine is inviting submissions of original research articles, reviews, and perspectives exploring the clinical efficacy, safety, mechanisms of action, and real-world application of these transformative therapies.
The Collection, edited by Editor-In-Chief Prof. RDK Misra, will be included in Taylor and Francis’ Game Changer Series. This series features Article Collections focused on breakthrough therapies, drugs, or technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes. Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.
While the call is open to receive manuscripts across the broad spectrum of LNP in mRNA therapeutics, the Editors are particularly interested in manuscripts relating to the following areas:
Please review the journal’s aims and scope and author submission instructions prior to submission.
Please submit your manuscript through the Dovepress website. During submission, enter the promo code 0BEC2 for a 20% discount on the publishing fee and to indicate that your submission is for consideration in this Article Collection. The manuscript submission deadline is 30 June 2026.
Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.
Nanomedicine for Cancer and Autoimmune Immunotherapy
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in the International Journal of Nanomedicine on "Nanomedicine for Cancer and Autoimmune Immunotherapy", organized by Dr. Yonghyun Lee (Ewha Womans Unniversity, South Korea).
Immune-mediated diseases, including autoimmune disorders and cancer, represent major global health burdens arising from immune system dysfunction. Conventional therapies aim to suppress or activate immune responses, yet their lack of specificity often results in systemic toxicity, off-target effects, and limited therapeutic efficacy. Current immunotherapies often involve a trade-off between therapeutic efficacy and safety. In autoimmune diseases, broad immunosuppression increases infection risk, causes systemic side effects, and provides limited activity at disease sites. In cancer, immunotherapies such as immune checkpoint blockade, cancer vaccines, and tumor microenvironment (TME) modulators aim to activate antitumor responses but often lack specificity, leading to systemic toxicity and limited effectiveness. Therefore, the development of nanotechnology-based therapeutic strategies is urgently needed to enhance target-site efficacy while minimizing systemic side effects in both cancer immunotherapy and autoimmune disease treatment.
Nanomedicine has emerged as a promising approach to address these challenges by enabling precise control over drug release, biodistribution, and immune cell targeting. Using nanocarriers, immunomodulatory agents can be selectively delivered to inflamed tissues or lymphoid organs via various administration routes, including intravenous, subcutaneous, intramuscular, oral, and mucosal. With rational nanocarrier design and route optimization, nanomedicine facilitates context-specific immune modulation—tailoring therapies to induce either anti-inflammatory or immunostimulatory effects with high precision. This strategy offers particular promise for achieving localized immunosuppression in autoimmune diseases and enhancing tumor-specific immunity in cancer therapy.
This Collection aims to spotlight recent advances in nanomedicine that harness diverse delivery strategies to fine-tune immune responses in both autoimmune diseases and cancer immunotherapy. Thus, this Collection invites submissions focused on nanomedicine-based strategies for immune modulation in both autoimmune diseases and cancer immunotherapy. We welcome original research articles and comprehensive reviews. Interdisciplinary contributions that integrate pharmaceutics, nanotechnology, immunology, and translational science are particularly encouraged.
Relevant topics include, but are not limited to: (1) nanomedicine for cancer immunotherapy, including the targeted delivery of antigens, immune enhancers, or modulators to tumors or lymphoid tissues; and (2) nanomedicine for autoimmune diseases, involving site-specific delivery of antigens or immunosuppressive agents to inflamed tissues or immune organs.
This Collection aims to catalyze the development of next-generation immune-modulating therapies that are safer, more effective, and precisely targeted.
Please review the journal’s aims and scope and author submission instructions prior to submission.
Please submit your manuscript through the Dovepress website. During submission, enter the promo code 855FE to indicate that your submission is for consideration in this Article Collection. The manuscript submission deadline is 30 April 2026.
Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.
Guest advisor
Prof. Yonghyun Lee, Ewha Womans Unniversity
Professor Yonghyun Lee is an Associate Professor at the College of Pharmacy, Ewha Womans University. He is focusing on the development of innovative strategies, aimed at targeted-modulating gut microbiome, apoptosis, and/or immune systems for the effective management of inflammation-related diseases, especially inflammatory bowel diseases, and cancer. He has published extensively in high-impact journals such as Nature Materials, Nature Communications, Angewandte Chemie, and ACS Nano. Also, he has been recognized with multiple research excellence awards including the KAST Promising Young Scientist Award and Ewha’s Award for Research Excellence.
Shaping the Tumor Microenvironment with Nanomedicine
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in the International Journal of Nanomedicine on "Shaping the Tumor Microenvironment with Nanomedicine", organized by Guest Advisor Dr. Yong Teng.
The tumor microenvironment (TME) is a unique ecosystem surrounding a tumor, comprising various cells, molecules, and structures that interact with cancer cells. This environment plays a critical role in promoting tumor growth, enabling immune evasion, and driving treatment resistance. Traditional cancer therapies often struggle to penetrate and alter this dynamic ecosystem, making the TME a prime target for innovative therapeutic approaches.
Nanomedicine has emerged as a powerful tool to directly modulate the TME. By designing nanoparticles to deliver drugs, genetic material, or immunomodulatory agents specifically to the tumor site, researchers can precisely target and remodel components of the TME. One notable application is the use of immunostimulatory nanoparticles to enhance T-cell infiltration into the TME to counteract the immunosuppressive conditions established by many tumors. Nanoparticle-based neoantigen vaccines are another promising frontier in cancer treatment, exploiting the specificity of tumor neoantigens to engage the immune system in a targeted and personalized attack on cancer. These innovations hold great potential for more effective and targeted cancer therapies. In addition, recent advances in nanomedicine are enabling responsive nanoparticles that can release their therapeutic payload upon detection of specific signals within the TME, such as a drop in pH or the presence of certain enzymes. While challenges remain - such as ensuring targeted delivery and minimizing off-target effects - ongoing research continues to reveal innovative ways to use nanomedicine to alter the TME and improve therapeutic outcomes. As these technologies evolve, nanomedicine has the potential to reshape the therapeutic landscape by transforming the TME from a cancer-supportive niche to an environment that actively combats tumor growth.
All manuscripts submitted to this Article Collection will undergo full peer-review; Guest Advisors will not be handling submitted articles. Please review the journal’s aims and scope and author submission instructions prior to submission.
Please submit your manuscript through the Dovepress website. During submission, enter the promo code UUQVA for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
The manuscript submission deadline is 1 March 2026.
Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.
Guest advisor
Dr. Yong Teng, Emory University
Dr. Teng’s primary research interests focus on connecting three major themes—tumor microenvironment, tumor metabolism, and metastasis—by studying tumor-immune interactions and developing combination antitumor therapies and treatment strategies. He also has extensive experience in drug discovery, nanomedicine, and biomarker studies. He has published over 160 papers in high-profile journals.
- Technological advancements in screening methods: HPV-based testing, AI-assisted cytology, and novel biomarkers for early detection.
- Addressing health disparities: strategies to improve screening access in low-resource settings, marginalized communities, and high-risk populations.
- Implementation challenges: cost-effectiveness, national program scalability, and overcoming cultural/behavioral barriers to screening adherence.
- Follow-up and clinical management: protocols for abnormal results, colposcopy, biopsy and treatment of precancerous lesions, balancing overtreatment risks and undertreatment delays
- Emerging paradigms: role of self-sampling, telemedicine, and vaccination-screening synergies in eradicating cervical cancer.
International Journal of Women's Health
Cervical Cancer Screening: From Detection to Management
We are pleased to announce a new Article Collection in the International Journal of Women’s Health, dedicated to the game-changing role of screening in the management of cervical cancer. Since their introduction, cervical cancer screening programs have revolutionized patient care, offering significant benefits in the early detection and prevention of advanced disease. As a cost-effective public health strategy, screening has reduced cervical cancer mortality rates worldwide, particularly in countries with organized screening programs.
Given its global importance, the International Journal of Women’s Health is welcoming the submission of original research articles, reviews, and perspectives on the topic of cervical cancer screening.
The collection, edited by the Editor-In-Chief Professor Elie D. Al-Chaer, is part of the new Game Changer series of Article Collections, focusing on breakthrough therapies, technologies, or protocols that have significantly altered the standard of care.
While the call is open to receive manuscripts across the broad spectrum of screening in cervical cancer, the Editors are particularly interested in manuscripts relating to the following areas:
Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.
All manuscripts submitted to this Article Collection will undergo desk assessment and a full peer-review. Please review the journal scope and author submission instructions prior to submitting a manuscript. The deadline for submitting manuscripts is 1 April 2026.
Please submit your manuscript on our website, quoting the promo code 2341B for a 20% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
Conservative Management of Endometriosis: Strategies, Insights, and Innovations
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Conservative Management of Endometriosis: Strategies, Insights, and Innovations" in the International Journal of Women's Health.
Endometriosis is a complex clinical entity with a large socioeconomic impact. It affects women during their reproductive years and is a major cause of infertility in the developed world. Endometriosis has a multifactorial etiology and its management can be divided into two categories: 1. Conservative 2. Interventional-surgical. In many cases they can be combined in order to achieve better therapeutic results. The main clinical symptom is pelvic pain, which can be acute or chronic. Conservative management is based on pharmacotherapy mainly of the clinical entity. In addition, it may encompass various non-surgical methods and remedies that may ameliorate the symptoms and limit the expansion of the disease. In this Article Collection, we will endeavor to focus on the conservative management of endometriosis. New strategies, insights and innovations will be discussed in detail. Possible future perspectives, limitations and side effects of the conservative management will be analyzed.
Endometriosis is a global disease which may lead to social and financial issues in aspects of a national health system. It is related to numerous surgical interventions on young women that endanger their future fertility. It is a major cause of absence of women during their reproductive period from their educational and work activities. Therefore, a conservative treatment is an alternative which may decrease the leave of women due to surgical interventions and also assist women in their everyday activities without requiring hospitalization. Surgical interventions for endometriosis require skilled surgeons and everyday training, a reality which is not cost-effective. So, the importance of inventing new regimens and new conservative technologies is without doubt a necessity. In the new era of artificial intelligence, the possible implementation of a new strategy in the assistance of medicine has to be emphasized.
In this Article Collection we welcome all type of articles, original research, clinical studies, reports, editorials, reviews, and commentaries. The articles should be related with the conservative management of Endometriosis and will focus on the following topics.
1. New experimental drugs for the management of Endometriosis.
2. Conservative management of pain symptomatology in patients with Endometriosis.
3. Side-effects and contra-indications for conservative management of Endometriosis.
4. Induction of ovulation and assisted reproductive techniques in patients with Endometriosis.
5. Alternative conservative management of Endometriosis.
6. Genetic mechanisms of treatment and future perspectives.
9. The role of artificial intelligence in the conservative management of endometriosis.
10. Classical treatment and etiological factors.
11. Evaluation and review of current guidelines.
All manuscripts submitted to this Article Collection will undergo desk assessment and a full peer-review. Please review the journal scope and author submission instructions prior to submitting a manuscript. The deadline for submitting manuscripts is 31 March 2026.
Please submit your manuscript on our website, quoting the promo code 82D45 to indicate that your submission is for consideration in this Article Collection.
Please contact Menghan Li at [email protected] with any queries and discount codes regarding this Article Collection.
Guest advisors
Prof. George Iatrakis, University of West Attica, Greece
Dr. Nikolaos Vlachadis, General Hospital of Messinia, Greece
- Rare or underreported malignancies
- Unusual presentations or complications of common cancers
- Innovative uses of targeted therapies, immunotherapies, or combination regimens
- Ethical and logistical challenges in oncological care
- Long-term survivorship and quality-of-life considerations
International Medical Case Reports Journal
Advancing Oncology through Clinical Case Reports: Insights, Challenges, and Future Directions
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in the International Medical Case Reports Journal on “Advancing Oncology through Clinical Case Reports: Insights, Challenges, and Future Directions”, organized by our Associate Editors-in-Chief Prof. Xudong Zhu from University of Kentucky, USA, and Prof. Jiawen Bu from Shengjing Hospital of China Medical University, China.
Clinical case reports in oncology provide critical insights into rare malignancies, atypical treatment responses, and novel therapeutic approaches. These reports bridge the gap between theoretical research and real-world clinical practice, offering clinicians and researchers actionable knowledge to improve patient outcomes.
This Article Collection aims to compile high-quality case studies that highlight diagnostic dilemmas, innovative therapies, and multidisciplinary management strategies in oncology.
Oncology is a rapidly evolving field where individualized patient care is paramount. Case reports serve as foundational tools for identifying emerging trends, unexpected side effects, and therapeutic breakthroughs. By documenting unique clinical scenarios, this collection will foster a deeper understanding of tumor biology, resistance mechanisms, and personalized treatment paradigms. Such knowledge is vital for advancing global cancer care and informing future clinical trials.
We invite submissions of case reports, case series, and clinical vignettes that address the following subtopics:
All submissions must align with the journal's scope of translational and clinical research.
Please submit your manuscript on our website, using the promo code FB6C1 for 20% off the advertised article processing charge and to indicate that your manuscript will be considered for the “Advancing Oncology through Clinical Case Reports: Insights, Challenges, and Future Directions” Collection. We will be welcoming relevant papers up until the 30th June 2026.
Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.
Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.
Diagnostic Dilemmas and Therapeutic Insights in Cardiovascular Case Reports
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Diagnostic Dilemmas and Therapeutic Insights in Cardiovascular Case Reports", in the International Medical Case Reports Journal, organized by our Associate Editors-in-Chief Dr. Vinay Kumar from Pennsylvania State University Hershey Medical Center, USA, and Ms. Anuradha Tyagi from Institute of Nuclear Medicine & Allied Sciences, India.
Cardiovascular diseases remain the leading cause of morbidity and mortality worldwide, spanning a broad spectrum of presentations, complexities, and therapeutic challenges. Case reports play a unique and indispensable role in cardiology by capturing novel presentations, rare complications, unexpected treatment responses, and innovative diagnostic approaches. This Article Collection aims to highlight clinically significant case reports that enhance our understanding of cardiovascular and vascular conditions and inform frontline clinical decision-making.
Despite rapid advances in cardiovascular medicine, clinicians continue to encounter unexpected or atypical patient scenarios. Case reports serve as valuable educational tools, offering real-world insights beyond the confines of large trials and guidelines. They often provide the first glimpse of emerging diseases, drug side effects, procedural innovations, and complex comorbidities. By systematically gathering high-quality case reports, we create a platform that promotes shared clinical learning and fosters global dialogue on rare and instructive cardiovascular phenomena.
This Article Collection invites submissions that align with the scope of Case Reports in Cardiology, focusing on all aspects of heart and vascular health. Subtopics may include - but are not limited to - ischemic heart disease, structural heart defects, electrophysiological disorders, valvular diseases, cardiomyopathies, vascular anomalies, endovascular interventions, and cardio-oncology. We welcome classical case reports, case series, clinical images, and brief communications that offer new insights, challenge existing paradigms, or prompt further investigation. Submissions should clearly articulate the educational value and clinical relevance of the case, ideally supported by imaging, histopathology, or procedural documentation where applicable.
Please submit your manuscript on our website, using the promo code 71858 for 20% off the advertised article processing charge and to indicate that your manuscript will be considered for the “Diagnostic Dilemmas and Therapeutic Insights in Cardiovascular Case Reports” Collection. We will be welcoming relevant papers up until the 31st May 2026.
Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.
Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.
- Signaling pathways and cellular targets
- Novel mechanisms of action of new candidate biologics
- Anti IL-4 and IL-13 combination biologics and monoclonal antibodies
- Treatment and dosing strategies based on asthma typing
- Biologic switching and combination therapy
- Long-term efficacy and safety studies
Journal of Asthma and Allergy
Targeted Personalized Biologic Therapies: Changing the Game in Asthma Treatment
Dove Medical Press is pleased to invite you to submit your research to the upcoming Article Collection “Targeted Personalized Biologic Therapies: Changing the Game in Asthma Treatment” in the Journal of Asthma and Allergy.
This Collection, edited by the Editor-In-Chief Dr. Amrita Dosanjh, is part of the new Game Changer series of Article Collections, focusing on breakthrough therapies, drugs, and technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes.
Asthma is a chronic inflammatory lung condition that results in airway obstruction and difficulty breathing. Left untreated, severe asthma flares can lead to hospitalization and even death. Typical front-line treatments of asthma include corticosteroids (which cause immunosuppression with long-term use) and bronchodilators (such as albuterol inhalers). While biologic therapy is relatively new in asthma treatment, Global Initiative For Asthma (GINA) guidelines include biologics as therapeutic options. There are several biologics currently available and in development for the treatment of asthma.
While the call is open to receive manuscripts across the broad spectrum of asthma-modulating biologics, the Editors are particularly interested in manuscripts relating to the following areas:
Submitting authors are eligible for a 20% discount on the Article Publishing charge by applying the following code at the point of submission SRNMA. If you have any queries regarding the Article Collection or would like to discuss a submission, then please email the Commissioning Editor Ashley Ambros at [email protected].
Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.
All manuscripts submitted to this Article Collection will undergo desk assessment and a full peer-review. Please review the journal scope and author submission instructions prior to submitting a manuscript as it will be rejected if it does not fall within the scope of the journal.
Please submit your manuscript on our website. The deadline for submitting manuscripts is 1 April 2026.
- Papers focusing on peri-operative immunotherapy approaches in early-stage HCC to improve resectability, induce pathologic responses at time of surgery, and/or reduce rate of recurrence after resection.
- Papers related to the intermediate/advanced HCC setting focusing on potential mechanisms of:
- Resistance to immunotherapy in advanced HCC based on different risk factor, e.g. viral vs. non-viral related HCC and MASH-related HCC.
- Synergy between immunotherapy and targeted and other systemic therapies.
- Synergy between immunotherapy and localized therapy approaches to improve response rates and survival outcomes.
Journal of Hepatocellular Carcinoma
Addressing Global Differences in HCC Risk Factors and Management Strategies
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Addressing Global Differences in HCC Risk Factors and Management Strategies" in the Journal of Hepatocellular Carcinoma.
The Journal of Hepatocellular Carcinoma solicits papers addressing global diversity in HCC risk factors and their effect on outcomes. Although significant advances have been made in multidisciplinary and individualized screening and treatments for HCC, such sophisticated methods are relatively expensive and therefore remain beyond the reach of many patients in less economically developed countries where local resources and healthcare budget are limited. To address the global differences in treatment provision, the journal Editors are seeking to publish multidisciplinary clinical and translational studies, cost-effective screening and treatment strategies and consensus statements, including those which consider available local resources.
Please contact Cassie Houtz at [email protected] with any queries.
Please view the journal Aims and Scope and author submission guidelines. The deadline for submissions is 1 December 2025.
Please submit your manuscript on our website, quoting the promo code UIPMT for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
Immune Checkpoint Inhibitors (PD-1/PD-L1) in Hepatocellular Carcinoma Treatment
The Journal of Hepatocellular Carcinoma is pleased to announce an upcoming Article Collection dedicated to the transformative role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Immune checkpoint inhibitors targeting PD-1 and PD-L1 have significantly impacted the treatment landscape for HCC. By blocking the signals that prevent T-cells from attacking cancer cells, these inhibitors enhance the immune system's ability to combat tumors. These therapies have shown potential in improving survival rates, reducing tumor burden, and providing durable responses in patients who previously had few effective options.
Given the impact and continued role of immune checkpoint inhibitors in treating HCC, we welcome submissions of original research articles, reviews, and perspectives that contribute to the understanding and advancement of these therapies. Of particular interest would be:
This Article Collection will be included in a wider Game Changer Series focused on breakthrough therapies across medicine. Papers published within the Game Changer series will benefit from additional promotional activities across Taylor & Francis and Dove Medical Press, increasing the discoverability and visibility of your research.
Please view the journal Aims and Scope and author submission guidelines. The deadline for submissions is 1 April 2026.
Please submit your manuscript on our website. Submitting authors are eligible for a 20% discount on the Article Publishing Charge. To apply this discount, enter the code SDSZG when prompted during submission.
Please contact Commissioning Editor Cassie Houtz at [email protected] with any questions.
- Tumor necrosis factor inhibitors
- Interleukin inhibitors
- Monoclonal antibody specificity studies
- Novel mechanisms of action of new candidate biologics
- The role of biosimilars in treating inflammatory disease
- Indications and contraindications
- Cell-based therapies to quell inflammation
- Molecular drivers of inflammaging
- Biomarkers of inflammaging for early detection of cardiovascular and age-related diseases
- Emerging signalling pathways linking chronic low-grade inflammation, oxidative stress and mitochondrial dysfunction in aging vascular system
- Interplay between immune cell senescence and inflammaging in chronic disease progression
- Novel animal models and experimental tools for studying inflammaging mechanisms.
- Therapeutic strategies for counteract inflammaging, such as cytokine inhibitors, senolytics or anti-inflammatory drugs aimed at restoring vascular and systemic health
- Dietary and lifestyle interventions including the impact of prebiotics, and probiotics on inflammaging and healthy aging
- Inflammaging
- Cardiovascular disease (CVD)
- Immunosenescence
- Senolytics
- Chronic inflammatory diseases
- Clinical studies on the efficacy and safety of IL-4 and/or IL-13 inhibitors
- Novel drug mechanistic actions
- Biologics directed against cells or pathways involved in the IL-4/IL-13 axis
- New drug candidates directed against IL-4 and/or IL-13
- Tailoring treatment in individuals with multiple Type 2 inflammatory conditions
- Drugs to treat non-allergic type 2 inflammation, such as nasal polyps
- Treatment strategies and potential side effects
Journal of Inflammation Research
Anti-inflammatory Biologics – A Game Changer for Chronic Inflammation
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Anti-inflammatory Biologics – A Game Changer for Chronic Inflammation", in the Journal of Inflammation Research.
This Collection, edited by the Editor-In-Chief Prof. Ning Quan, is part of the new Game Changer series of Article Collections, focusing on breakthrough therapies, drugs, and technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes.
Chronic inflammation is the hallmark of many diseases. These conditions can be crippling to patients. Traditional anti-inflammatory drugs, such as non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids, are non-specific, causing further systemic problems with continued use. By contrast, biologic therapies harness the specificity necessary to relieve inflammation while also reducing off-target and non-specific effects.
While this call is open to receive manuscripts highlighting all anti-inflammatory biologics, the Editors are particularly interested in manuscripts relating to the following areas:
Submitting authors are eligible for a 20% discount on the Article Publishing charge by applying the following code at the point of submission: OTIPZ. If you have any queries regarding the Article Collection or would like to discuss a submission, then please email the Commissioning Editor Ashley Ambros ([email protected]). Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.
All manuscripts submitted to this Article Collection will undergo a full peer-review. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript. Please submit your manuscript on our website. The deadline for submitting a manuscript is 1 April 2026.
Cellular and Molecular Drivers of Lung Inflammation in Respiratory Diseases
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Cellular and Molecular Drivers of Lung Inflammation in Respiratory Diseases", in the Journal of Inflammation Research.
Lung inflammation is a hallmark characteristic feature of many respiratory diseases, from asthma and chronic obstructive pulmonary disease (COPD) to pulmonary fibrosis and acute respiratory distress syndrome (ARDS). While inflammation serves as a protective role in response to infection or injury, dysregulated or persistent inflammatory responses can lead to progressive lung damage and impaired respiratory structure and function. Understanding the cellular and molecular drivers behind lung inflammation is crucial for developing targeted therapies that can modulate these pathways without compromising host defense. This topic explores the intricate network of immune and structural cells, signaling pathways, and other cofounding factors that orchestrate inflammatory responses in the lung. This study will offer valuable insight into both disease mechanisms and potential intervention points.
This topic is important because it establishes the foundational understanding of lung inflammation, a key driver of the onset, progression, and severity of numerous respiratory diseases that together pose a significant global health burden.
Studying this topic also matters as it provides following additional advantages:
• Better Understanding of Disease Mechanisms
• Development of Targeted Therapies
• Early Diagnosis and Biomarkers tools
• Understanding Environmental and Infectious Triggering agent
The subject of this Collection, "Cellular and Molecular Drivers of Lung Inflammation in Respiratory Diseases," explores the complex cellular and molecular processes that drive and regulate lung inflammation. It covers key subtopics including immune cell activation, structural cells dysfunction, cytokine and chemokine signaling, and the impact of environmental and infectious triggers on pulmonary inflammation. Special attention will also be given to emerging therapeutic targets and biomarker discovery. This scope is well-aligned with the Journal of Inflammation Research, which emphasizes cutting-edge studies on inflammation-related processes. The ail of this collection will be to encourage the submission of original research articles, comprehensive reviews, and brief reports that will provide new insights into the cellular and molecular understanding of lung inflammation in both acute and chronic respiratory diseases.
Keywords
1. Lung inflammation
2. Respiratory diseases
3. Immune cell signaling
4. Cytokines and chemokines
5. Biomarkers of lung disease
All manuscripts submitted to this Article Collection will undergo a full peer-review. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.
Please submit your manuscript on our website, using the promo code 5DF61 to indicate that the manuscript is intended for this Article Collection. The deadline for submitting a manuscript is 2 March 2026.
Guest Advisors
Dr. Ashish Kumar, North Dakota State University
I am a Doctoral Graduate Research Assistant in pharmaceutical sciences, specializing in the pathophysiology of asthma. My research explores the dynamic relationship between lung physiology and hormonal influences in disease conditions, aiming to advance respiratory pharmacology and personalized medicine.
Dr. Nilesh Sudhakar Ambhore,University of Minnesota
I am a dedicated and self-motivated research scientist with over 8 years of extensive experience in pharmacology, molecular biology, small molecule drug discovery, and target validation. My proven expertise encompasses the entire preclinical drug development process, including development of in vivo disease models, mechanism of action investigation, endpoint analysis, and disease modelling.
Inflammaging in Cardiovascular and Chronic Disease
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Inflammaging in Cardiovascular and Chronic Disease", in the Journal of Inflammation Research.
Inflammaging is a persistent, low-grade sterile inflammation associated with aging. It is characterized by elevated circulation of proinflammatory cytokines, chemokines and other inflammatory mediators in the circulation, reflecting a fundamental imbalance in intercellular communication and inflammatory control. Multiple lines of evidence indicate that inflammaging arises from a convergence of factors including immune cell dysregulation, immunosenescence, chronic infections, cellular senescence and genetic predisposition. Other than this, metabolic and environmental contributors such as central obesity, increased gut permeability, shifts in microbiota composition further exacerbates this process. At the molecular level, excessive production of reactive oxygen species, dysfunctional mitochondria play pivotal role in chronic inflammation. This persistent inflammatory state not only accelerates cellular senescence but also impairs immune system, leading to severe implications in tissue homeostasis. Thus, inflammation is recognized as an intrinsic driver of aging process and key contributor to pathogenesis of multiple chronic diseases.
Inflammaging is the major contributor to cardiovascular disease (CVD), the leading cause of morbidity and mortality worldwide. In 2021 alone, CVDs were responsible for 20.5 million deaths, accounting for roughly one-third of all global deaths. Beyond CVD, inflammaging is also recognized as a risk factor for several chronic conditions including cancer, kidney disease, diabetes mellitus, depression, dementia, sarcopenia, and frailty. Despite its well documented pathologic role across diverse diseases the precise molecular mechanism that regulate inflammaging remains incompletely understood and relatively understudied. Therefore, a comprehensive understanding of these processes holds great promise for the development of novel treatment strategies that could significantly improve the clinical outcome. Targeting inflammaging is a particularly appealing as it offers potential not only to prevent CVD but also to slow the broader health decline associated with ageing. Importantly interventions that modulating inflammation may be most effective if implemented early in the trajectory of age-related physiological decline.
This Article Collection aims to focus on the latest developments in understanding the role of inflammaging in the pathogenesis of cardiovascular and chronic inflammatory diseases. We welcome contributions that explore inflammaging across molecular, cellular and disease levels, with a focus on uncovering its mechanism and identifying innovative therapeutic strategies. By advancing knowledge in this area, the collections seeks to highlight novel targets for preventing and alleviating CVD, chronic inflammation and age-related diseases.
Submissions to this topic may include, but are not limited to, the following potential areas of research:
This Article Collection welcomes submissions of the following article types: Original Research Articles, Brief Research Reports, Case Reports, Reviews and Mini-reviews.
Keywords
All manuscripts submitted to this Article Collection will undergo a full peer-review. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.
Please submit your manuscript on our website, using the promo code 2E6D0 to indicate that the manuscript is intended for this Article Collection. The deadline for submitting a manuscript is 1 June 2026.
Please contact Ashley Ambros at [email protected] with any queries and discount codes regarding this Article Collection.
Guest Advisor
Dr. Vigneshwaran Vellingiri, University of Illinois, Chicago
Inflammatory Disorders and Diseases of Environmental Etiology
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Inflammatory Disorders and Diseases of Environmental Etiology", in the Journal of Inflammation Research.
Chronic inflammation is a key pathological feature underlying development and progression of chronic diseases including cardiovascular, respiratory, and neurodegenerative disorders. Inflammation is triggered by various environmental insults such as long-term exposure to toxic particles (PM2.5, ultrafines or nanoparticles), industrial chemicals (immunotoxicants), biological agents and infections, and climate change. On the other hand, occupational exposures to toxic particles or fibers, industrial and agricultural chemicals are among the major factors associated with chronic inflammatory disorders in adults. Certain communities living in the areas with inadequate zonal policies, or working in settings with higher and prolonged exposure to such pollutants, are at a greater risk of developing chronic inflammatory disorders. Additionally, children born in or living in such areas have arrested growth and higher rate of developmental disorders.
Published studies have consistently reported that exposed individuals may suffer chronic inflammation in different organs due to differential modulation of innate or adaptive pathways locally or systematically leading to development or exacerbation of inflammatory and/or developmental disorders. Chronic inflammatory and developmental disorders with environmental origins are poorly characterized in terms of their etiology, underlying mechanisms, potential therapeutic targets and targeted therapeis due to unique pathological manifestations in these disorders.
Environmental etiology of chronic inflammatory and developmental disorders is an important public health concern that needs to be addressed. Vulnerable communities often suffer from greater exposure risks and limited healthcare access leading to underdiagnosis of inflammatory and developmental disorders. Advancements in public health and mechanistic research to address these issues may unravel the causative factor(s), pathological mechanisms, and exposure limits of the key environmental factors responsible for disease burden. Additionally, such research advancements could help unravel potential therapeutic targets and facilitate development of targeted therapies for environmentally-induced chronic disroders. Research in these directions will promote the health equity and minimize the disease burden.
Original Research articles: Original articles may be focused on either mechanistic or epidimiological studies addressing the chronic inflammatory and developmental disorders associated with exposure to pollutants including particulates (natural or engineered) or chemical agents (metals, PFAS, pesticides, etc.), infectious agents or their antigens, climate change, or other environmental factors. Experimental studies using cellular or animal models should define the resemblance of the models with the real-world exposure scenario in human population. Animal studies could be focused on addressing the toxicological aspects, identifying molecular targets, biomarkers of exposure or effect, and/or targeted therapies, and proposing potential intervention/mitigation strategies. Epidimiological studies could focus on identifying the populations at risk of chronic inflammatory or developmental disorders and the associated environmental exposures and risk factors. Besides focusing on the current levels of exposure in the populations at risk, epidemiological studies may also focus on developing/recommending the permissible limits of these toxicants in residential and occupational settings.
Comprehensive Review Articles: Review articles addressing the pathologies of chronic inflammatory or developmental disordrs of environmental origin using experimental models could incorporate source of release of toxicant in the environment, exposure routes, biological effects and organ toxicities, mechanistic aspects, and therapeutic targets. Reviews based on human epidemiological studies may focus on consideration the zonal policies, vulnerable populations, current problem of unequal disease burdern due to toxicants, environmental regulation of the toxicants, and biomonitoring data addressing the level of exposure to humans and the environment. Comprehensive reviews may take into account both experimental and human studies. It is strongly recommended to propose potential strategies to improve the public health and promote health equity.
Keywords:
1. Experimental models of inflammatory effects of pollutant exposures
2. Respiratory, cardiovascular, metabolic, or neurological inflammatory disorders.
3. Developmental immunotoxicity disorders
4. Immune dysfunction in adulthood due to early life environmental exposures
5. Transgenerational immune effects of environmental origin
All manuscripts submitted to this Article Collection will undergo a full peer-review. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.
Please submit your manuscript on our website, using the promo code 874E2 to indicate that the manuscript is intended for this Article Collection. The deadline for submitting a manuscript is 11 March 2026.
Please contact Ashley Ambros at [email protected] with any queries and discount codes regarding this Article Collection.
Guest Advisors:
Afzaal N. Mohammed, University of Arizona COM-Phoenix
Dr. Mohammed is a ResearchScientist III at University of Arizona COM-Phoenix. His research interest centered around broad range or topics including developmental biology, respiratory toxicology and pathogenesis, public health, and drug discovery. His major contribution is in the field of developmental biology where is addressed emerging public health issues related to respiratory and neurological disorders using rodent models. Currently, he is focused 1) Identifying novel drugs and biological agents to treat developmental respiratory disorders. 2) Addressing the respiratory disorders associated with occupational exposure to carbon nanomaterials.
Jagjit S. Yadav, University of Cincinnati College of Medicine
Dr. Yadav is Professor in the Department of Environmental and Public health, Division of Environmental genetics and Molecular Toxicology, at the University of Cincinnati College of Medicine, Cincinnati, Ohio, USA. He has been serving as a Deputy Director of the NIH’s P30 Center for Environmental Genetics at UC and Director of the Inhalation Toxicology Resource Unit. His research lab focuses on Pulmonary pathogenesis and immunotoxicology research as related to environmental health. He is also interested in understanding the role of host microbiome and genetic background in respiratory toxicity/infections/disease susceptibility from exposure to environmental pollutants (particles/nanoparticles, chemicals, microbial agents/antigens) using in vitro and in vivo (rodent) models and role of Gut-Lung axis in lung inflammatory disorders/disease.
Integrating Artificial Intelligence into Inflammation and Cancer Immunology: From Biomarkers Discovery and Mechanistic Insights to Precision Therapeutics
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Integrating Artificial Intelligence into Inflammation and Cancer Immunology: From Biomarkers Discovery and Mechanistic Insights to Precision Therapeutics", in the Journal of Inflammation Research.
Inflammation exerts a complex and context-dependent influence on both oncogenesis and the efficacy of cancer therapies. Acute inflammatory responses may enhance anti-tumor immunity; however, chronic inflammation is more commonly implicated in tumor initiation, progression, and the facilitation of immune evasion. Persistent inflammatory signaling contributes to the development of an immunosuppressive tumor microenvironment (TME) by promoting the infiltration of immunoregulatory cell populations, including regulatory T cells, myeloid-derived suppressor cells, and M2-polarized macrophages. This immunosuppressive milieu hinders the therapeutic effectiveness of immune checkpoint inhibitors and adoptive cell therapies such as chimeric antigen receptor T cells. Inflammatory cytokines such as IL-6, IFN-, and TNF-α also play dual roles, with context-dependent capacities to either promote immune resistance or augment immune activation.
Consequently, the modulation of inflammatory pathways holds promise for the development of patient-specific therapeutic strategies aimed at enhancing responses to anti-cancer treatments. For example, the combination of anti-inflammatory agents with immune checkpoint inhibitors may be particularly beneficial in patients exhibiting elevated baseline levels of inflammation. Among the most promising anti-inflammatory approaches is the use of epigenetic inhibitors, including histone deacetylase (HDAC) inhibitors and DNA methyltransferase (DNMT) inhibitors, which have demonstrated synergistic potential when used in combination with immunotherapies to overcome resistance mechanisms. Importantly, the identification of inflammation-associated biomarkers is essential for effective patient stratification. Such biomarkers would enable the rational design of combinatorial treatment regimens and improve the predictive capacity for therapeutic responses in the context of cancer immunotherapy.
The complex regulatory networks that control inflammation within TME are pivotal to the rational design of combinatorial strategies. Recent advances in artificial intelligence (AI), multi-omics technologies, and computational biology now offer powerful tools for the identification and validation of inflammation-associated biomarkers, as well as for elucidating the epigenetic alterations that drive their activation. These insights can be leveraged to inform the development of targeted therapeutic approaches, thereby facilitating the identification of individuals most likely to benefit from specific immunoepigenetic interventions.
This Article Collection seeks interdisciplinary research that investigate the role and underlying mechanisms of epigenetic alterations in the regulation of inflammation and tumor immunity. We welcome original research articles, reviews, clinical trial studies, and case reports. Submissions are also encouraged that examine the application of AI in predicting therapeutic responses and guiding precision immuno-oncology strategies.
Keywords
1. Inflammation and Tumor Immunity
2. Epigenetic Modulation
3. Artificial Intelligence in Oncology
4. Tumor Microenvironment and Metabolism
5. Diagnostic and Prognostic Biomarkers
All manuscripts submitted to this Article Collection will undergo a full peer-review. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.
Please submit your manuscript on our website, using the promo code 34582 to indicate that the manuscript is intended for this Article Collection. The deadline for submitting a manuscript is 15 April 2026.
Please contact Ashley Ambros at [email protected] with any queries and discount codes regarding this Article Collection.
Neutrophils in a New Light: Emerging Roles in Inflammation
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Neutrophils in a New Light: Emerging Roles in Inflammation", in the Journal of Inflammation Research.
Neutrophils are among the most abundant and evolutionarily conserved components of the innate immune system, long recognized for their frontline role in microbial defense and acute inflammation. However, our understanding of these cells has significantly evolved. Beyond their classical functions, neutrophils are now appreciated as highly plastic and multifunctional cells with the capacity to influence a wide range of immune responses, including those involved in chronic and sterile inflammation, tissue repair, autoimmunity, and even cancer.
This proposed Article Collection of the Journal of Inflammation Research aims to highlight the growing complexity of neutrophil biology and its implications for understanding and treating inflammatory diseases. By assembling a focused collection of high-quality original research articles, reviews, and short communications, this issue will provide readers with a comprehensive and up-to-date overview of the novel roles of neutrophils across diverse inflammatory contexts.
The field of neutrophil research is currently undergoing a paradigm shift. Advances in single-cell RNA sequencing, in vivo imaging, and functional assays have revealed striking heterogeneity among neutrophil populations, suggesting that they are far from being a homogenous cell type. Moreover, their ability to engage in crosstalk with other immune cells, influence adaptive responses, shedding neutrophil extracellular traps (NETs), and contribute to chronic inflammatory states has far-reaching implications for disease progression and therapy.
Despite this, neutrophils remain understudied compared to other immune cells, particularly in chronic disease settings where their roles are less obvious but no less critical. A dedicated special issue in the Journal of Inflammation Research would provide a much-needed platform for consolidating recent discoveries, showcasing state-of-the-art methodologies, and highlighting clinical relevance. Such an issue is well aligned with the journal’s mission to advance understanding of inflammatory mechanisms and foster translational insights into inflammation-related disorders.
This Article Collection will explore the evolving landscape of neutrophil biology with particular emphasis on novel and disease-relevant functions. The field in which submissions are welcomed address the following (but not limited to) subtopics:
1) Neutrophil heterogeneity and plasticity: Insights from single-cell and spatial profiling.
2) Neutrophil roles in chronic inflammation and autoimmunity: Contributions to diseases such as lupus, rheumatoid arthritis, and vasculitis.
3) NETs in inflammation: Molecular mechanisms, regulation, and pathological consequences.
4) Tissue-specific neutrophil behavior: Adaptation and function in lungs, liver, gut, CNS, and tumors.
5) Neutrophil interactions with adaptive immunity: Mechanisms of T cell modulation and antigen presentation.
6) Neutrophils in infection and viral inflammation: Including roles in COVID-19, sepsis, and chronic infections.
This Article Collection will serve as a comprehensive reference for scientists and clinicians working across immunology, inflammation, infectious disease, and translational medicine. By focusing on neutrophils, a cell type once considered simple but now recognized as highly influential, this issue aims to stimulate further research and innovation in the field of inflammation.
Keywords
1. Neutrophils Biology
2. Innate Immunity
3. Inflammation Resolution
4. Neutrophil Heterogeneity
5. Neutrophil Extracellular Traps (NETs)
All manuscripts submitted to this Article Collection will undergo a full peer-review. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.
Please submit your manuscript on our website, using the promo code 5480B to indicate that the manuscript is intended for this Article Collection. The deadline for submitting a manuscript is 2 March 2026.
Guest Advisor
Dr. Tomasz W Kaminski, Thrombosis and Hemostasis Program, Versiti Blood Research Institute, Milwaukee, WI
Tomasz W. Kaminski earned his doctoral degree from the Medical University of Bialystok, Poland. During his PhD training, he focused on studying hemostasis disturbances in chronic kidney disease. He joined the Sundd Lab as a postdoctoral associate in 2019. Dr. Kaminski’s research centers on innate immune mechanisms in platelets and neutrophils, as well as the pathophysiology of thrombo-inflammation. He employs state-of-the-art intravital microscopy techniques to capture real-time interactions between neutrophils and platelets during the initial phases of immune system activation. His work exhibits a truly interdisciplinary nature, as he investigates the neutrophil and platelet biology in hemophilic arthropathy, sickle cell disease and influenza. Dr. Kaminski has been recognized with numerous awards from both national and international societies and institutions. Furthermore, his research endeavors receive support from external funding sources.
Omics, Microbiome, and Artificial Intelligence: Novel Insights into Human Disease-Associated Inflammatory Responses
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Omics, Microbiome, and Artificial Intelligence: Novel Insights into Human Disease-Associated Inflammatory Responses", in the Journal of Inflammation Research, with Guest Advisors Dr. Swarna Kanchan and Dr. Minu Kesheri.
Understanding the integrative boost powered by omics technologies, human microbiota, and artificial intelligence is transforming our approach to various human diseases. Omics technologies such as epigenomics, genomics, transcriptomics, proteomics, and metabolomics provide comprehensive molecular insights for both host and microbial factors inducing inflammation, especially the dysregulated and chronic inflammation leading to various human diseases. The gut microbiota plays a pivotal role in modulating the immune system often linked to the onset and progression of various inflammatory and autoimmune diseases and maintaining homeostasis. Recent advances in multi-omics integration, powered by artificial intelligence, are enabling researchers to unravel complex host-microbe interactions, identify disease-associated molecular signatures such as driver genes and molecular pathways, and predict patient-specific responses to various therapies advancing precision medicine by facilitating earlier diagnosis, personalized treatment strategies, and improved outcomes for individuals affected by inflammatory conditions.
This topic is important because it addresses the growing need for comprehensive strategies to tackle inflammatory diseases responsible for one of the major causes of morbidity and mortality worldwide. By integrating multi-omics data, understanding the role of the microbiota, and leveraging the capabilities of artificial intelligence, researchers can gain exceptional insights into the complex mechanisms driving inflammatory responses. A comprehensive understanding of the molecular mechanisms, microbial influences, and individual variations is essential for developing effective therapies. This interdisciplinary approach has the potential to identify unique biomarkers, new therapeutic targets to develop novel and personalized medicines, and improve patient outcomes in a wide range of conditions, including inflammatory, autoimmune disorders, metabolic diseases, and cancer. Ultimately, a deeper understanding of these interactions will lead to more effective and targeted treatments, reducing the burden of inflammatory diseases on individuals and healthcare systems.
This Article Collection delves into how multi-omics approaches, gut microbiota dynamics, and artificial intelligence (AI) synergize to provide novel insights into inflammatory responses and mechanisms. The journal welcomes original research manuscripts, reviews, hypothesis formation, expert opinions, etc., relating to all aspects of inflammation.
Potential Subtopics
• Multi-Omics Profiling of Inflammatory Diseases: Integrating epigenomics, genomics, transcriptomics, proteomics, and metabolomics to identify key molecular signatures associated with different inflammatory conditions leading to various diseases.
• Microbiota's Role in Inflammation: Investigating how gut microbiota composition and function influence inflammation (dysregulated and chronic), including various metagenomics studies on dysbiosis, and host-microbe interactions.
• AI-Driven Analysis of Inflammatory Data: Applying machine learning and bioinformatics to analyze complex omics and clinical data, predict disease biomarkers, identify potential therapeutic targets, develop diagnostic personalized therapies, and improve patient management
• Novel Therapeutic Strategies Targeting Inflammation: Exploring new treatments, including precision medicine approaches, that modulate inflammatory responses by targeting specific molecular pathways or the gut microbiota.
Keywords
1. Multi-Omics
2. Microbiome
3. Machine learning
4. Precision Health
5. Inflammatory Diseases
All manuscripts submitted to this Article Collection will undergo a full peer-review. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.
Please submit your manuscript on our website, using the promo code 08045 to indicate that the manuscript is intended for this Article Collection. The deadline for submitting a manuscript is 15 November 2025.
Targeting the IL-4/IL-13 Axis in the Treatment of Type 2 Inflammation
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Targeting the IL-4/IL-13 Axis in the Treatment of Type 2 Inflammation", in the Journal of Inflammation Research.
This Collection, edited by the Editor-In-Chief Prof. Ning Quan, is part of the new Game Changer series of Article Collections, focusing on breakthrough therapies, drugs, and technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes.
Type 2 inflammation occurs when immune cells, including eosinophils and mast cells, are activated, producing the cytokine IL-4 and Il-13. These cytokines are responsible for signaling the production of eosinophils, mast cells, and IgE antibodies, that lead to the release of more pro-inflammatory cytokines. Type 2 inflammatory conditions affect 10-30% of the global population, and include common conditions such as allergy, asthma, eczema, and eosinophilic esophagitis. By targeting IL-4 and IL-13, overactive immune systems can be regulated, and many patients will see a better quality of life.
While this call is open to receive manuscripts highlighting all aspects of drugs targeting the IL-4/Il-13 axis, the Editors are particularly interested in manuscripts relating to the following areas:
Submitting authors are eligible for a 20% discount on the Article Publishing charge by applying the following code at the point of submission: YXVCF. If you have any queries regarding the Article Collection or would like to discuss a submission, then please email the Commissioning Editor Ashley Ambros ([email protected]). Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.
All manuscripts submitted to this Article Collection will undergo a full peer-review. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.
Please submit your manuscript on our website. The deadline for submitting a manuscript is 1 April 2026.
The Translation of Discovery: Cutting Edge Research to Study Airway Inflammation
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "The Translation of Discovery: Cutting Edge Research to Study Airway Inflammation", in the Journal of Inflammation Research, with Guest Advisors Dr. Reynold Panettieri and Dr. Cynthia Koziol-White.
All currently-approved pharmaceuticals have had the same humble beginnings – a hypothesis and experiment in a laboratory. Translational research is a crucial component in drug discovery, though results obtained using in vivo animal models such as mice do not always translate well from bench to bedside. Moreover, technological advancements have made it possible to study aspects of inflammatory processes we never thought possible.
The field of translational immunology allows researchers to learn more about inflammatory processes contributing to airway disorders such as asthma and allergy. These inflammatory airway disorders are found in over 25 million individuals worldwide, and severe inflammatory responses can lead to hospitalization and even death. Preclinical and clinical research have led to the identification and production of drugs with new therapeutic targets, such as interleukin-4, interleukin-1, interleukin-33 and thymic stromal lymphopoietin.
The Guest Advisors welcome relevant clinical Original Research, Reviews, Reports, Hypothesis Formation, Commentaries, and Expert Opinions. These articles may pertain broadly to translational immunology of asthma and allergy, though special attention will be given to the following subareas:
1. Novel in vitro, in vivo, and ex vivo models to study airway inflammation such as organoids
2. New therapeutic targets
3. Genome-wide CRISPR screening for drug discovery
4. Translational information derived from Single-cell RNA seq
5. Whole tissue dynamics using spatial transcriptomics
6. Exome sequencing
7. Immunological synapses between immune cells and structural/mesenchymal cells
All manuscripts submitted to this Article Collection will undergo a full peer-review. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.
Please submit your manuscript on our website, using the promo code 79538 for a 10% discount on the Article Processing Charge. The deadline for submitting a manuscript is 31 March 2026.
- AI-driven sleep staging algorithms
- IoT-enabled wearable and non-contact sensors
- Digital biomarkers for sleep health
- Home-based diagnostic platforms
- Remote therapeutic monitoring
- Smart CPAP or MAD devices
- Development and validation of low-cost pharmacogenetic testing methodologies.
- Application of innovative technologies for pharmacogenetic analysis in resource-limited settings.
- Studies on the genetic variability of drug-metabolizing enzymes and drug targets in diverse populations within developing countries.
- Investigation of gene-environment interactions influencing drug response in these populations.
- Clinical utility and cost-effectiveness analyses of pharmacogenetic testing in specific disease areas relevant to developing countries
- Strategies for the implementation of pharmacogenetics in routine clinical practice, including education and training of healthcare professionals.
- Ethical, legal, and social implications of pharmacogenetic testing in diverse cultural contexts.
- Policy recommendations for the integration of pharmacogenetics into healthcare systems in developing countries.
- Studies and pilot projects demonstrating the successful application of pharmacogenetics in improving patient care.
- Relevant topics include, but are not limited to:
- AI applications in reproductive and maternal health
- Digital mental health interventions
- Mobile health platforms for underserved populations
- Ethical and regulatory considerations in algorithmic design
- Strategies to reduce bias in women’s health technologies
- Innovative models of care and interventions: Highlighting new and emerging practices, as well as workforce solutions, that improve patient care and outcomes
- Interdisciplinary collaboration: Exploring the value of teamwork across healthcare professions and its positive impact on care delivery
- Educational Advancements: Demonstrating innovative teaching strategies and curriculum developments that enhance allied health training and professional development
- Technological integration: Exploring how technology and digital health tools are transforming allied health practices and patient engagement
- Cultural Competency and Equity: Examining practices that promote inclusivity, cultural sensitivity, and health equity within allied health services
- Consumer Experiences and Perspectives: Showcasing research on how allied health services impact patients' lived experiences, satisfaction, and engagement in care
- Policy and Advocacy: Addressing how allied health professionals influence healthcare policy, access to services, and advocacy for underserved populations.
- AI-driven analysis of multi-source datasets to unravel immune-disease associations
- Machine learning for predictive modeling of comorbidities and treatment responses in autoimmune and inflammatory conditions
- Ethical AI deployment in global health contexts
- Art therapists
- Dietitians
- Dramatherapists
- Music therapists
- Occupational therapists
- Operating department practitioners
- Orthoptists
- Osteopaths
- Paramedics
- Physiotherapists
- Podiatrists
- Prosthetists and orthotists
- Radiographers
- Speech and language therapists
- Early intervention and access to healthcare
- Inclusive education strategies and policies
- Assistive technologies and accessibility innovations
- Family and caregiver perspectives
- Social inclusion and community participation
- Mental health and emotional well-being
- Legal frameworks and advocacy efforts
- Empirical studies exploring topics related to healthcare patients, systems, and data privacy and security.
- Comprehensive reviews summarizing the current state of healthcare cybersecurity.
- Comparing blockchain and active Artificial Intelligence to more traditional intrusion detection mechanisms.
- Healthcare professionals’ leadership: Leadership among healthcare professionals is essential to improve telehealth care delivery by collaborating with telehealth technology and service providers, while also contributing to the evidence base through comparisons of telehealth outcomes with traditional care.
- Reimbursement: Research on reimbursement in fee-for-service contexts and the impact of alternative payment models that use bundled telehealth services to calculate buyer returns on investment could be made easier by the current procedural terminology codes.
- Licensure: The needed licensing requirement, which may be bolstered by continuing research on potential quality-of-care concerns.
- Liability: Evidence to enhance understanding of any quality and safety risks that may distinguish telehealth service delivery from traditional in-person care.
- Human factors: Investigating user-centered design to enhance the incorporation of telehealth into clinical workflows and improve patient engagement
- Device interoperability and data integration: Exploring evidence-based best practices and standards that facilitate the optimal integration of devices and data streams from physician and patient telehealth engagement.
- Privacy and security: Establishing evidence-based standardized norms to facilitate adequate safeguards and regulatory control.
- Performance measurement: Improved evidence to fill deficiencies in current telehealth-related clinical performance metrics and augment those presently available.
- Patient engagement: Evidence-based recommendations to assist health professionals in counseling and engaging with patients and caregivers over the entire range of telehealth services and technologies.
- Multidisciplinary Literature Informatics: Cross-disciplinary approaches such as bibliometric analyses to map trends in disease research, therapeutic innovations, and knowledge gaps across fields like pharmacology, genomics, and public health.
- Mining Large-Scale Biomedical Databases: Methodological advances and applications leveraging datasets such as NHANES (nutrition and health trends), GBD (global disease burden), UK Biobank (genomic and health data), TriNetX (real-world clinical data), and other repositories to uncover disease mechanisms, treatment patterns, and population health insights.
- Data-Driven Discovery of Disease and Therapeutic Targets: Computational strategies including network pharmacology, bioinformatics analyses, and multi-omics integration to identify novel drug candidates, repurpose existing therapies, or elucidate disease pathways.
- Machine Learning for Precision Therapeutics: Predictive models to forecast individual patient responses to treatments (e.g., chemotherapy efficacy, adverse drug reactions) or stratify high-risk populations (e.g., early detection of sepsis, cardiovascular events) using clinical, genomic, and demographic data.
- Ethical and Technical Challenges in Clinical Data Mining: Addressing biases in heterogeneous datasets, ensuring interoperability across platforms, and balancing data utility with patient privacy in global health contexts.
- The role of dietary modifications (Mediterranean diet, low-carbohydrate diets, intermittent fasting)
- Impact of physical activity and structured exercise programs
- Behavioral strategies to improve long-term adherence
- Bariatric surgery and metabolic interventions in NAFLD/NASH
- Emerging drug targets (FXR agonists, PPAR modulators, GLP-1 receptor agonists, etc.)
- Repurposing existing medications (e.g., SGLT2 inhibitors, statins) for NAFLD
- Challenges in clinical trial design and endpoints for NAFLD therapies
- Personalized medicine approaches based on genetic and metabolic profiling
- Gut microbiome modulation (probiotics, prebiotics, fecal microbiota transplantation)
- Gene therapy and RNA-based interventions
- The role of digital health and AI in NAFLD diagnosis and monitoring
- Integrative medicine and alternative therapeutic strategies
- Screening and early detection strategies in high-risk populations
- Economic burden and healthcare policies for NAFLD management
- Global disparities in NAFLD prevalence and treatment access
- Teachers' perspective: how do teachers in different educational contexts integrate Chatbots in teaching strategies? what are facilitating or hindering factors of a teacher-chatbot co-creation?
- Learners: what kind of learning outcomes do they achieve by what kind of interaction with chatbots?
- Informal, self-paced health learning: How do chatbots support health literacy? Which target groups, outcomes, context-specific features can be identified?
Journal of Multidisciplinary Healthcare
Advanced Technologies for Improving the Screening, Diagnosis, and Treatment of Sleep
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Advanced Technologies for Improving the Screening, Diagnosis, and Treatment of Sleep", in the Journal of Multidisciplinary Healthcare.
Sleep disorders, including insomnia, obstructive sleep apnea, restless leg syndrome, and circadian rhythm disturbances, affect millions of individuals worldwide and are increasingly recognized as critical public health concerns. Recent years have seen a surge in research and development focused on applying emerging technologies to improve the detection, understanding, and management of these disorders. From advanced biosignal acquisition to intelligent pattern recognition, technology is playing an ever-expanding role in transforming the sleep health landscape.
Sleep disorders not only impair daily functioning but also contribute to the development of chronic conditions such as cardiovascular disease, metabolic disorders, and neurodegeneration. However, traditional sleep evaluation tools, such as polysomnography, remain resource-intensive and often inaccessible to the broader population. The integration of artificial intelligence, machine learning, and Internet of Things (IoT)-based wearables offers new possibilities for scalable, cost-effective, and continuous sleep monitoring. These advancements open the door to early detection, remote diagnosis, personalized interventions, and real-time treatment optimization—ultimately enhancing clinical outcomes and patient well-being.
The goal of this Collection is to showcase cutting-edge work that advances the science and practice of sleep medicine through innovation. We seek high-quality original research articles, reviews, and perspectives focused on the development and application of advanced technologies for sleep disorder research and management. Submissions addressing multidisciplinary collaborations and translational research that bridge clinical, engineering, and data science domains are especially encouraged.
Topics of interest include but are not limited to:
All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.
The deadline for submitting manuscripts is 31 January 2026.
Please submit your manuscript on our website, quoting the promo code D065F for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
If you have any questions about this Article Collection, please contact Krista Thom at [email protected].
Guest Advisors
Dr. Cheng-Yu Tsai, Taipei Medical University, Taiwan
Prof. Wen-Te Liu, Taipei Medical University, Taiwan
Advancing Dental Healthcare: Multidisciplinary Approaches, Biomaterials, and Clinical Innovations
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Advancing Dental Healthcare: Multidisciplinary Approaches, Biomaterials, and Clinical Innovations", in the Journal of Multidisciplinary Healthcare.
Dental healthcare is rapidly evolving, driven by advances in biomaterials, innovative clinical techniques, and interdisciplinary collaborations. From restorative and regenerative solutions to digital dentistry and precision medicine, the field is embracing cutting-edge approaches to redefine diagnostics, treatment planning, and patient care. This Article Collection aims to explore the latest developments in dental research, with a focus on novel biomaterials, emerging technologies, and multidisciplinary approaches that shape the future of oral healthcare.
Addressing the growing complexity of dental diseases and patient needs requires a comprehensive approach that extends beyond traditional dentistry. The integration of biocompatible materials, minimally invasive procedures, and artificial intelligence in diagnostics is transforming clinical practice. Furthermore, collaborative efforts between dental professionals, researchers, and specialists in other medical fields contribute to more effective treatments and enhanced patient experiences. Advancements in these areas impact oral and systemic health equally, underscoring the significance of cutting-edge research in the dental field.
This Article Collection invites original research articles and reviews that examine the development and clinical application of novel biomaterials, tissue engineering in dentistry, digital and AI-driven diagnostics, interdisciplinary treatment planning, and personalized dental care. We welcome contributions from researchers and practitioners across multiple disciplines, aiming to bridge the gap between scientific discovery and clinical practice.
All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.
The deadline for submitting manuscripts is 15 December 2025.
Please submit your manuscript on our website, quoting the promo code IMCZX for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
Guest Advisor
Dr. Eman Allam, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, UAE
Advancing Pharmacogenetics in Limited Resources Countries: Affordable Testing Methods, Genetic Variability, and Clinical Implications
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Advancing Pharmacogenetics in Limited Resources Countries: Affordable Testing Methods, Genetic Variability, and Clinical Implications", in the Journal of Multidisciplinary Healthcare.
One of the current prominent topics in treatment individualization is pharmacogenetics, a method for tailoring drug selection and dosages based on an individual's genetic profile. Although pharmacogenetic testing is prevalent in developed countries, developing countries are behind in this area due to resource constraints.
This Article Collection aims to address the critical need for advancing pharmacogenetics research and implementation within developing countries. These regions often face unique challenges related to healthcare infrastructure, economic constraints, and significant genetic diversity, all of which profoundly impact drug response and efficacy.
Topics of interest include:
We believe this Collection will serve as a valuable resource for researchers, clinicians, policymakers, and stakeholders committed to advancing pharmacogenetics and achieving equitable healthcare outcomes in developing countries.
All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.
The deadline for submitting manuscripts is 15 February 2026.
Please submit your manuscript on our website, quoting the promo code D14E0 to indicate that your submission is for consideration in this Article Collection.
If you have any questions about this Article Collection, please contact Krista Thom at [email protected].
Guest Advisors
Dr. Harri Hardi, Universitas Indonesia
Dr. Mohamed Nagy, Children’s Cancer Hospital, Egypt
Advancing Women’s Health Through Digital Health and Artificial Intelligence in Global Contexts
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Advancing Women’s Health Through Digital Health and Artificial Intelligence in Global Contexts", in the Journal of Multidisciplinary Healthcare.
Women’s experiences with healthcare are worthy of dedicated exploration. Across global contexts, women often face distinct and multifactorial challenges in accessing and navigating healthcare systems. These challenges may arise from complex healthcare needs, socioeconomic and cultural influences that sometimes dismiss or devalue women’s health concerns, and political or legal constraints that limit access to essential care.
In parallel, the rapid evolution of digital health and artificial intelligence is reshaping how healthcare is delivered, offering new possibilities to enhance personalization, accessibility, and system efficiency.
The integration of digital technologies into women’s healthcare requires collaboration across a wide range of professional disciplines including clinicians, nurses, public health professionals, technologists, and healthcare managers. Equally essential is the presence of women in leadership roles where they guide strategic priorities, influence system level decisions, and ensure that digital solutions are designed and implemented with gender equity in mind. Although the contribution of women to digital health leadership is increasingly recognized, research exploring how women lead, manage, and shape digital transformation within healthcare institutions remains underdeveloped.
This Article Collection explores the intersection of women’s health, leadership and management, and digital innovation with a particular focus on multidisciplinary approaches that contribute to more equitable and responsive health systems. We welcome original research articles and reviews (though not meta analyses) focused on the use of digital health and artificial intelligence in the delivery of women’s healthcare by multidisciplinary teams.
Submissions that address women’s roles in digital health leadership and management such as organizational change, governance models, capacity building, or the impact of women leaders on innovation outcomes are especially encouraged. Contributions from diverse disciplines and global perspectives are welcome to advance a more inclusive and effective digital health future for women.
All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.
The deadline for submitting manuscripts is 31 December 2025.
Please submit your manuscript on our website, quoting the promo code 4B8A6 to indicate that your submission is for consideration in this Article Collection.
If you have any questions about this Article Collection, please contact Krista Thom at [email protected].
Guest Advisors
Prof. Raniah N. Aldekhyyel, King Saud University, Saudi Arabia
Prof. Ruaim Muaygil, King Saud University, Saudi Arabia
Allied Health Matters: Showcasing Value, Driving Impact
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Allied Health Matters: Showcasing Value, Driving Impact", in the Journal of Multidisciplinary Healthcare.
The term “allied” refers to being joined or associated with others for a common goal. It implies a supportive relationship between individuals and groups, characterized by cooperation, collaboration, and mutual support. Allied health professionals exemplify this concept and are at the heart of healthcare delivery, making significant contributions to patient outcomes, organizational efficiencies, and driving system-wide innovation. This Article Collection aims to highlight and celebrate the essential value that allied health services bring to individuals and communities, emphasizing the profound and lasting impact these professionals have on both healthcare systems and the lives of those they serve.
We welcome submissions that showcase the transformative impact of allied health practices through cutting-edge research, evidence-based practices, end-user-centered approaches, innovative clinical models and workforce solutions, interdisciplinary collaboration, policy advancements, and technological integration.
Topics of interest include, but are not limited to:
All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.
The deadline for submitting manuscripts is 15 January 2026.
Please submit your manuscript on our website, quoting the promo code RNTHT for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
If you have any questions about this Article Collection, please contact Krista Thom at [email protected].
Guest Advisors
Prof. Saravana Kumar, University of South Australia
Ms. Esther Jie Tian, University of South Australia
Big Data and AI in Immune-Mediated Conditions: Bridging Systems Biology and Clinical Practice
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Big Data and AI in Immune-Mediated Conditions: Bridging Systems Biology and Clinical Practice", in the Journal of Multidisciplinary Healthcare.
Immune-mediated conditions, spanning panvascular diseases and metabolic disease, are driven by dysregulated immune mechanisms that challenge diagnosis and therapeutic precision. The integration of artificial intelligence (AI) and big data analytics has emerged as a transformative force in immunology and system biology. These datasets—rich in longitudinal health records, multi-omics profiles, and sociodemographic variables—provide unparalleled opportunities to uncover disease patterns and predict outcomes. This Article Collections highlights how AI-driven analyses of real-world and population-level data—from global cohorts to clinical registries—are redefining research and care in immune-mediated conditions.
The importance of leveraging these resources lies in addressing the heterogeneity of immune-mediated diseases, where patient-specific factors, environmental influences, and genetic variability complicate traditional research paradigms. For instance, AI models trained on integrated datasets can identify biomarkers for early detection, stratify autoimmune disease risk in diverse populations, or predict infection outcomes by combining immunological, nutritional, and lifestyle data. However, challenges persist in harmonizing fragmented data sources, ensuring algorithmic generalizability across populations, and maintaining ethical standards in data usage—issues this Collection seeks to explore.
This Article Collection invites contributions that demonstrate innovative applications of AI and big data in immune-mediated conditions, emphasizing both methodological advances and translational impact. Topics include, but are not limited to:
Article types such as Original Research, Reviews, and Methods papers are welcomed, particularly those bridging gaps between computational innovation, systems biology, and clinical practice. By uniting cutting-edge analytics with scalable health data, this issue aims to catalyze breakthroughs in understanding and managing immune-mediated conditions worldwide.
All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.
The deadline for submitting manuscripts is 15 February 2026.
Please submit your manuscript on our website, quoting the promo code ED93F to indicate that your submission is for consideration in this Article Collection.
If you have any questions about this Article Collection, please contact Krista Thom at [email protected].
Guest Advisors
Dr. Jian Chen, Shanghai TCM-Integrated Hospital, China
Dr. Krit Pongpirul, Chulalongkorn University, Thailand
Building a Sustainable Allied Health Workforce: Recruitment, Retention, and Resilience
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Building a Sustainable Allied Health Workforce: Recruitment, Retention, and Resilience", in the Journal of Multidisciplinary Healthcare.
The Allied Health Professions (AHPs) provide specialist emergency, diagnostic, treatment, and rehabilitative services that help people and whole communities from birth to end of life. AHPs make up a large proportion of the international health workforce, yet their vital contribution is too often marginalized in a public discourse that tends to refer only to "doctors and nurses." As a result, the focus on prevention and rehabilitation is also less well understood by patients and the public who focus on hospital-based, acute medical care. Further research is needed to inform policy and practice in sustaining the whole AHP workforce including assistant practitioners and support staff.
As the demand for Allied Health Services continues to grow there is a need to understand how best to build and maintain the Allied Health workforce, including non-traditional routes into the professions, diversification of educational options and challenging conceptions of siloed and stressful roles that lead to poor retention. There are multiple challenges across different communities and contexts including rural and coastal and urban deprived places, and evidence is needed to support planning, decision-making and investment in new roles and ways of working.
This Article Collection will explore the sustainability of the Allied Health workforce, with topics including retention, routes into the Allied Health Professions, burnout and other mental health difficulties facing the Allied Health workforce. The impact of workforce shortages, strategies for improving recruitment and diversity, the role of leadership and professional development in building resilience, and innovations in service delivery, including the integration of digital health and interprofessional collaborations are relevant. This collection aims to gather robust AHP-specific research that evidences the issues facing the sustainability of the AHP workforce, and the outcomes of local, national, and international workforce innovations.
Specialties within the Allied Health Professions include:
We welcome original articles, reviews, perspectives, and commentaries.
All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.
The deadline for submitting manuscripts is 1 April 2026.
Please submit your manuscript on our website, quoting the promo code C5C22 to indicate that your submission is for consideration in this Article Collection. Standard Article Publishing Charges apply.
If you have any questions about this Article Collection, please contact Krista Thom at [email protected].
Guest Advisors
Dr. Sarah Etty, Sheffield Hallam University, UK
Prof. Sally Fowler-Davis, Anglia Ruskin University, UK
Children with Disabilities and Chronic Diseases: Perspectives, Challenges, and Opportunities
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Children with Disabilities and Chronic Diseases: Perspectives, Challenges, and Opportunities", in the Journal of Multidisciplinary Healthcare.
Children with disabilities represent a diverse population with unique strengths, needs, and challenges. Their experiences are shaped by various factors, including healthcare access, inclusive education, family support, social policies, and community engagement.
This Article Collection seeks to explore multidisciplinary perspectives on the well-being, rights, and development of children with disabilities, highlighting both systemic barriers and innovative solutions that promote inclusivity and equity.
Potential topics include, but are not limited to:
We welcome submissions from researchers, clinicians, educators, policymakers, and advocates working in fields such as disability studies, special education, pediatric healthcare, rehabilitation, psychology, and social work. Institutions, advocacy organizations, and multidisciplinary teams working on disability-related initiatives are also encouraged to submit.
All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.
The deadline for submitting manuscripts is 1 January 2026.
Please submit your manuscript on our website, quoting the promo code MQUOM for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
If you have any questions about this Article Collection, please contact Krista Thom at [email protected].
Guest Advisor
Prof. Sawsan Abuhammad, University of Sharjah, UAE
Cybersecurity in Healthcare: Ensuring Patient Safety and Data Privacy
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Cybersecurity in Healthcare: Ensuring Patient Safety and Data Privacy", in the Journal of Multidisciplinary Healthcare.
All computer systems are vulnerable to cyberattacks, but healthcare systems are especially at risk due to the pervasive use of interconnected digital health systems for service delivery, insurance billing, pharmaceutical ordering, diagnostics test reporting, and telehealth. Medical device usage, remote patient monitoring, patient portals, and the increasing number of connected smart devices provide multiple entry points for cyber actors. Moreover, healthcare targets are ten times more valuable than financial targets because they can enable fraudulent billing.
Healthcare security specialists may wish for a universal application to scan computer systems and detect all cyber threats, but that app does not exist. The reason is that cybersecurity issues are intricate and multifaceted, involving human factors, system vulnerabilities, technological vulnerabilities, physical access issues, and legal compliance challenges.
Information sharing and remote access make healthcare systems more susceptible to viruses and phishing. Cyberattacks in one system can have a domino effect, resulting in issues in multiple connected internal and external systems. As an illustration, the February 2024 ransomware data breach at Change Healthcare, a company that supplied revenue cycle and payment management services to over 900,000 healthcare providers and 5,500 hospitals, significantly impacted healthcare systems in several states. This breach, the largest ever reported, affected approximately 190 million individuals, and resulted in revenue losses due to delays in processing clinical, financial, and operational transactions.
At a minimum, cyberattacks in healthcare can delay care due to healthcare databases being held for ransom. The worst-case scenario is when the Internet of Medical Things is hijacked and causes malfunction. Disruptions to healthcare systems harm the financial stability of the affected healthcare facility and pose serious risks to patient safety and data privacy. This was a concern as far back as 2000 when the U.S. Secret Service disabled the Wi-Fi capabilities of the pacemaker in Vice President Dick Cheney’s chest.
During cyberattacks, patient information can be compromised, lost, stolen, or held for ransom, endangering the ability to diagnose and treat the patient efficiently and safely. The Department of Health and Human Services Office for Civil Rights' analysis of healthcare data breaches revealed a substantial increase in the number and severity of data breaches over the last fourteen years, and the average cost is higher than data breach costs for other industries.
This Article Collection welcomes original research articles and systematic reviews. Topics of interest include, but are not limited to:
All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.
The deadline for submitting manuscripts is 1 January 2026.
Please submit your manuscript on our website, quoting the promo code JJGXV for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
If you have any questions about this Article Collection, please contact Krista Thom at [email protected].
Guest Advisors
Prof. Diane Dolezel, Texas State University, USA
Prof. Scott Kruse, Texas State University, USA
Prof. Rohit Pradhan, Texas State University, USA
Empowering Public Health through Advancements in Telehealth
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Empowering Public Health through Advancements in Telehealth", in the Journal of Multidisciplinary Healthcare.
Telehealth has indeed seen rapid adoption and expansion in recent years, especially due to the COVID-19 pandemic. The convenience, accessibility, and efficiency it provides have proven to be game changers for both patients and healthcare providers. It allows healthcare professionals to reach patients in remote or underserved areas, alleviating the burden of travel and time constraints for both parties. Additionally, telehealth enables quicker and more efficient management of chronic conditions, routine follow-ups, mental health services, and urgent care needs, all of which contribute to better overall healthcare delivery. Another significant advantage of telehealth is its role in reducing healthcare costs. By minimizing the need for in-person visits, healthcare systems can reduce overhead costs associated with clinics and hospital visits. Furthermore, telehealth can facilitate better coordination of care, reducing the likelihood of medical errors and improving patient outcomes. The rapid uptake of telehealth also led to the development of regulations and technologies that support secure and reliable communication, such as encrypted video calls and electronic health records. These advancements help maintain patient confidentiality and ensure compliance with health standards like HIPAA in the U.S. Given the rise in patient demand and the efficiency benefits to healthcare providers, telehealth is likely to continue playing a central role in modern healthcare systems, especially as technologies evolve and integrate with other digital health tools, like remote monitoring devices, and become more seamless.
However, some challenges remain, including technological barriers for certain populations, reimbursement models, and varying regulations across regions. Several important trends are anticipated to impact the expansion of telehealth care delivery including advancements in the consumer technology market, ongoing progress in electronic health records and clinical decision support systems, shortages in the health professional workforce, restructuring in the delivery and financing of medical care, and consumerism. Healthcare professionals must integrate new technologies into their workflows while ensuring they improve patient care. Both patients and clinicians may struggle with adoption, and reimbursement models remain complex due to varying policies. Interoperability between electronic health record (EHR) systems is crucial, but smaller facilities may lack the infrastructure for bandwidth-intensive telehealth. Regulatory barriers, including varying accreditation and insurance policies, add to the complexity. Additionally, concerns about technical reliability, privacy, and accountability in telehealth need to be addressed for successful integration.
This Article Collection highlights key trends in telehealth adoption, examines the current state of telehealth evidence, and discusses the challenges in promoting its implementation. It also aims to guide healthcare professionals and researchers in identifying critical priorities for telehealth research. Such research is essential for maximizing telehealth’s potential to improve patient experience, advance population health, reduce healthcare costs, and enhance the delivery of care. Papers submitted for this Article Collection should concentrate on the general theme of telehealth service delivery, addressing the following subtopics or research priorities:
All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.
The deadline for submitting manuscripts is 15 February 2026.
Please submit your manuscript on our website, quoting the promo code 3A08C to indicate that your submission is for consideration in this Article Collection.
If you have any questions about this Article Collection, please contact Krista Thom at [email protected].
Guest Advisors
Dr. Salah Alshagrawi, The Saudi Electronic University, Saudi Arabia
Dr. Krzysztof Laudanski, Mayo Clinic, USA
Exploring the Intersection of Internet Addiction and Pain Syndromes
The Journal of Multidisciplinary Healthcare invites submissions for an Article Collection addressing the emerging and multifaceted relationship between internet addiction and pain syndromes. As digital technology becomes increasingly integral to daily life, excessive internet use is being recognized not only as a behavioral health issue but also as a potential contributor to a range of physical and psychological pain conditions.
Recent studies suggest that internet addiction may exacerbate or even precipitate pain syndromes through a variety of mechanisms, including:
●くろまる Increased Pain Perception: Continuous digital engagement may interfere with the body's natural pain regulation systems, such as those affected by sleep disruption and heightened stress responses.
●くろまる Chronic Pain and Comorbid Mental Health Conditions: Anxiety and depression—often comorbid with internet addiction—are known to amplify chronic pain, creating a complex interplay between emotional and physical health.
●くろまる Musculoskeletal Strain: Sedentary behaviors, poor ergonomics, and prolonged device use are contributing factors to neck, back, and wrist pain, as well as digital eye strain.
●くろまる Sleep Disturbances: Irregular sleep patterns linked to excessive screen time may impair the body’s ability to manage and recover from pain.
●くろまる Pain as a Coping Mechanism: Individuals experiencing chronic pain may turn to the internet for distraction or relief, potentially reinforcing maladaptive behaviors and worsening both emotional and physical outcomes.
●くろまる Neurological and Inflammatory Pathways: Emerging evidence suggests that chronic internet use may affect neural activity and immune function, potentially increasing systemic inflammation and contributing to conditions such as arthritis or migraines.
We welcome original research articles, reviews, hypotheses, and commentaries from all relevant disciplines—including psychology, pain medicine, psychiatry, neurology, rehabilitation, digital health, and public health—that explore:
●くろまる Mechanisms linking internet use with pain perception
●くろまる The role of digital behavior in chronic pain management
●くろまる Interventions for individuals with co-occurring internet addiction and pain disorders
●くろまる Prevention strategies and public health implications
●くろまる Interdisciplinary approaches to diagnosis and treatment
All submissions will undergo rigorous peer review and must align with the journal’s mission to promote integrated, patient-centered care through cross-disciplinary collaboration.
All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.
The deadline for submitting manuscripts is 1 March 2026.
Please submit your manuscript on our website, quoting the promo code 10AED to indicate that your submission is for consideration in this Article Collection.
If you have any questions about this Article Collection, please contact Krista Thom at [email protected].
Guest Advisor
Prof. Gergely Feher, University of Pécs, Hungary
Female Sexual Function and Functioning Across the Life Cycle: Multidisciplinary Perspectives in Healthcare
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Female Sexual Function and Functioning Across the Life Cycle: Multidisciplinary Perspectives in Healthcare", in the Journal of Multidisciplinary Healthcare.
Female sexual function and functioning across the life cycle are fundamental aspects of women's health and quality of life. These aspects are influenced by multiple biological, psychological, and sociocultural factors that interact in various ways from adolescence to senescence. Understanding these interactions is essential for promoting multidisciplinary healthcare approaches grounded in scientific evidence.
The study of female sexual function still faces significant challenges, including persistent taboos, knowledge gaps, and the need for individualized approaches. Additionally, functioning, recognized as the third key indicator of health conditions, requires further investigation throughout the female life cycle. Women’s functioning may be affected by events such as pregnancy, postpartum, menopause, and various clinical conditions. Thus, research on these aspects is crucial for developing effective health promotion strategies and preventive measures tailored to the female population.
This Article Collection aims to bring together original research, systematic reviews, and clinical studies addressing the interrelationship between female sexual function and functioning in different contexts. Studies exploring healthcare interventions, biopsychosocial factors, the use of the International Classification of Functioning, Disability, and Health (ICF), the impact of chronic diseases, and multidisciplinary approaches to women's health promotion are welcome.
All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.
The deadline for submitting manuscripts is 15 January 2026.
Please submit your manuscript on our website, quoting the promo code TYHOK for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
If you have any questions about this Article Collection, please contact Krista Thom at [email protected].
Guest Advisor
Prof. Vanessa Patrícia Soares de Sousa, Federal University of Rio Grande do Norte, Brazil
Harnessing Database Mining for Advancing Clinical Practice: From Insights to Therapeutic Innovation
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Harnessing Database Mining for Advancing Clinical Practice: From Insights to Therapeutic Innovation", in the Journal of Multidisciplinary Healthcare.
The integration of advanced database mining techniques into clinical practice is reshaping how healthcare professionals diagnose, treat, and manage diseases. Modern clinical databases - encompassing electronic health records (EHRs), genomic profiles, treatment outcome registries, and real-time patient monitoring data - hold immense, untapped potential to uncover actionable insights that directly improve patient care. This Article Collection focuses on cutting-edge methodologies and applications of database mining to bridge the gap between data-driven discoveries and their practical implementation in therapeutic decision-making, ultimately enhancing precision, efficacy, and equity in clinical practice.
The urgency of leveraging database mining in clinical settings lies in its capacity to address critical healthcare challenges. Traditional approaches to treatment optimization often rely on generalized protocols, which may fail to account for individual patient variability, comorbidities, or emerging patterns in population health. By systematically analyzing large-scale clinical datasets, researchers and practitioners can identify novel biomarkers, predict treatment responses, and tailor interventions to specific patient subgroups. For example, mining oncology databases may reveal correlations between genetic mutations and drug efficacy, enabling personalized cancer therapies, while analyzing longitudinal EHR data could uncover early warning signs of treatment complications. Furthermore, in resource-limited settings, database-driven insights can guide cost-effective, evidence-based care. Despite this potential, challenges such as data heterogeneity, ethical constraints, and the translation of mined patterns into clinical workflows remain significant barriers to widespread adoption.
This Article Collection invites submissions that explore the transformative role of database mining in advancing therapeutic strategies and clinical outcomes. Key subtopics include, but are not limited to:
We welcome original research articles, method and methodology papers, and reviews that demonstrate rigorous data mining approaches with clear clinical relevance. Submissions should emphasize scalable solutions, reproducibility, and direct implications for improving therapeutic decision-making, aligning with the journal’s commitment to fostering innovation at the intersection of data science and clinical care.
All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.
The deadline for submitting manuscripts is 1 January 2026.
Please submit your manuscript on our website, quoting the promo code MFNEB for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
If you have any questions about this Article Collection, please contact Krista Thom at [email protected].
Guest Advisors
Prof. Qingwen Tao, China-Japan Friendship Hospital, Beijing, China
Dr. Guangyao Chen, China-Japan Friendship Hospital, Beijing, China
Dr. Caixian Qiu, Beijing University of Chinese Medicine, China
Targeting Non-Alcoholic Fatty Liver Disease: Lifestyle, Pharmacotherapy, and Beyond
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Targeting Non-Alcoholic Fatty Liver Disease: Lifestyle, Pharmacotherapy, and Beyond", in the Journal of Multidisciplinary Healthcare.
Non-alcoholic fatty liver disease (NAFLD) has rapidly become one of the most significant liver disorders globally, affecting nearly a quarter of the world’s population. It encompasses a spectrum of liver conditions, starting with simple steatosis (fat accumulation in hepatocytes) and progressing in some individuals to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and even hepatocellular carcinoma (HCC). Unlike other liver diseases, NAFLD is not driven by alcohol abuse or viral infections but is closely linked to metabolic dysfunction, including obesity, insulin resistance, and type 2 diabetes mellitus (T2DM).
Despite its high prevalence, NAFLD remains underdiagnosed and undertreated, partly due to its asymptomatic nature in early stages and the lack of universally approved pharmacotherapies. Current management primarily relies on lifestyle modifications, such as weight loss and exercise, while emerging drugs target specific molecular pathways involved in disease progression. However, the heterogeneity of NAFLD poses challenges in developing one-size-fits-all treatments, necessitating a deeper understanding of individualized therapeutic approaches.
This Article Collection, "Targeting NAFLD: Lifestyle, Pharmacotherapy, and Beyond," aims to explore the latest advancements in NAFLD management, from foundational lifestyle interventions to cutting-edge pharmacological and non-pharmacological strategies. By compiling high-quality research and reviews, we seek to provide a comprehensive resource for researchers, clinicians, and policymakers working to combat this growing epidemic.
The importance of addressing NAFLD cannot be overstated, given its substantial and expanding global burden. As the hepatic manifestation of metabolic syndrome, NAFLD is not just a liver-specific disease but a multisystem condition associated with increased risks of cardiovascular disease (CVD), chronic kidney disease (CKD), and extrahepatic cancers. With the rising prevalence of obesity and diabetes, NAFLD is projected to become the leading cause of liver-related morbidity and mortality worldwide, surpassing even viral hepatitis and alcoholic liver disease.
One of the most pressing challenges in NAFLD management is the absence of universally approved drug therapies. While lifestyle interventions (diet, exercise, and weight loss) remain first-line treatments, long-term adherence is often poor, and not all patients achieve sufficient metabolic improvement to reverse liver damage. Additionally, the progression from simple steatosis to NASH and fibrosis varies among individuals, highlighting the need for personalized treatment strategies.
Beyond lifestyle and pharmacotherapy, novel approaches—such as microbiome modulation, gene therapy, and artificial intelligence (AI)-driven diagnostics—are opening new frontiers in NAFLD research. Understanding these emerging strategies is crucial for developing effective, targeted therapies that can halt or reverse disease progression. This Article Collection will serve as a platform to discuss these innovations, bridging the gap between preclinical research and clinical application.
We welcome original research articles, systematic reviews, clinical trials, and perspective pieces that advance the understanding of NAFLD treatment strategies. We encourage submissions that explore, but are not limited to, the following key themes:
By compiling diverse perspectives on NAFLD management, this Article Collection aims to foster interdisciplinary collaboration and accelerate the translation of research into clinical practice. We invite contributions from hepatologists, endocrinologists, nutritionists, pharmacologists, and public health experts to provide a holistic view of current and future directions in NAFLD therapy.
Through this Collection, we hope to inspire innovative solutions that will ultimately reduce the global impact of NAFLD and improve patient outcomes.
All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.
The deadline for submitting manuscripts is 2 February 2026.
Please submit your manuscript on our website, quoting the promo code 878F6 for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
If you have any questions about this Article Collection, please contact Krista Thom at [email protected].
Guest Advisors
Dr. Asghar Ali, Jamia Hamdard, New Delhi, India
Dr. Mohan Kamthan, Jamia Hamdard, New Delhi, India
Unraveling AI: The Use of Interactive AI, Conversational AI, and Generative AI in Teaching and Learning or Health and Care
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Unraveling AI: The Use of Interactive AI, Conversational AI, and Generative AI in Teaching and Learning or Health and Care", in the Journal of Multidisciplinary Healthcare.
The concept of artificial intelligence (AI) has a long history. Due to the growing availability of data, its relevance in research and application has steadily increased. Three terms dominate the actual research landscape: interactive AI (iAI), conversational AI (cAI) and generative AI (genAI).
This call for papers is dedicated to the aforementioned terms with respect to the following two application areas:
1. Learning Environments
Chatbots get increasing attention as learning assistants. They support individual, social, or metacognitive learning, offering feedback and guidance. They serve as mentors or assistants, providing motivation, cues, and instant feedback to enhance learning. In informal learning or care settings, and for individual health questions, empirical insights into chatbot-mediated learning are required.
With the growing use of chatbots, it's crucial to ask in which contexts they lead to which learning outcomes. Contributions can refer to the following or related questions:
2. Health
iAI, cAI and genAI in healthcare have the potential to ensure and, ideally, increase the effectiveness and efficiency of healthcare in the future. This call for papers explicitly welcomes contributions from the entire spectrum of healthcare, i.e. prevention, diagnostics, therapy, rehabilitation and care.
Example iAI: The proportion of people with at least one chronic disease is constantly growing. Such conditions require lifelong support and care. Solutions from the field of iAI can support such people in the form of a virtual coach and bring together various care situations (medication, appointments, etc.).
The type of research must be clearly recognizable e.g. systematic literature review, qualitative study or observational studies. Submissions must rigorously refer to established reporting guidelines, such as PRISMA, COREQ, STROBE and similar.
All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.
The deadline for submitting manuscripts is 15 January 2026.
Please submit your manuscript on our website, quoting the promo code C4247 for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
If you have any questions about this Article Collection, please contact Krista Thom at [email protected].
Guest Advisors
Prof. Dr. Daniela Schmitz, Witten/Herdecke University, Germany
Prof. Dr. Sven Meister, Witten/Herdecke University, Germany
Journal of Pain Research
Advancing Inclusion in Pediatric Pain Research, Training, and Practice
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Advancing Inclusion in Pediatric Pain Research, Training, and Practice", in the Journal of Pain Research.
Much of our current understanding of pediatric pain mechanisms and interventions is informed by an evidence base that does not adequately reflect the broader population of youth living with acute and chronic pain. Individuals who are marginalized due to sociocultural characteristics including (but not limited to) racialized identity, ethnicity, indigeneity, age, sex, gender identity, disability status, educational attainment, socioeconomic position, immigration and refugee status, and geographic location are underrepresented in pain research. These same groups are also at highest risk for experiencing profound inequities in pain care and outcomes.
Numerous calls to action have been made to improve inclusion in the design, conduct, reporting, and dissemination of pain research. Alongside efforts to meaningfully engage communities in research and recruit and retain diverse study participants, these calls highlight the importance of diversifying the research environment itself to accelerate translation of findings to real-world efforts to alleviate pain for all youth. Additionally, culturally aware mentoring resources and training for providers in culturally attuned, evidence-based pain care are imperative to foster the talents of trainees from diverse backgrounds and adequately prepare the next generation of pain scientists and clinicians. Ultimately, inclusive pediatric pain research, training, and practice seeks to ensure that innovations in pain science and care meet the needs of all youth with pain and their families.
This Article Collection seeks to advance this cause by highlighting inclusive approaches to pediatric pain research, training, and practice. Articles that focus on underrepresented groups (e.g., infants, young adults, indigenous populations, people of color, people with disabilities, LGBTQ2A+), biopsychosocial risk and resilience factors associated with chronic primary or secondary pain in young people, use of innovative methodologies or technologies to improve the quality and equity of pediatric pain care, projects that exemplify community engagement in knowledge production and/or mobilization, and approaches to enhancing diversity and inclusion within pediatric pain research and clinical workforce are especially welcome.
All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.
The deadline for submitting manuscripts is 15 January 2026.
Please submit your manuscript on our website, quoting the promo code KQQFZ for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
If you have any questions about this Article Collection, please contact Krista Thom at [email protected].
Guest Advisors
Aimee Hildenbrand, Nemours Children’s Health, USA
Shreela Palit, Nemours Children’s Health, USA
- Synthetic Strategies: Development of cutting-edge methodologies for nanozyme synthesis, including green and bio-inspired approaches.
- Mechanistic Insights: Elucidation of catalytic mechanisms and exploration of structure-property relationships.
- Biomedical Applications: Deployment of nanozymes in diagnostics, therapeutic interventions, and targeted drug delivery systems.
- Environmental Applications: Applications of nanozymes in pollutant degradation, waste management, and sustainable catalysis.
- Integration in Multifunctional Systems: Design and incorporation of nanozymes into hybrid materials and advanced devices.
- Bio/molecular nanosystems, nanoparticles including nanoscale bio/therapeutics and nano drug carriers, extracellular vesicles, smart and stimuli responsive nanobiosystems
- Nanotoxicity, nanotoxicology, biomedical sensors including sensor fusion
- Nanomedicine
- Gene therapy
- Biomimetic nanoengineering
- Single particle and single cell analysis, biomedical imaging, nanobiotechnology
- Photothermal therapy
- Nanomedicines in Skin cancer
- Nanomedicines in Lung cancer
Nanotechnology, Science and Applications
Advancing Novel Nanozymes: Preparation, Performance Analysis, and Functional Application Design
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in Nanotechnology, Science and Applications on "Advancing Novel Nanozymes: Preparation, Performance Analysis, and Functional Application Design", organized by Dr. Amin Zhang (Shanghai Jiao Tong University, China), Dr. Qian Zhang (Shanghai Jiao Tong University, China) and Dr. Jin Cheng (Wuxi Center for Disease Control and Prevention, China).
Nanozymes, a class of nanomaterials with enzyme-like catalytic properties, have emerged as a ground-breaking innovation in the fields of nanotechnology and biotechnology. These artificial enzymes replicate the catalytic activities of natural enzymes while offering enhanced stability, cost-efficiency, and remarkable potential for multifunctional design. Since their discovery, nanozymes have garnered significant attention due to their versatility, enabling diverse applications in catalysis, biosensing, medicine, and environmental remediation.
The significance of nanozymes lies in their ability to overcome the inherent limitations of natural enzymes, such as their susceptibility to denaturation and high production costs. These challenges are particularly pressing in industries that require robust and reusable catalytic agents, including industrial processing, clinical diagnostics, and therapeutic applications. Moreover, the rapid evolution of nanozyme technologies has paved the way for ground-breaking innovations, such as combating antimicrobial resistance, engineering targeted cancer therapies, and fostering sustainable environmental solutions. By focusing on the preparation, performance optimization, and functional application design of novel nanozymes, this research not only enhances foundational scientific understanding but also delivers practical benefits across a broad spectrum of scientific and industrial domains.
This Article Collection aims to highlight the latest advancements in nanozyme research, covering their preparation, performance evaluation, and innovative applications. The scope includes, but is not limited to:
Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript. The deadline for submitting manuscripts is 31 December 2025.
Please submit your manuscript on our website, using the promo code ZKKJU for 20% off the advertised article processing charge and to indicate that your manuscript will be considered for the “Advancing Novel Nanozymes: Preparation, Performance Analysis, and Functional Application Design” Collection.
Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.
Guest Advisors
Dr. Amin Zhang, Shanghai Jiao Tong University
Dr. Amin Zhang graduated from Shanghai Jiao Tong University in 2020 with a Ph.D. in Instrument Science and Technology (Biomedical and Engineering track), she finished postdoctoral research there and became an Assistant Researcher at the School of Agriculture and Biology in March 2024. Her research focuses on developing nanozyme sensing technologies and designing functional active component delivery systems. She has published over 30 papers in top international journals, such as Advanced Materials, Biosensors and Bioelectronics, Nano Research, Theranostics, and Sensors and Actuators B: Chemical.
Dr. Qian Zhang, Shanghai Jiao Tong University
Dr. Qian Zhang graduated in 2015 with a Ph.D. in Science from Philipps-Universität Marburg, Germany, under the supervision of Professor Wolfgang J. Parak. From 2016 to 2017, conducted postdoctoral research in Professor Da-Xiang Cui's research group at the School of Electronics. Served as an Assistant Researcher at the same institution from 2018 to 2022 and was promoted to Associate Researcher in 2023. In recent years, she focuses primarily on the controlled synthesis and performance studies of various inorganic nanomaterials and the development of nanodrug delivery systems to achieve multimodal tumor therapy under MRI/NIR guidance. She has published over 50 SCI papers, including 17 as the first or corresponding author, with 3 ESI Highly Cited Papers. These works have been cited more than 3,200 times, with an H-index of 29. Additionally, the applicant has contributed to two books (in both Chinese and English) and holds three authorized patents.
Dr. Jin Cheng, Wuxi Center for Disease Control and Prevention
Dr. Jin Cheng graduated from Shanghai Jiao Tong University in 2021 with a Ph.D. in Instrument Science and Technology (Biomedical and Engineering track). Since July 2021, serves as an Assistant Researcher at the Wuxi Center for Disease Control and Prevention. His research focuses on DNA nanotechnology, tumor therapy, and disease diagnosis and detection. He has published over 20 papers in top international journals like Angewandte Chemie International Edition, Nature Communications, and Nanoscale.
Current Advances in Nanotechnology: Prospects and Challenges of Nanotherapeutics in Treating Cancers
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in Nanotechnology, Science and Applications on "Current Advances in Nanotechnology: Prospects and Challenges of Nanotherapeutics in Treating Cancers", organized by Prof. Veena Agrawal (University of Delhi, India).
Cancer is a major health issue globally, with an estimated 20 million new cases and 9.7 million deaths in 2022. By 2050, projections indicate a significant increase to over 35 million new cases. Discovering novel medicines is an urgent need. Nanomedicine has emerged as a new multidisciplinary field capturing the attention of scientists. Nanotherapeutics have capabilities for effectively transporting medicines or gene fragments to tumor tissues via passive or active targeting processes; thus there are immense possibilities for enhancing treatment outcomes while causing minimum harm to healthy tissues. Nanoparticles can also be employed for advanced imaging techniques, such as MRI and PET scans, providing better visualization of internal organs and tissues. The engineered nanoparticles can be employed as contrast agents in cancer diagnostics to enable high sensitivity and high-resolution imaging examinations and tumor detection. Novel approaches for tumor labeling and detection are also made possible by the use of nanoprobes. While nanotechnology shows great potential, clinical translation faces challenges related to biocompatibility, toxicity, and the complexity of the tumor microenvironment.
Nanotechnology holds great potential where it enables targeted drug delivery, development of nano-biosensors for early disease detection, and advanced imaging techniques such as MRI and PET scans. Nanoparticles can be designed for improved cancer detection, and enhanced immune responses. Nanoparticles can be employed in the context of radiation sensitization and photothermal therapy to enhance the therapeutic efficacy of malignant tumors. The combination of nanotechnology and conventional tumor therapy can not only enhance the properties of chemoradiotherapy drugs but also reduce the incidence of poisoning and other side effects. These NPs can rapidly cross the human biological barriers, even in a targeted manner and continuously release the content to maintain the appropriate blood concentration of the drug.
Potential subtopics related to recurrent miscarriage include (but are not limited to):
Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript. The deadline for submitting manuscripts is 30 June 2026.
Please submit your manuscript on our website, using the promo code E639F to indicate that your manuscript will be considered for this Article Collection.
Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.
Guest Advisor
Prof. Veena Agrawal, University of Delhi
Professor Veena Agrawal, Senior Professor (R)of Botany (Level-15), University of Delhi, specializes in medicinal plant biotechnology, nanobiotechnology (green synthesis of nanoparticles and their efficacy against, different cancer cells, malaria vectors and diabetes), isolation and characterization of natural biomolecules, sex-linked molecular markers and genetic diversity analysis. She has published over 125 research articles in leading international journals with high impact factors, including Artificial Cells, Nanomedicines, Material Science and Engineering, Industrial Crops, Plant cell reports, Current Cancer Drug Target, Plant Science, Plant Physiology and Biochemistry, Process safety & Environmental Research, etc., Twenty five Ph. D and 21 M.phil. students obtained their degrees under her supervision in different disciplines. She is a Fellow of the Linnean Society of London (FLS) and a member of many international and national academic societies. She is on the editorial board of many journals including Arti. Cells Nanomedicines and Biotechnology. She is on the expert panels of international/national institutions for reviewing and evaluating research projects and Ph,D. theses. She has immensely contributed research to international and national platforms through presentations at conferences, seminars, and publications, as well as registering patents and receiving many awards and recognitions.
Uniting Natural Products and Biotechnology for the Next Generation of Nanomedicine
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection in Nanotechnology, Science and Applications on "Uniting Natural Products and Biotechnology for the Next Generation of Nanomedicine", organized by Dr. Przemysław Sitarek (Medical University of Lodz, Poland) and Dr. Tomasz Kowalczyk (University of Lodz, Poland).
This Article Collection focuses on the convergence of nanotechnology, natural bioactive compounds, and biotechnology to develop advanced therapeutic approaches for a wide range of diseases. The integration of plant-derived phytochemicals, animal-based molecules, and recombinant proteins into nanoscale delivery systems opens new frontiers in precision medicine, offering improved biocompatibility, targeted delivery, and enhanced therapeutic efficacy. Recent advancements in biotechnology have enabled the design and production of engineered proteins and biomolecules with high specificity and functional versatility, further enriching the potential of nanomedical platforms. When combined with the diverse pharmacological properties of naturally sourced compounds, these hybrid nanosystems present promising strategies for treating cancer, infectious diseases, inflammatory conditions, metabolic disorders, and neurodegenerative diseases. This Collection invites original research, reviews, and perspectives that explore the design, synthesis, characterization, and biomedical application of nature-inspired and bioengineered nanostructures. The aim is to provide a multidisciplinary outlook on how the fusion of nanotechnology with natural and recombinant therapeutic agents can drive innovation in diagnosis, treatment, and regenerative medicine.
This Article Collection title encapsulates a timely and significant convergence of nanotechnology, biotechnology, and nature-derived bioactive compounds originating from plant and animal sources. In the context of escalating global health challenges—such as cancer, antimicrobial resistance, chronic inflammation, and neurodegenerative disorders—there is a pressing demand for the development of therapeutic strategies that are not only safe and effective, but also precisely targeted.
Natural molecules exhibit potent biological activity and favorable biocompatibility; however, their clinical potential is often limited by low stability and bioavailability. Advances in biotechnology and nanocarrier systems offer powerful tools to overcome these limitations by enhancing molecular stability, enabling controlled delivery, and improving therapeutic precision. The incorporation of recombinant proteins further broadens the therapeutic arsenal, supporting the design of personalized and multifunctional treatment modalities.
This title reflects the essence of an interdisciplinary approach that synergistically integrates nature’s pharmacological potential with the precision and adaptability of modern scientific innovation. It signals the emergence of a new era in nanomedicine—one in which nanoscale and molecular-level technologies converge to yield next-generation solutions for complex and treatment-resistant diseases.
Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript. The deadline for submitting manuscripts is 30 June 2026.
Please submit your manuscript on our website, using the promo code F4163 to indicate that your manuscript will be considered for this Article Collection.
Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.
Guest Advisors
Dr. Przemysław Sitarek, Medical University of Lodz
Przemysław Sitarek is an Associate Professor at the Medical University of Łódź (Poland), where he heads the Department of Medical Biology at the Faculty of Pharmacy. His interdisciplinary research spans biotechnology and nanotechnology, with a strong focus on biologically active compounds, recombinant proteins, and metabolic engineering. He is particularly interested in investigating metabolic pathways and developing nature-inspired biomedical solutions to address contemporary therapeutic challenges. His work contributes to advancing the role of both natural and engineered molecules in next-generation nanomedicine.
Dr. Tomasz Kowalczyk, University of Lodz
Tomasz Kowalczyk, PhD, is an assistant professor in the Department of Molecular Biotechnology and Genetics, Faculty of Biology and Environmental Protection, University of Łódź and Department of Medical Biology, Faculty of Pharmacy, Medical University of Lodz. Research interests: Biotechnological production of natural biologically active compounds from plant and other natural sources Development of plant-based and microbial expression systems for production of valuable secondary metabolites and recombinant proteins Application of nanotechnology in combination with biotechnology.
- Animal models of sleep disorders, including sleep apnea, insomnia, and circadian rhythm disorders
- Mathematical models of sleep regulation, including two-process models and circadian oscillators
- Translational studies bridging animal model findings to human sleep medicine
- Computational approaches to sleep stage scoring and sleep architecture analysis
- Machine learning applications in sleep medicine diagnosis and treatment
- Pharmacokinetic and pharmacodynamic modeling of sleep medications
- Network analysis of sleep-related brain circuits
- Predictive models for sleep disorder outcomes and treatment response
- Requiring data availability statements for computational studies
- Encouraging submission of analysis code and mathematical model parameters
- Providing as Supplementary Materials the software allowing the model-based computations
- Novel biomarkers & digital health tools for sleep and circadian rhythm assessment
- AI-driven and precision medicine approaches to sleep health interventions
- Cross-disciplinary research networks integrating neurology, psychiatry, cardiology, and public health
- Sleep inequities & social determinants of health in marginalized communities
- Translational Sleep Science
- Circadian Health
- Precision Sleep Medicine
- Interdisciplinary Sleep Research
- Digital and AI-Driven Sleep Technologies
Nature and Science of Sleep
Animal and Mathematical Models in Sleep Science and Sleep Medicine
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Animal and Mathematical Models in Sleep Science and Sleep Medicine", in Nature and Science of Sleep.
Animal models are crucial for studying sleep and sleep disorders. They provide insights into the mechanisms of sleep regulation and the underlying causes of various sleep-related conditions, helping in the development of potential treatments. The previously used models include laboratory dogs, cats, rodents, zebrafish, fruit flies, and nematodes etc. These models have previously helped in understanding the mechanisms and in the development of new treatments for insomnia, restless legs syndrome, narcolepsy, and sleep apnea etc. The basic properties of the mechanisms regulating the sleep-wake cyclicity and behavior have easily lent themselves to mathematical modeling. Therefore, such modeling works together with experimental approaches to sleep research to provide a better understanding and prediction of findings in future studies of sleep regulation and sleep pathology. The two-process model of sleep-wake regulation (Daan et al, 1984) serves as an example of a successful story of mathematical modeling and model-based simulations in the field of sleep and biological rhythm research. This model has been the major contributor to our insights into the mechanisms underlying the 24-hour sleep-wake pattern for more than four decades.
Using animal models provides the following benefits: 1) help elucidate the brain areas, neural circuits, neurotransmitters involved in sleep regulation and sleep pathology; 2) environmental and genetic factors can be strictly controlled, allowing for the identification of specific causes and mechanisms of sleep and sleep disorders; 3) genetically modified models help to study the role of specific genes in sleep and sleep disorders; 4) used to test the efficacy and safety of new drugs for sleep disorders; 5) ethically justifiable than human studies, particularly when involving risky interventions and previously untested treatments. The mission of mathematical modeling includes: 1) to force a critical analysis of existing empirical datasets; 2) to enable the extraction of additional information from current datasets beyond what can be reported from common statistical analysis; 3) to allow more effective use of research resources; 4) to help in designing experimental protocols; 5) to provide accurate predictions of results in as-yet-untested conditions; 6) to point to hypothetical structures and processes that can be discovered in later experimental studies; 7) to uncover the underlying mechanisms and their basic components; 8) to give a common language to researchers studying not only sleep but also various other rhythmic phenomena in different species, organs, systems, and processes.
Sleep research has evolved from purely observational studies to sophisticated investigations employing animal models and mathematical frameworks. This Article Collection aims to showcase cutting-edge research that bridges experimental animal and human studies with computational approaches in sleep science and sleep medicine. Animal models have been instrumental in advancing our understanding of sleep regulation, circadian mechanisms, and sleep disorders. From rodent models of sleep apnea to non-human primate studies of circadian disruption, these approaches provide controlled experimental conditions impossible to achieve in human studies. Simultaneously, mathematical modeling has emerged as a powerful tool for understanding sleep homeostasis, predicting treatment outcomes, and analyzing complex sleep data. This Collection welcomes original research, reviews, and methodological papers covering in particular:
The Collection encourages submissions that demonstrate clear translational potential, methodological innovation, or novel insights into sleep mechanisms that could inform clinical practice.
Special Considerations
Given the technical nature of this collection, pls also consider:
All manuscripts submitted to this Article Collection will undergo desk assessment and peer review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are existing members of the Editorial Board. Please review the journal's Aims and Scope and author submission instructions prior to submitting a manuscript.
Please submit your manuscript through the Dovepress website. During submission, enter the promo code AF478 to indicate that your article should be considered for this Collection. Standard article publishing charges apply.
The manuscript submission deadline is 31 March 2026.
Please contact Catherine Teng at [email protected] with any queries regarding this Article Collection.
Guest Advisor
Arcady A. Putilov, Independent Research Group for Math-Modeling of Biomedical Systems, Berlin, Germany; Laboratory of Sleep/Wake Neurobiology, Institute of Higher Nervous Activity and Neurophysiology of the Russian Academy of Sciences, Moscow, Russia
Dr. Arcady A. Putilov studies rhythmic phenomena in living nature and individual variation in the fields of chronophysiology, psychology, and psychiatry. He is the first and/or corresponding author in more than 95% of his published journal articles. Starting from 1991, he has served as a member of editorial board of Biological Rhythm Research and, since 2016, as a co-editor of this journal. He also serves as Section Editor-in-Chief for Clock&Sleep, Review Editor for Frontiers in Physiology, Assistant Editor for Frontiers in Network Physiology, and Consulting Editor for Nature and Science of Sleep.
Bridging Bench to Bedside and Beyond: Advancing Sleep and Circadian Science for Precision Health Across All Ages
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Bridging Bench to Bedside and Beyond: Advancing Sleep and Circadian Science for Precision Health Across All Ages", organized by Guest Advisors Dr. Azizi Seixas, Dr. Carolina Scaramutti and Dr. Mairead Moloney in Nature and Science of Sleep.
Sleep and circadian rhythms are fundamental to human health and well-being, influencing cognitive function, metabolic regulation, cardiovascular health, mental health, and immune function. Disruptions in sleep and circadian biology have been linked to a wide range of diseases, from neurodegenerative disorders and cardiometabolic conditions to mood disorders and impaired developmental trajectories in children. Yet, sleep and circadian health remain underutilized as modifiable targets in preventive medicine, clinical care, and public health initiatives.
This Article Collection will focus on translational sleep and circadian health across the lifespan, highlighting research that spans developmental, clinical, and population health perspectives. We seek contributions that integrate basic science, clinical applications, and public health strategies to address sleep and circadian disruptions from infancy through older adulthood. The goal is to foster a lifespan approach to sleep health, identifying key windows for intervention, personalized treatment strategies, and innovative translational solutions that bridge laboratory research with real-world applications.
From molecular insights into circadian rhythms to population-level interventions for sleep equity, this issue will showcase groundbreaking research that leverages multi-disciplinary methodologies, digital health tools, and precision medicine approaches to tackle sleep-related challenges at every stage of life.
Understanding translational sleep and circadian health across the lifespan is critical for advancing precision medicine, public health, and clinical care. Sleep and circadian rhythms are foundational to nearly every aspect of human health—affecting brain function, cardiovascular health, metabolic regulation, immune response, and mental well-being. However, sleep remains underrecognized as a modifiable risk factor and is often excluded from mainstream healthcare strategies.
This Article Collection will bridge the gap between basic science, clinical applications, and public health interventions, bringing together experts across neurology, psychiatry, cardiology, and digital health to explore novel, data-driven, technology-enhanced solutions for sleep-related disorders. By integrating AI, digital biomarkers, and multi-modal precision health approaches, this research will redefine sleep medicine and improve health outcomes across diverse populations and life stages. Ultimately, addressing sleep and circadian health inequities can lead to more effective, scalable, and personalized interventions, making healthcare more proactive, equitable, and transformative.
Sleep and circadian health are critical yet underappreciated determinants of overall well-being, influencing neurodevelopment, cognitive aging, cardiometabolic health, mental health, and disease resilience across the lifespan. Advances in translational sleep research now offer unprecedented opportunities to integrate basic science, clinical medicine, public health, and digital health technologies to improve sleep-related outcomes for diverse populations.
This Article Collection seeks cutting-edge contributions that bridge multiple disciplines, highlighting collaborative and interdisciplinary approaches to advancing sleep health. We encourage original research, systematic reviews, meta-analyses, and methodological papers exploring topics such as:
By bringing together leading experts, this collection will advance the field toward equitable, scalable, and personalized sleep health solutions that can transform clinical and public health practices worldwide.
Keywords
All manuscripts submitted to this Article Collection will undergo desk assessment and peer review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are existing members of the Editorial Board. Please review the journal's Aims and Scope and author submission instructions prior to submitting a manuscript.
Please submit your manuscript through the Dovepress website. During submission, enter the promo code B71DF to indicate that your article should be considered for this Collection. Standard article publishing charges apply.
The manuscript submission deadline is 31 December 2025.
CPAP Therapy for Obstructive Sleep Apnea
We are pleased to announce a new Article Collection in Nature and Science of Sleep, dedicated to the game-changing role of Continuous Positive Airway Pressure (CPAP) therapy in the management of obstructive sleep apnea (OSA). Since its clinical introduction, CPAP therapy has revolutionized patient care, offering significant benefits in improving sleep quality, reducing daytime fatigue, and enhancing overall cardiovascular health for eligible patients.
Given the importance of CPAP therapy in managing obstructive sleep apnea, Nature and Science of Sleep invites submissions of original research articles, reviews, and perspectives exploring the clinical efficacy, safety, mechanisms of action, and real-world application of these transformative therapies.
The Collection, edited by Editor-In-Chief Professor Ahmed BaHammam, is part of the new Game Changer series of Article Collections, focusing on breakthrough therapies, drugs, or technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes.
While the call is open to receive manuscripts across the broad spectrum of CPAP therapy in obstructive sleep apnea, the Editors are particularly interested in manuscripts relating to the following areas:
• Pathophysiological mechanisms of CPAP and alleviation of OSA symptoms
• Randomized controlled trials assessing the clinical effectiveness of CPAP therapy in OSA
• Observational studies examining the relationship between CPAP use and outcomes in the real-world setting.
• Studies focused on CPAP adherence and patient adherence
• Personalized CPAP approaches - Given the growing recognition that OSA treatment needs individualization beyond the traditional "one-size-fits-all" approach.
• Technology integration and telemedicine - The role of remote monitoring, mobile health applications, and digital therapeutics in improving CPAP adherence.
• Health economics and accessibility - Studies examining cost-effectiveness and strategies to improve access, particularly in developing countries where simpler, lower-cost CPAP devices show promise.
• Cardiovascular outcomes research - More robust studies addressing the ongoing debate about CPAP's cardiovascular benefits, particularly focusing on adherent patients.
Submitting authors will be eligible for a 20% discount on the Article Publishing charge by entering the code B2707. The code must be applied at the point of submission.
Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.
Please review the journal's Aims and Scope and author submission instructions prior to submitting a manuscript. Please submit your manuscript through the Dovepress website. The manuscript submission deadline is 1 April 2026.
If you have any queries regarding the Article Collection or would like to discuss a submission, please email the Commissioning Editor at [email protected].
Orexin Receptor Antagonists for Insomnia
We are pleased to announce a new Article Collection in Nature and Science of Sleep, focused on the role of orexin receptor antagonists in the management of insomnia.
Where behavioral interventions are not effective, pharmacological treatments can offer an alternative for insomnia patients. However, while benzodiazepines and "Z-drugs" can be effective in the short term, long-term use is associated with side effects including the development of tolerance and addiction. Orexin receptor antagonists, a relatively new class of medications, have reduced dependance and tolerance-inducing effects, showing promise for longer-term use.
Given the emerging importance of orexin receptor antagonists in managing insomnia, Nature and Science of Sleep invites submissions of original research articles, reviews, and perspectives exploring the clinical efficacy, safety, mechanisms of action, and real-world application of these therapies.
The Collection, edited by the Editor-In-Chief Professor Ahmed BaHammam, is part of the new Game Changer series of Article Collections, focusing on breakthrough therapies and drugs.
While the call is open to receive manuscripts across the broad spectrum of orexin receptor antagonists in insomnia, the Editors are particularly interested in manuscripts relating to the following areas:
• Studies exploring the neurobiological pathways and mechanisms through which orexin receptor antagonists exert their effects.
• Studies evaluating the efficacy of orexin receptor antagonists in different patient populations.
• Studies assessing the safety and tolerability of orexin receptor antagonists.
• Comorbid conditions - Studies examining orexin antagonists in patients with insomnia and concurrent sleep disorders or psychiatric conditions.
• Comparative effectiveness research - Head-to-head studies with other insomnia treatments.
• Long-term safety profiles - Extended follow-up studies given the relatively recent introduction of these medications.
Submitting authors will be eligible for a 20% discount on the Article Publishing charge by entering the code 20F21. The code must be applied at the point of submission.
Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.
Please review the journal's Aims and Scope and author submission instructions prior to submitting a manuscript. Please submit your manuscript through the Dovepress website. The manuscript submission deadline is 1 April 2026.
If you have any queries regarding the Article Collection or would like to discuss a submission, please email the Commissioning Editor at [email protected].
- Novel antipsychotic drug mechanisms, pharmacology, and targets
- Clinical effectiveness of antipsychotic drugs on reduction of psychotic symptoms and emotional regulation
- Impact of antipsychotic treatments on cognition, functional recovery, and neurobiological changes
- Efficacy and safety of antipsychotics for optimizing treatment and minimizing side effects
- Long-acting injectable (LAI) antipsychotic drugs for improving treatment adherence and patient outcomes
- Innovations and technologies in personalized antipsychotic treatment
- AI/ML in Neuropsychiatric Disease Diagnosis and Prognosis: Studies on how AI models, including deep learning and reinforcement learning, can be used to predict disease onset, progression, and therapeutic response.
- AI/ML Models for Biomarker Discovery: Utilizing machine learning algorithms to identify novel biomarkers for neuropsychiatric conditions, focusing on genetic, neuroimaging, and clinical data integration.
- Personalized Treatment through AI/ML: Exploration of AI-driven approaches in tailoring treatments for patients based on their unique genetic, clinical, and environmental factors.
- Data Mining Techniques in Cognitive Disorder Management: Application of advanced data mining algorithms to clinical datasets for the early detection and monitoring of conditions like schizophrenia, bipolar disorder, and depression.
- Neuroimaging and Neuroinformatics in AI/ML: Development of AI/ML algorithms to analyze neuroimaging data (e.g., MRI, PET scans) for better understanding of brain structures associated with neuropsychiatric disorders.
- Challenges and Ethical Considerations in AI/ML in Neuropsychiatry: Addressing issues related to data privacy, ethical implications, and bias in AI/ML models when applied to sensitive health data.
- Transcranial magnetic stimulation (TMS) for depression and obsessive-compulsive disorder (OCD)
- Electroconvulsive therapy (ECT) for depression and other mood disorders
- Vagus nerve stimulation (VNS) for depression and epilepsy
- Deep brain stimulation (DBS) for Parkinson’s disease and OCD
- Cranial electrotherapy stimulation (CES) for depression, anxiety, and insomnia
- Neurological mechanisms and pathways
- Clinical benefits and long-term outcomes
- Cognitive and emotional effects
- Risks, side effects, and safety considerations
- Technical innovations and personalized approaches
- Neuropsychiatric disorders
- Autoimmunity
- Infection
- Neuroinflammation
- Mind-body connection
Neuropsychiatric Disease and Treatment
Antipsychotic Treatments - Transforming Schizophrenia Management in the Modern Era
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Antipsychotic Treatments - Transforming Schizophrenia Management in the Modern Era" in Neuropsychiatric Disease and Treatment.
We are pleased to announce a new Article Collection in Neuropsychiatric Disease and Treatment, dedicated to the game-changing role of antipsychotic treatments in the management of schizophrenia.
Since their clinical introduction, antipsychotic treatments have revolutionized care for patients with schizophrenia, offering benefits in reducing psychotic symptoms, stabilizing mood and emotions, improving cognitive and occupational functioning, and suicide prevention.
Given their global importance, Neuropsychiatric Disease and Treatment invites submissions of original research articles, reviews, and perspectives exploring the mechanisms of action, clinical efficacy, safety, and real-world application of antipsychotics in the management of schizophrenia.
The Collection, edited by the Editor-In-Chief Dr. Roger Pinder, is part of the new Game Changer series of Article Collections, focusing on breakthrough therapies, drugs, or technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes.
While the call is open to receive manuscripts across the broad spectrum of antipsychotic treatment in schizophrenia, the Editors are particularly interested in manuscripts relating to the following areas, including but not limited to:
Please submit your manuscript on our website. Submitting authors will be eligible for a 20% discount of the Article Publishing Charge by applying the following code at the point of submission TQYVE. If you have any queries regarding the Article Collection or would like to discuss a submission, then please email the Commissioning Editor Sam Zhang at [email protected].
Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.
Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript. The deadline for submissions is 1 April 2026.
Artificial Intelligence and Machine Learning in Neuropsychiatric Disease Diagnosis, Prognosis, and Treatment
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Artificial Intelligence and Machine Learning in Neuropsychiatric Disease Diagnosis, Prognosis, and Treatment" in Neuropsychiatric Disease and Treatment.
Artificial intelligence (AI), machine learning (ML), and data mining (DM) have become pivotal tools in revolutionizing the diagnosis, treatment, and management of neuropsychiatric diseases. These technologies, capable of handling vast amounts of complex data, offer innovative solutions to traditional clinical approaches. The intersection of AI, ML, and neuropsychiatry is expanding rapidly, bringing about groundbreaking advancements in understanding conditions such as Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder, Anxiety and Depressive Disorders, Schizophrenia, and other cognitive disorders. By leveraging data-driven techniques, it is now possible to detect patterns in patient data that were previously difficult to identify, enabling early detection, personalized treatment, and improved patient outcomes. This Article Collection will explore how AI, ML, and DM are being applied to neuropsychiatric diseases, highlighting recent research and methodologies.
The importance of this topic lies in its potential to address some of the most pressing challenges in neuropsychiatric healthcare. Traditional diagnostic methods, based on clinical judgment and limited patient data, often fail to capture the complexity of brain disorders. The integration of AI and ML techniques, such as neural networks, deep learning, and reinforcement learning, promises to enhance diagnostic accuracy, predict disease progression, and optimize treatment strategies. Additionally, the ability of AI and ML to analyze multimodal data, including genetic, neuroimaging, and behavioral data, could lead to the discovery of novel biomarkers and personalized therapeutic interventions. As these technologies become more refined, they hold the potential to revolutionize how neuropsychiatric conditions are understood and treated.
This Article Collection will focus on the cutting-edge applications of AI, ML, and DM in the field of neuropsychiatry. We welcome original research, survey papers, meta-analyses, and review articles that explore the following subtopics including but not limited to:
This Article Collection will appeal to researchers, clinicians, and technologists interested in how AI and ML can improve the diagnosis, treatment, and management of neuropsychiatric diseases.
All manuscripts submitted to this Article Collection will undergo desk assessment and peer review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are existing members of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.
The deadline for submissions is 30 June 2026.
Please submit your manuscript on our website, quoting the promo code HXCWA for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
Guest Advisors
Dr Sathishkumar V Easwaramoorthy, Sunway University
Professor Vetriselvan Subramaniyan, Sunway University
Autism, Autonomy, and Policy: Approaches to Enhancing Choice and Long-Term Cost Savings Across ASD Communities
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Autism, Autonomy, and Policy: Approaches to Enhancing Choice and Long-Term Cost Savings Across ASD Communities" in Neuropsychiatric Disease and Treatment.
Individuals with Autism Spectrum Disorder (ASD) and/or Intellectual Development Disorder (IDD) face significant barriers to autonomy in key areas such as healthcare, education, employment, therapy modalities, housing, and daily living. Policy frameworks often prioritize standardized interventions rather than individualized support, limiting choice and self-determination. This Article Collection explores how policy-driven, data-informed approaches may enhance autonomy for individuals with ASD and/or IDD and their caregivers, improve well-being, and reduce long-term costs associated with restrictive care models. By integrating perspectives from neuropsychiatry, public health, and social policy, this collection will provide insights into the intersection of ASD/IDD, mental health, and systemic reforms needed to support choice and inclusion.
Autonomy-supportive policies are crucial for improving the quality of life of individuals with ASD or IDD while also reducing economic burdens on healthcare, social services, and government programs. Research has shown that when individuals are given greater control over their care, educational pathways, and employment opportunities, they experience better mental health outcomes, greater social integration, and increased economic productivity. However, disparities exist in access to such opportunities, particularly among racially and ethnically diverse communities. By examining how autonomy-driven policies may enhance self-determination while providing long-term cost savings, this Article Collection will highlight solutions that benefit both individuals and broader societal structures.
This Article Collection will focus on but not limited to the following four key areas:
(1) Supported decision-making models and policy interventions that investigate autonomy in education, healthcare, and employment for individuals with autism spectrum disorder (ASD) and or Intellectual Development Disorder (IDD).
(2) The intersection of ASD/IDD and mood disorders, with a focus on improving mental health outcomes through autonomy-supportive approaches and investigating self-efficacy in ASD or IDD.
(3) Racial and ethnic disparities in ASD or IDD diagnosis and services, highlighting how culturally competent policies and understanding of varying conceptions of autism may bridge gaps in care.
(4) Economic analyses of long-term cost savings associated with autonomy-supportive policies in relation to housing, supportive care and therapy modalities, and education.
We welcome original research, systematic reviews, and case studies that provide data-driven recommendations for understanding the role of autonomy within the scope of neuropsychiatric disease and treatment.
Please submit your manuscript on our website. Submitting authors will be eligible for a 10% discount of the Article Publishing Charge by applying the following code at the point of submission 3C3FF. If you have any queries regarding the Article Collection or would like to discuss a submission, then please email the Commissioning Editor Sam Zhang at [email protected].
Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript. The deadline for submissions is 31 January 2026.
Guest Advisors
Allyson Kristofik, Saint Michael’s College
Independent Researcher
Ms. Kristofik is an autistic self-advocate and researcher with ten years of experience in research-based institutions, the government sector, and leading autism-focused nonprofit organizations. As a co-advisor for the Neuropsychiatric Disease and Treatment Autism Article Collection, she brings a unique perspective that integrates lived experience with scholarly expertise. Her published work focuses on addressing service gaps, policy improvements, and transitional support for autistic individuals and their caregivers. With a background in psychology and neuropsychoanalysis, Ms. Kristofik is committed to advocating for meaningful, evidence-based systemic change.
Katandria Love Johnson, Abilene Christian University
Dr. Katandria Demps is co-founder of KLD Consulting. She is a multi-lingual, nationally certified speech-language pathologist, linguist, certified autism specialist, certified public health researcher and certified in the practice of cognitive rehabilitation, ACA advanced national caregiving and assisted living.
Environmental Factors in Neuropsychiatric Pathophysiology and the Role of Alternative Therapeutic Approaches
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Environmental Factors in Neuropsychiatric Pathophysiology and the Role of Alternative Therapeutic Approaches" in Neuropsychiatric Disease and Treatment.
Neuropsychiatric disorders, including depression, anxiety, schizophrenia, and bipolar disorder, arise from a complex interplay of genetic, neurobiological, and environmental factors. Among these, environmental influences play a pivotal role in shaping brain function and mental health. Exposure to psychological stress, trauma, sleep dysfunction, toxicants, infections, and socioeconomic factors can contribute to neuropsychiatric pathophysiology by altering neurochemical balance, inflammatory pathways, and neuronal signaling and plasticity. While conventional treatments such as pharmacotherapy and psychotherapy remain the cornerstone of management, alternative therapeutic approaches are gaining recognition for their potential to complement traditional treatments. New concepts in nutritional psychiatry, gut microbiome, mindfulness-based therapies, transcranial magnetic stimulation, exercise, and herbal medicine have led to propositions and explorations of alternative interventions for treating mental health disorders based upon their neuroprotective and neuromodulatory effects. This Article Collection aims to explore the intricate relationship between environmental factors and neuropsychiatric disorders, while also evaluating the efficacy and mechanisms of alternative therapeutic approaches for holistic, personalized treatment.
With increased life expectancies coupled with detrimental life-style changes, there has been a tremendous rise in the global burden of neuropsychiatric disorders. They have become a leading cause of disability worldwide, affecting millions of individuals. Environmental influences (e.g., chronic stress, pollution, urbanization, socioeconomic disparities, trauma, sleep issues, poor nutrition, etc.) play a crucial role in both the development and progression of these multifactorial and heterogeneous of neurological conditions. While pharmacotherapy and psychotherapy remain standard treatments, they are not always effective for all patients and may have side effects. Novel alternative treatments are being proposed regularly and are gaining scientific validation for a more comprehensive, patient-centered approach to neuropsychiatric care. Thus, identification of modifiable environmental risk factors and exploring alternative therapies can lead to prevention and early intervention, and more effective, personalized, and holistic treatment strategies.
This Article Collection will explore the complex interaction between environmental exposures and neuropsychiatric pathophysiology while evaluating the potential of alternative treatment approaches. The subtopics include, but are not limited to, (i) environmental factors contributing to neuropsychiatric disorders: chronic stress, trauma, and early-life adversity, influence of pollutants, heavy metals, and endocrine disruptors, urbanization, socioeconomic status, and lifestyle factors, (ii) neurobiological mechanisms linking environmental stressors to psychiatric disorders: neuroendocrine changes, alterations in neurotransmitter (dopamine, serotonin, glutamate) systems and neuroplasticity, oxidative stress, neuroinflammation and gut microbial dyshomeostasis, and (iii) alternative therapeutic approaches for neuropsychiatric disorders: nutritional psychiatry (ketogenic diet, micronutrients, and omega-3 fatty acids, etc.), mindfulness-based interventions and meditation, mental and physical activity, gut microbiome modulation, non-invasive brain simulation (TMS, tDCS, etc.), herbal medicines. Both reviews and original research will be entertained.
All manuscripts submitted to this Article Collection will undergo desk assessment and peer review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are existing members of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.
The deadline for submissions is 30 April 2026.
Please submit your manuscript on our website, quoting the promo code NRCCP for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
Guest Advisors
Dr. Faraz Ahmad, Vellore Institute of Technology, India
Dr. Faraz Ahmad’s research focusses on understanding the molecular mechanisms of synaptic pathology in a range of neuronal disorders, ranging from early-life stress to ageing-induced cognitive decline. He’s also interested in devising and evaluating phytotherapy-based strategies for neuroprotection.
Dr. Shafiul Haque, Jazan University, Saudi Arabia
Dr. Shafiul Haque has been offering 15+ years of accomplished experience in health sciences/ biomedical sciences /life sciences research, academia, bio-business with flare of research strategy and scientific management, team leadership, design & development of biological research projects/products, research application support and R&D project management.
Neuromodulation in Neuropsychiatric Disorders
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Neuromodulation in Neuropsychiatric Disorders" in Neuropsychiatric Disease and Treatment.
We are pleased to announce a new Article Collection in Neuropsychiatric Disease and Treatment, dedicated to the game-changing role of neuromodulation therapies in the management of neuropsychiatric disorders.
The collection, edited by the Editor-In-Chief Dr. Roger Pinder, is part of the new Game Changer series of Article Collections, focusing on breakthrough therapies, drugs, or technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes.
While the call is open to receive manuscripts across the broad spectrum of neuromodulation in neuropsychiatric disorders, the Editors are particularly interested in those that are being used within the clinic:
Submissions on other neuromodulation therapies in treating neuropsychiatric disorders are also welcome. The subtopics of interest include but are not limited to:
Please submit your manuscript on our website. Submitting authors will be eligible for a 20% discount of the Article Publishing Charge by applying the following code at the point of submission NZIEY. If you have any queries regarding the Article Collection or would like to discuss a submission, then please email the Commissioning Editor Sam Zhang at [email protected].
Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.
Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript. The deadline for submissions is 1 April 2026.
Neuropsychiatric Aspects of Autoimmune Illness and Infectious Disease
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Neuropsychiatric Aspects of Autoimmune Illness and Infectious Disease" in Neuropsychiatric Disease and Treatment.
In the 17th century, Rene Descartes posited that the mind and body are fundamentally distinct, but the boundary between physical and mental health has been challenged by awareness that psychological factors influence physical health. It was in 1818 that the German physician Johann Christian introduced the term “psychosomatic”. Over the past century it has become increasingly apparent that physical disease can cause psychiatric symptoms, or “somatopsychic” illness. While this pattern has long been apparent in conditions such as thyroid disorders, brain tumors and vitamin deficiencies, there is now widespread research documenting the role of neuroinflammation as a cause of neuropsychiatric disorders. Autoimmune illnesses and infections are increasingly recognized as potential contributors to neuropsychiatric illness.
The immune system is tasked with defending the body against pathogens and aberrant cell growth that may lead to malignancies. When the immune response becomes misdirected, the resulting inflammation can attack healthy tissues, including those in the brain. Neuroinflammation can manifest as cognitive changes, depression, anxiety, psychosis, irritability or other neuropsychiatric symptoms. Understanding the capacity of autoimmune conditions and infections to cause a wide range of mental health issues is crucial for accurate diagnosis and treatment, especially when psychiatric symptoms emerge suddenly or atypically, or precede physical complaints.
The intersection of the immune system and brain function has emerged as a crucial frontier in medicine. Autoimmune diseases and infections are increasingly recognized not only for their systemic manifestations but also for their profound neuropsychiatric effects. Conditions such as lupus, multiple sclerosis, post-Covid syndrome, Lyme disease and even common viral illnesses can trigger a wide range of cognitive, emotional, and behavioral symptoms. Understanding these complex interactions is vital for early diagnosis, effective treatment, and improved quality of life for affected individuals. This Article Collection brings together cutting-edge research and expert perspectives on the mechanisms, clinical presentations, and therapeutic approaches to neuropsychiatric complications of autoimmune and infectious diseases. Through a multidisciplinary lens, we aim to highlight the biological underpinnings, diagnostic challenges, and evolving management strategies at this dynamic interface between immunology, neurology, and psychiatry.
Keywords
All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisors for this Collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.
Please submit your manuscript on our website, quoting the promo code 80BEE to indicate that your submission is for consideration in this Article Collection. The deadline for submitting manuscripts is 31st Mar 2026.
Please contact Sam Zhang at [email protected] with any queries and discount codes regarding this Article Collection.
Guest Advisors
Dr. Daniel A. Kinderlehrer, Private practice
Daniel A. Kinderlehrer M.D. is a nationally recognized physician with expertise in the fields of nutrition, allergy, environmental medicine, Lyme disease and the healing of mind-body-spirit as a unified whole. Dr. Kinderlehrer has taught extensively, including practitioner training courses at the Omega Institute, The National Institute of Behavioral Medicine, and the International Lyme and Associated Diseases Society. He is the author of several articles in medical journals, the Lyme Times, and Psychology Today. His integrated medical practice in Denver, Colorado focuses on the diagnosis and treatment of tick-borne disease. Dr. Kinderlehrer is the author of Recovery From Lyme Disease: The Integrative Medicine Guide to the Diagnosis and Treatment of Tick-Borne Illness, which was released in 2020.
Dr. Robert C Bransfield, Hackensack Meridian School of Medicine Rutgers-RWJ School of Medicine
Dr. Robert C. Bransfield, MD, DLFAPA has held a number of administrative positions with hospitals and organizations involved with health, mental health and community related activities and has received multiple awards from the American Psychiatric Association and the International Lyme and Associated Diseases Society. Dr. Bransfield’s clinical activities has focused upon treating patients who are considered to be treatment resistant. Many of these patients were found to have infectious disease contributors to their psychiatric symptoms. As a result, his research has often focused upon the association between infectious disease and mental illness. Dr. Bransfield has authored and co-authored a number of publications in peer-reviewed and other literature and has been active in political advocacy.
- Innovative radiation techniques, including proton therapy, carbon ion therapy, and stereotactic body radiotherapy (SBRT).
- Technological innovations in radiation oncology, including the development and implementation of technologies such as artificial intelligence, machine learning, and image-guided radiation therapy (IGRT) in clinical practice.
- Radiation therapy and immunotherapy combinations.
- Personalized radiation therapy
- Radiation-induced toxicity management
OncoTargets and Therapy
Radiation Therapies for Cancer
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Radiation Therapies for Cancer" in OncoTargets and Therapy.
Radiation therapy remains a cornerstone in the treatment of various cancers. With continuous advancements in technology and a deeper understanding of cancer biology, radiation therapies are becoming more precise and effective. This Article Collection seeks to explore these advancements, including novel radiation techniques, toxicity management, and integration of radiation therapies with other treatment modalities.
We invite papers on topics including but not limited to:
The deadline for submissions is 1 December 2025. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.
Please submit your manuscript on our website, quoting the promo code MMCTR for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
Patient Preference and Adherence
Comprehensive Management of Chronic Respiratory Diseases
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection entitled “Comprehensive Management of Chronic Respiratory Diseases” in Patient Preference and Adherence.
Chronic respiratory diseases, such as Chronic Obstructive Pulmonary Disease (COPD) and asthma, represent a significant global health burden. Effective management of these conditions requires a multifaceted approach that includes inhalation therapy, pulmonary rehabilitation, biologic therapies, physical activity, and psychological support.
This Article Collection aims to explore these key components in the management of chronic respiratory diseases, with a focus on enhancing treatment adherence and improving patient outcomes. Inhalation therapy is the cornerstone of treatment, but adherence challenges related to device complexity and patient understanding persist. The Collection examines strategies to improve inhaler use, such as patient education and simplified devices. Pulmonary rehabilitation, which combines physical activity, education, and behavioral interventions, is increasingly recognized as an essential aspect of managing respiratory conditions, particularly in COPD.
The Collection will explore how pulmonary rehabilitation programs can improve functional capacity, reduce symptoms, and enhance quality of life. Additionally, the growing role of biologic therapies, particularly in severe asthma and COPD, will be addressed, focusing on their ability to reduce exacerbations and improve long-term control. Psychological support will also be discussed, as mental health conditions like depression and anxiety can significantly impact treatment adherence and overall well-being. By integrating these diverse elements—pharmacological, physical, and psychological care—this Collection offers a comprehensive perspective on optimizing care and outcomes for patients with chronic respiratory diseases.
Key topics appropriate for this Article Collection include, but are not limited, to:
• Inhalation therapy: multiple devices vs. single device, adherence challenges, patient preferences, improving adherence, device usability, and patient education
• Pulmonary rehabilitation: benefits, components, and integration into treatment plans
• Physical activity as part of a holistic management strategy
• The role of biologic therapies in severe asthma and COPD
• Psychological support: addressing mental health issues and enhancing treatment adherence
• Personalizing care through patient preferences and shared decision-making
All manuscripts submitted to this Article Collection will undergo desk assessment and peer review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are existing members of the Editorial Board. Please review the journal Aims and Scope and Author Submission Instructions prior to submitting a manuscript.
The deadline for submissions is 31 January 2026.
Please submit your manuscript on our website, quoting the promo code RLZYR for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
If you have any queries regarding this Article Collection, please reach out to the Commissioning Editor, Darcy Hodge ([email protected]).
Guest Advisor
Dr. Alessandra Tomasello, Vanderbilt University Medical Center
Dr. Alessandra Tomasello is currently a Visiting Research Fellow at Vanderbilt University Medical Center, joining the Cahill Group. She attended Comenius University of Bratislava (SK) where she obtained her MD degree. She then attended the School of Respiratory Diseases at the University of Palermo, where she completed her residency in Pulmonology. Her primary research interest is mainly focused on chronic respiratory diseases with particular interest in asthma and COPD: pathophysiological mechanisms, biomarkers, characterization of phenotypes of the disease, evaluation of airway remodeling processes and the effects of treatments and target therapy.
Digital Healthcare Solutions for Patient Experience and Medication Adherence
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection entitled “Digital Healthcare Solutions for Patient Experience and Medication Adherence”, organized by Dr. Krzysztof Laudanski in Patient Preference and Adherence.
The introduction of technology into healthcare has developed from humble beginnings into an essential for many aspects of medicine. Recently, as with many other industries, there has been increased interest in the digital solutions available worldwide. Such solutions include those developed in times of need, such as the introduction of telemedicine during the COVID-19 pandemic, and some have emerged in tandem with developments in other areas, including machine learning and artificial intelligence.
The potential benefits of digital solutions for patients are vast, and as this Article Collection aims to highlight, the application and implementation of digital technologies are crucial to their success in healthcare settings. This is with the end goal of maximizing the patient experience and using technologies to promote good health-related outcomes. One facet of this includes medication adherence, for both communicable and non-communicable diseases, which presents challenges to patient care, recovery and disease maintenance. Certain medical specialties may endure more challenges with medication adherence than others, but it is also crucial to recognize the patient in this process; for example, the reasons behind failure to adhere to medication regimens, side-effects, comorbidities and additional aspects of the patient experience – all of which are important to recognize for their care.
The importance of medication regimens in healthcare cannot be overstated and, therefore, barriers to adherence ought to be overcome. This is with the aim of delivering the best-quality care. Digital healthcare solutions help healthcare professionals embark on a new age of medical care, including the ability to accommodate various preferences and environments. This not only changes the practical aspects of providing care, but indeed how patients may perceive and experience healthcare settings across their lifespan. However, that is not to suggest that digital technologies can provide a ‘one-size-fits-all’ solution for all patients and all conditions. It is paramount to the future of digital healthcare technologies to investigate the specific relationships certain technologies have with multiple factors.
In order to provide effective care, digital healthcare technologies must be sensitive to patients' authentic needs and experiences. This includes assisting with patient care beyond inpatient settings, as the power of preventative medicine and patient self-care continues to be highlighted, particularly in light of overburdened and underfunded global health systems. Knowledge of the digital healthcare technologies in development, and their implementation, is paramount to continuing serving patient needs as effectively as possible.
This Article Collection aims to highlight the value of digital healthcare solutions, such as telemedicine for patient care and experience. It is hoped that by launching this Collection, we will help readers feel better empowered to utilize digital healthcare solutions and to research ways of improving these technologies, with the goal of enhancing the patient experience further. The Collection is open to submissions from all disease areas and all patient groups, but submissions must have a focus on digital healthcare solutions and the patient experience.
Topics of interest may include, but are not limited to:
• Development and implementation of digital healthcare solutions and technologies
• Adaptations and strategies relating to patient groups, disease areas and more
• Relationship between digital healthcare and patient outcomes
• Telehealth, remote monitoring, electronic health records and artificial intelligence in healthcare settings
• Role of technology in diagnoses, medication adherence and overall patient experience
All manuscripts submitted to this Article Collection will undergo desk assessment and peer review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are existing members of the Editorial Board. Please review the journal Aims and Scope and Author Submission Instructions prior to submitting a manuscript.
The deadline for submissions is 21 November 2025.
Please submit your manuscript on our website, quoting the promo code NSENH for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
Guest Advisor
Dr. Krzysztof Laudanski, Mayo Clinic: Rochester, Minnesota, US
Dr. Laudanski is a board-certified anesthesiologist and critical care doctor. He holds a Regional Anesthesia Certificate from the American Association of Anesthesiologists. His clinical experience focuses on managing ECMO, VAD, postoperative recovery, sepsis, and senescence secondary to maladaptive allostasis after critical illnesses. Additionally, he has expertise in neuro-critical care and telemedicine. Krzysztof “Kris” Laudanski’s research focuses on the regulation of DNA in critical care illnesses survivors and innovation in healthcare. His passion is providing support to future generations of medical professionals. In these efforts, he creates a tailored plan that fits both the mentee’s and mentor’s interests, goals, and passion.
Pharmacogenomics and Personalized Medicine
Breaking Down the Intricacies of Catabolic Enzymes
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection entitled “Breaking Down the Intricacies of Catabolic Enzymes”, organized by Editor-in-Chief Dr. Martin Bluth in Pharmacogenomics and Personalized Medicine.
Genetic polymorphisms are one way in which people vary from one another. While initial thoughts of "variance" might include a person’s physical features, it is well established that the body’s internal processes are also subject to differ dependent on a multitude of factors. This could include traits that follow them from birth, but also polypharmacy, or even diet.
In line with the advances in modern medicine and genetic testing, research has started to explore the plethora of information linked to catabolic enzyme polymorphisms. This can involve specifying polymorphisms of interest, such as the Cytochrome P450 (CYP) family such as those including the location on the chromosome, possible allelic variations and the impact of these polymorphisms on their parent compound, metabolites or other molecules.
Genetic polymorphisms affect many parts of human function, irrespective of specific health status. This stresses the importance of such polymorphisms further, for both promoting wellbeing in times of health, but to also understand how to approach certain illnesses given the variance in each individual case. This Collection aims to explore the role of catabolic enzyme polymorphisms for a wide variety of disease areas, such as oncology, pulmonology, immunology, psychology, cardiology and more.
The advances in medicine can also leave researchers asking more questions. As more drug compounds reach regulators and medicine agencies, should we be considering how enzyme polymorphisms influence the efficacy and reaction of new medicines? What dangers exist when you inhibit or enhance an enzyme reaction? When considering these possibilities for new medicines, it is also imperative to acknowledge the range of possible reactions and their severity, given that polymorphisms highlight how differences between people should not be underestimated. In turn it is hoped that this Article Collection can promote best practices when prescribing treatments, by placing leading research in this collection.
It is also hoped that research can investigate catabolic enzyme polymorphisms with a wider lens, to understand global trends in such polymorphisms and our understanding of variance on a larger scale. Thus, exploring upcoming topics of interest in this field, such as genomic testing and the use of bioinformatics in predictive technologies, elucidating the intricacies of such interaction are now within reach. These possibilities may provide more control to the individual, their medical practitioners, drug manufacturers by acknowledging human variance stretches beyond what meets the eye. These investigations, questions and early research outcomes highlight the importance of this topic for sustaining our health as a population.
The journal is seeking original submissions and review articles from all disease areas on the following topics related to catabolic enzyme polymorphisms:
• Identifying and understanding polymorphisms (e.g., single-nucleotide polymorphisms)
o All aspects of enzyme metabolism (e.g., catabolism, anabolism)
o Associated mutations, location and allelic compositions
o Functions of interest (e.g., CYPs, steroidogenic enzymes)
• Incidence and variance of poor metabolizers
• Biochemical impact of polymorphisms (e.g., on parent compound, metabolites)
• Impact of polymorphisms on drug reaction symptoms, severity and consequences
o Variance in pro-drug and active drug reactions
• Non-drug consumables (i.e. diet, infectious diseases) and polymorphisms
• How epigenetic and infectious processes affect polymorphism function
• Treatment efficacy and polymorphisms
o Role of polypharmacy on reactions
o Personalized dosages, drug classes and emergency medical care
• Global trends and variation in polymorphisms
• Progress in polymorphism genomic testing and associated benefits and costs
• Use of bioinformatics and modelling systems for predictive testing
All manuscripts submitted to this Article Collection are subject to desk assessment and peer review processes as part of our standard editorial process. We kindly ask all submitting authors to review the Aims and Scope of the journal, alongside the Author Information prior to completing your submission.
The deadline for submissions is 31 May 2024.
Please submit your manuscript on our website, quoting the promo code XSMPT for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
- Illustration of best practices of RWD with use cases demonstrating improved drug development and evaluation and health outcomes
- The integration of drug development and evaluation with RWD and AI/ML, including EHRs, insurance claims, patient registries, and other data sources with linkage to public health entities
- The development and applications of novel approaches (e.g., novel AI/ML and causal principled models) to study drug development and evaluation
- Opportunities and challenges for digital health technologies to transform drug development and evaluation and improve patient care
- The improvement of clinical research enrollment diversity for drug development and evaluation
- Use cases of studying drug development and evaluation and enabling learning health systems and learning health communities
- Infrastructure, including governance, IT support from EHRs, and key implementation best practices to support RWD and AI/ML to conduct research for drug development and evaluation
Pragmatic and Observational Research
Real world data and AI/machine learning for drug development and drug evaluations
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Real world data and AI/machine learning for drug development and drug evaluations” in Pragmatic and Observational Research.
This Article Collection will focus on studies that use real world data (RWD) and artificial intelligence (AI) and machine learning (ML) to conduct drug development and drug evaluation research. Our goal is to highlight the integration of RWD with AI/ML to promote pragmatic and observational research.
RWD, such as electronic health records (EHRs) and insurance claims, when combined with AI/ML, offer a unique opportunity to develop innovative approaches to conduct drug development and evaluation research. By combining AI/ML and RWD, drug development and evaluation can become more data-driven, efficient, and patient-centric, ultimately leading to faster discovery, development, and delivery of safe and effective drugs.
Manuscripts should be written for a broad target audience within the field of pragmatic and observational research. Manuscripts addressing the spectrum of the integration of RWD with AI/ML for drug development and evaluation research will be considered, with the following being of interest:
All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisors for this Collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.
Please submit your manuscript on our website, quoting the promo code ZNFGI to indicate that your submission is for consideration in this Article Collection.
The deadline for submitting manuscripts is 31 December 2025. For questions about this Article Collection, including inquiries regarding discounts off of the article publishing charges, please contact Commissioning Editor Haoyang Yi at [email protected].
Guest Advisors
Jiang Bian, Professor & Chief Data Scientist, University of Florida
Dr. Bian is currently a Professor and Division Chief of Biomedical Informatics in the Department of Health Outcomes & Biomedical Informatics, College of Medicine, at the University of Florida (UF) and the Chief Data Scientist & Chief Research Information Officer (CRIO) for the UF Health system. He also serves as the Chief Data Scientist for the OneFlorida+ Clinical Research Consortium, Director of Biomedical Informatics program of the Clinical and Translational Science Institute (CTSI) at UF, and the Director of Cancer Informatics Shared Resource at the University of Florida Health Cancer Center (UFHCC). Dr. Bian has a diverse yet strong multi-disciplinary background and extensive expertise in machine learning, natural language processing, network science, ontology development and evaluation, semantic web technology and software engineering. He has extensive experience in developing informatics tools and systems, as well as expertise in data science methods for the analysis and interpretation of biomedical and textural data. Especially, he has a track record of building data infrastructure and using electronic health records (EHRs) for research and natural language processing (NLP) tools.
Serena Guo, Assistant Professor, University of Florida
Dr. Guo is an Assistant Professor in the Department of Pharmaceutical Outcomes and Policy at the University of Florida (UF) College of Pharmacy. She received her MD from Peking University in Beijing, China and her PhD in Epidemiology from the University of Pittsburgh. Dr. Guo conducts research in pharmacoepidemiology and pharmacoinformatics, primarily focused on cardiometabolic diseases and neurodegenerative conditions (e.g., dementia) with the goals of promoting precision health and health equity. Her research draws on large real-world data (e.g., electronic health records and insurance claims data) and advanced analytics (e.g., AI/machine learning, causal-principled modeling, and geospatial analyses).
Lixia Yao, CEO, Polygon Health Analytics LLC
Dr. Lixia Yao is the founder and CEO of Polygon Health Analytics LLC, which develops high-quality real-world data (RWD) and rigorous real-world evidence (RWE) in disease areas with pressing unmet medical needs. With two decades of experience in this field and by leading a team of data scientists and healthcare professionals and collaborating with world-renowned scholars and clinicians, she has published over 60 peer-reviewed scientific articles, including several high-impact publications in prestigious journals such as Nature Biotechnology, Genome Research, and Drug Discovery Today. Her H-index is 20. She is also the recipient of a Career Development Award in Biomedical Informatics (K01) from the National Library of Medicine for 2016-2019, a Fellow of American Medical Informatics Association (FAMIA), the Chair of the AMIA KDDM working group from 2020-2022, and the Member Engagement Co-Chair for The Professional Society for Health Economics and Outcomes Research (ISPOR) Oncology Special Interest Group for 2023-2024. Additionally, she serves as an adjunct associate professor in Department of Health Services Administration and Policy at Temple University.
Real-World Asthma Management: A Spotlight on Pragmatic and Observational Research
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Real-World Asthma Management: A Spotlight on Pragmatic and Observational Research” in Pragmatic and Observational Research.
Asthma is a chronic respiratory disease affecting millions of people worldwide. While significant advances have been made in understanding asthma pathophysiology and developing treatments, managing the condition in real-world clinical practice remains a challenge.
Classical randomized controlled trials (RCTs) are designed to maximize internal validity and to establish an unequivocal cause-and-effect relationship between an intervention and an outcome; however, these trials often exclude patients in minority groups, those with comorbidities, severe illness, or those that do not adhere to treatments. Consequently, there is a critical need for complementary data derived from pragmatic and observational studies that reflect the complexities of real-world asthma management.
To help bridge this gap, Pragmatic and Observational Research is publishing a new hot-topic Article Collection to put a spotlight on studies that evaluate outcomes associated with real-world clinical practice. In doing so, we aim to inform clinical guidelines, improve the generalizability of results, and ultimately improve patient outcomes.
Key areas of focus for this Collection include (but are not limited to):
1. Prospective and Retrospective Observational Studies
2. Comparison of Pharmacological and Non-Pharmacological Interventions
3. Patient preference, satisfaction, convenience, acceptability and adherence
4. Pragmatic Clinical Trials
5. Real-World Data Collection Systems
6. Best practice and guideline reviews in real-world research
7. Statistical Approaches to real-world Research.
This collection is led by the Editor-In-Chief, Professor David Price, Founder and Head of The Observational and Pragmatic Research Institute, Observational and Pragmatic Research Institute, Singapore.
Please submit your manuscript on our website, using the promo code NBAJN for 20% off the advertised article processing charge and to indicate that your manuscript will be considered for the “Real-world Asthma Management: A Spotlight on Pragmatic and Observational Research” Collection. We will be welcoming relevant Original Research, Reviews and Editorials up until the 31 December 2025. Please review the journal scope and author submission instructions prior to submitting a manuscript.
Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.
Psoriasis: Targets and Therapy
PsoPsych: Insights on psychological processes, health and support in people with psoriatic disease
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "PsoPsych: Insights on psychological processes, health and support in people with psoriatic disease" in Psoriasis: Targets and Therapy.
It is widely recognized that psoriasis is "more than just skin deep", with a growing body of evidence supporting the link between psoriatic conditions and mental health. We know there is a bi-directional relationship between psoriasis, related co-morbidities, and common psychological conditions, such as depression and anxiety, due to shared inflammatory pathways. Psychological processes (thoughts, feelings and behaviors) play a key role in the clinical and patient self- management of psoriasis.
Over recent decades, there have been calls to increase the provision of specialist psychological support within dermatology settings and dedicated psychodermatology services to help people to cope with, and overcome, psychological and psychiatric challenges associated with psoriatic disease. However, societal, organizational, service and individual barriers exist, meaning progress is slow. Concerted efforts by policy makers, dermatology and other health organisations, clinicians, researchers and industry partners are needed to deliver the support people need to live well with psoriatic conditions.
This Article Collection focuses on the latest research addressing psychological impact, health and support in people with psoriasis and psoriatic arthritis. It is important to expand our understanding of:
• The psychological burden of psoriatic conditions and related co-morbidities.
• The interplay between psychological and physiological mechanisms in PsO/A.
• The challenges, and solutions to, managing the psychological aspects of these conditions, from the perspective of different dermatology stakeholders.
• Existing sources of psychological support.
• New and existing interventions designed to improve psychological outcomes.
• Patients’ psychological support needs and preferences.
This will continue efforts to raise awareness of this topic within the field of dermatology, identify knowledge gaps and new avenues for research, and strategies and approaches for supporting patients.
We encourage submissions of quantitative, qualitative and mixed methods research involving people living with psoriatic disease anywhere in the world. We particularly encourage submissions that:
• Build on current understanding of the psychological impact, and specifically those that identify, test and implement strategies to help patients/families/clinicians to mitigate and manage this impact.
• Focus on the development, evaluation and implementation of psychological interventions delivered via a range of mediums, and how interventions bring about change. We particularly encourage submissions on health behavior change/interventions given that support of this kind is typically generic or lacking within health services.
• Report on existing mental health support within dermatology, including, but not limited to, counselling, psychology, psychiatry and specialist psychodermatology provision. Of interest are examples of multi- and inter- disciplinary working.
• Explore patient peer and social support networks (in person or online), especially the arguably underrecognized role of patient organizations in supporting people with psoriasis.
• Enhance our knowledge of pharmacological treatments for people with psoriatic disease and comorbid psychological/psychiatric illness.
• Highlight epidemiological trends in mental/psychiatric diagnoses in psoriatic patients.
Keywords
1. Psoriasis
2. Psoriatic arthritis
3. Mental health
4. Psychological support
5. Psychodermatology
All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisors for this Collection will not be handling the manuscripts (unless they are an Editorial Board member).
Please review the journal scope and author submission instructions prior to submitting a manuscript. The deadline for submitting manuscripts is 1 June 2026.
Please submit your manuscript on our website, quoting the promo code B40CC to indicate that your submission is for consideration in this Article Collection.
Please contact Ashley Ambros at [email protected] with any queries and discount codes regarding this Article Collection.
Guest Advisor
Dr Rachael Hewitt, School of Healthcare Sciences, Cardiff University, Wales UK
Dr Hewitt is a Post-Doctoral Research Associate and Trainee Health Psychologist at Cardiff University with expertise in patient-practitioner communication, health behaviour change, complex intervention development and supporting patient self-management. She leads applied psychology and interdisciplinary research within the field of medical dermatology, especially psoriasis, and previously co-led the wellbeing arm of a specialist clinic for psoriatic disease within the Welsh Institute of Dermatology. Rachael led the national implementation of PsoWell™, training dermatology staff in Motivational Interviewing (MI) to address the psychological aspects of psoriasis and continues to deliver MI training internationally. Her research also explores clinicians’ personal models of psoriasis and patient-reported outcome measure development. She has authored 21 peer-reviewed publications, secured over 350,000ドル in research funding, and her work has been recognized internationally, including a Rising Star Scholarship award to present at the 25th World Congress of Dermatology.
- Effects of GLP-1 Receptor Agonists on Psychological Factors in Patients with Metabolic Disorders
- Effects of GLP-1 Receptor Agonists on Mental Health Disorders
- Temporal trends in GLP-1 Receptor Agonists’ Effects on Mental Health
- GLP-1 Receptor Agonists’ Effects on Reward Function, Suicidality, Anxiety, or Depression
Psychology Research and Behavior Management
Game-Changers in Mental Health: The Role of GLP-1 Receptor Agonists
We are pleased to announce a new Article Collection in Psychology Research and Behavior Management, dedicated to the game-changing role of GLP-1 receptor agonists (GLP-1 RAs) in psychological treatment and behavior management. Since their clinical introduction, GLP-1 RAs have revolutionized patient care beyond metabolic and cardiovascular diseases, offering significant benefits in reward regulation, cognitive functions, behaviour control, and mental health for eligible populations.
Given the global importance of GLP-1 RAs in management of psychological disorders, Psychology Research and Behavior Management invites submissions of original research articles, reviews, and perspectives exploring the clinical efficacy, safety, mechanisms of action, and real-world application of these transformative therapies.
The collection, edited by Editor-In-Chief Dr. Igor Elman, will be included in Taylor & Francis’ Game Changer Series. This series features Article Collections focused on breakthrough therapies, drugs, or technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes. Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.
While the call is open to receive manuscripts across the broad spectrum of GLP-1 Receptor Agonists in mental health, the Editors are particularly interested in manuscripts relating to the following areas:
All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisors for this collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.
Please submit your manuscript on our website. The deadline for submitting manuscripts is 1 April 2026.
Submitting authors will be eligible for a 20% discount of the Article Publishing Charge by applying the following code at the point of submission 25CF5. If you have any queries regarding the Article Collection or would like to discuss a submission, then please email the Commissioning Editor Sam Zhang at [email protected].
- Patient selection and biomarkers: advances in MRI-guided targeting, genomic profiling, and risk stratification for focal therapy candidacy.
- Energy modalities and technologies: comparative outcomes of HIFU, cryotherapy, laser ablation, and irreversible electroporation.
- Long-term oncologic outcomes: disease-free survival, recurrence patterns, and integration with active surveillance protocols.
- Complications and side effects: Short-term (urinary retention, infection) vs. long-term risks (erectile dysfunction), management strategies for adverse events.
- Technological advancements: AI in treatment planning and imaging interpretation, robotics/real-time imaging integration and nanotechnology, combination therapies (e.g., focal ablation + immunotherapy)
Research and Reports in Urology
Focal Therapy in Prostate Cancer: Advances and Clinical Applications
Dove Medical Press is pleased to announce a new Article Collection in Research and Reports in Urology, dedicated to the transformative role of focal therapy in the management of prostate cancer. Since its clinical introduction, focal therapy has revolutionized patient care, offering benefits in preserving urinary and sexual function, minimizing treatment-related morbidity, and enabling targeted cancer control.
Given the importance of focal therapy in managing prostate cancer, Research and Reports in Urology invites submissions of original research articles, reviews, and perspectives exploring the clinical efficacy, safety, mechanisms of action, and real-world application of these paradigm-shifting therapies.
This collection, edited by Editor-in-Chief Professor Panagiotis J Vlachostergios, is part of the new Game Changer series of Article Collections, spotlighting breakthrough therapies that redefine standards of care and deliver game-changing improvements in patient outcomes.
While the call welcomes manuscripts across the broad spectrum of focal therapy in prostate cancer, the Editors are particularly interested in submissions addressing the following priority areas:
Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.
All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.
The deadline for submissions is 1 April 2026.
Please submit your manuscript on our website, quoting the promo code BICXO for a 20% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
- AI applications in reducing diagnostic errors and adverse events
- AI-driven predictive modeling
- Ethical frameworks and policy implications of AI in clinical decision-making
- AI-driven remote monitoring systems for chronic disease management
- The impact of AI applications or technology on the healthcare system.
Risk Management and Healthcare Policy
Artificial Intelligence in Healthcare Risk Management
We are pleased to announce a new Article Collection in Risk Management and Healthcare Policy, dedicated to the game-changing role of Artificial Intelligence (AI) in the management of healthcare risk. Since their clinical introduction, AI technologies have revolutionized patient care, offering significant benefits in early disease detection, optimizing personalized treatments, and enabling real-time risk prediction to support healthcare providers in decision-making.
Given the importance of AI in healthcare risk management, Risk Management and Healthcare Policy invites submissions of original research articles, reviews, and perspectives exploring AI applications in managing risks, and their impacts on the healthcare system.
The Collection, edited by Editor-In-Chief Dr Gulsum Kubra Kaya, will be included in Taylor & Francis’ Game Changer Series. This series features Article Collections focused on breakthrough applications or technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes. Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.
While the call is open to receive manuscripts across the broad spectrum of AI applications in healthcare risk, the Editors are particularly interested in manuscripts relating to the following areas:
Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript. The deadline for submissions is 31 May 2026.
Please submit your manuscript on our website, quoting the promo code 65A27 for a 20% discount on the Article Publishing Charge and to indicate that your submission is for consideration in this Article Collection.
Please contact Haoyang Yi (Commissioning Editor) at [email protected] with any queries regarding this Article Collection.
Therapeutics and Clinical Risk Management
Biologic Treatment for Allergic Disease
We are pleased to announce a new Article Collection in Therapeutics and Clinical Risk Management, dedicated to the role of biologic treatments in the management of allergic disease. Since their clinical introduction, biologic treatments, particularly monoclonal antibodies, have transformed patient care, offering targeted therapies and improved outcomes for conditions including allergic asthma, allergic rhinitis, atopic dermatitis and urticaria.
Given the importance of biologics in managing allergic disease, we are welcoming submissions of original research articles, reviews, and perspectives exploring the mechanisms of action, clinical efficacy, safety, and real-world application of these therapies.
The Collection, edited by the Editor-In-Chief Prof. Garry Walsh, is part of the new Game Changer series of Article Collections, focusing on breakthrough therapies, drugs, or technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes. Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.
While the call is open to receive manuscripts across the broad spectrum of biologic treatments in allergic disease, the Editors are particularly interested in manuscripts relating to the following areas:
• Mechanisms of action and biomarkers for personalized treatment
• Clinical efficacy and safety profiles
• Real-world evidence and patient-reported outcomes
• Cost-effectiveness and health economic evaluations
• Reviews, perspectives and editorials discussing emerging therapies and future directions
All manuscripts submitted to this Article Collection will undergo a full peer-review. Please review the journal scope and author submission instructions prior to submitting a manuscript.
Please submit your manuscript on our website, quoting the promo code 7A889 to indicate that your submission is for consideration in this Article Collection.
The deadline for submitting manuscripts is 1 April 2026.
If you have any queries regarding the Article Collection or would like to discuss a submission, then please email the Commissioning Editor, Catherine Teng at [email protected].
- Risk factors for diabetes and CVD
- Mechanisms of cardiovascular protection for modern anti-diabetic treatments
- Clinical studies uncovering the efficacy and safety of antidiabetic drugs in CVD
- Epidemiological studies of CVD patients taking anti-diabetic medications
- The physiology of renal denervation in the treatment of hypertension
- Strengths and limitations of current renal denervation technologies
- Identification and evaluation of appropriate patients, including biomarkers and phenotype
- Advances in technologies, including catheter design, ultrasound, and radiofrequency
- Endpoint selection in clinical trials
- Long-term efficacy and safety studies
- Heart failure pathophysiology as it relates to potential therapeutic targets
- Emerging drugs for acute and chronic heart failure
- Efficacy and safety of heart failure pharmacotherapy, with special attention given to studies on patients with comorbidities
- Papers focused on the implementation of heart failure medications in clinical practice
- Genetics of vascular calcification
- Intimal vs medial calcification
- Cell biological and molecular pathways of vascular calcification
- Biomarkers for the detection of vascular calcification
- Detection of vascular calcification by clinical imaging modalities (MSCT, PET/ SPECT)
- Clinical significance of vascular calcification - Is calcification good or bad?
- Pharmacological treatment of vascular calcification
- Nutraceutical intervention of vascular calcification
- Calcification
- MGP
- Vitamin K.
- Treatment trials
- Vascular smooth muscle cells
Vascular Health and Risk Management
Exploring the Cardiovascular Effects of Modern Anti-Diabetic Treatments
We are pleased to announce a new Article Collection in Vascular Health and Risk Management, dedicated to the role of anti-diabetic drugs in the management of cardiovascular risk.
While anti-diabetic drugs are widely used in clinical practice for blood sugar control and to delay complications of diabetes, several anti-diabetic drugs – including GLP-1 receptor agonists and SGLT2 inhibitors – have also been shown to prevent adverse cardiovascular events and cardiovascular mortality.
Anti-diabetic drugs thus have an important role to play in cardiovascular medicine, with considerable potential for preventing further cardiac events in select populations.
To highlight this important area of research, Vascular Health and Risk Management invites submissions of original research articles, reviews, and perspectives exploring the clinical efficacy, safety, mechanisms of action, and real-world application of anti-diabetic therapies in the context of cardiovascular disease (CVD).
The Collection, edited by Editor-In-Chief Professor Roland Asmar, will be included in Taylor & Francis’ Game Changer Series. This series features Article Collections that highlight breakthrough therapies, drugs, or technologies that have the potential to lead to game-changing improvements in patient outcomes. Papers published within the Game Changer series will benefit from additional promotional activities across Taylor & Francis, increasing the discoverability and visibility of your research.
While the call is open to receive manuscripts across the broad spectrum of antidiabetic drugs in the management of cardiovascular risk, the Editors are particularly interested in papers relating to the following areas:
Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.
Please review the journal scope and author submission instructions prior to submitting a manuscript. Submitting authors are eligible for a 20% discount on the Article Publishing charge. Please use the promo code BWOME when prompted during the submission.
Please submit your manuscript on our website. The deadline for submitting manuscripts is 1 January 2026.
Please contact Zhiyuan Zhang at [email protected] with any queries and discount codes regarding this Article Collection.
Guest Advisor
Roland Asmar, Foundation-Medical Research Institutes (F-MRI), Switzerland
Harnessing Renal Denervation in the Battle Against Hypertension
We are pleased to announce a new Article Collection in Vascular Health and Risk Management, dedicated to the promising role of renal denervation in the treatment of hypertension. Renal denervation offers a new, minimally invasive option for patients with uncontrolled hypertension, effectively lowering blood pressure and potentially reducing the need for, or dosage of, antihypertensive medications.
Given the emerging importance of renal denervation in managing hypertension, Vascular Health and Risk Management invites submissions of original research articles, reviews, and perspectives exploring the clinical efficacy, safety, mechanisms of action, and real-world application of this transformative therapy.
The Collection, edited by Editor-In-Chief Professor Roland Asmar, will be included in Taylor & Francis’ Game Changer Series. This series features Article Collections focused on breakthrough therapies, drugs, or technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes. Papers published within the Game Changer series will benefit from additional promotional activities across Taylor & Francis, increasing the discoverability and visibility of your research.
While the call is open to receive manuscripts across the broad spectrum of renal denervation in hypertension, the Editors are particularly interested in manuscripts relating to the following areas:
Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.
Please review the journal scope and author submission instructions prior to submitting a manuscript. Submitting authors are eligible for a 20% discount on the Article Publishing charge. Please use the promo code OMDLY when prompted during the submission.
Please submit your manuscript on our website. The deadline for submitting manuscripts is 1 January 2026.
Please contact Zhiyuan Zhang at [email protected] with any queries and discount codes regarding this Article Collection.
Guest Advisor
Roland Asmar, Foundation-Medical Research Institutes (F-MRI), Switzerland
Pharmacotherapy for Heart Failure
We are pleased to announce a new Article Collection in Vascular Health and Risk Management, dedicated to the game-changing role of pharmacotherapy in the management of heart failure. Since their clinical introduction, heart failure medications have revolutionized patient care, leading to improved survival, reduced hospitalization and improved quality of life in eligible patients, especially in those with reduced ejection fraction.
Given the global importance of pharmacotherapy in managing heart failure, Vascular Health and Risk Management invites submissions of original research articles, reviews, and perspectives exploring the clinical efficacy, safety, mechanisms of action, and real-world application of these transformative therapies.
The collection, edited by Editor-In-Chief Professor Roland Asmar, will be included in Taylor & Francis’ Game Changer Series. This series features Article Collections focused on breakthrough therapies, drugs, or technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes. Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.
While the call is open to receive manuscripts across the broad spectrum of pharmacotherapy in the management of heart failure, the Editors are particularly interested in papers in the following areas:
Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.
Please review the journal scope and author submission instructions prior to submitting a manuscript. Submitting authors are eligible for a 20% discount on the Article Publishing charge. Please use the promo code VBOLK when prompted during the submission.
Please submit your manuscript on our website. The deadline for submitting manuscripts is 1 January 2026.
Please contact Zhiyuan Zhang at [email protected] with any queries and discount codes regarding this Article Collection.
Guest Advisor
Roland Asmar, Foundation-Medical Research Institutes (F-MRI), Switzerland
Vascular calcification in health and disease
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Vascular calcification in health and disease", in Vascular Health and Risk Management.
Calcification plays a significant role in the development and progression of vascular disease. It involves the abnormal deposition of calcium phosphate crystals within the vascular intimal or medial layer. Intimal calcification is commonly associated with atherosclerosis, a condition in which plaque builds up inside the arteries, leading to reduced elasticity and narrowed vessels. Intimal calcification is typically linked with inflammation and plaque rupture, contributing to acute cardiovascular events such as heart attacks. Vascular calcification can also occur in the medial layer of blood vessels. Medial calcification, more common in the ageing population, and in patients suffering from diabetes and chronic kidney disease, leads to arterial stiffening and increased systolic blood pressure. While once considered a passive process, calcification is now recognized as an actively regulated, cell-mediated phenomenon involving osteogenic signaling pathways. Understanding the mechanisms behind vascular calcification is crucial for developing targeted therapies to mitigate its impact on cardiovascular health.
Studying vascular calcification is crucial because it is a key contributor to cardiovascular morbidity and mortality, particularly in ageing populations and patients with chronic conditions like diabetes and chronic kidney disease. Vascular calcification is associated with arterial stiffness, reduced vessel elasticity, and increased risk of hypertension, heart attacks, and stroke. Despite its clinical significance, there are currently no effective therapies that specifically target or reverse vascular calcification. Understanding the underlying molecular and cellular mechanisms, such as the transformation of vascular smooth muscle cells into osteoblast-like cells, can help identify potential therapeutic targets. Additionally, early detection and improved imaging techniques can aid in risk stratification and treatment planning for patients. Given its active, regulated nature, vascular calcification represents a promising area for intervention. Studying it not only deepens our understanding of vascular biology but also has the potential to improve outcomes for millions of patients affected by cardiovascular disease worldwide.
This Article Collection seeks contributions that address the following key areas:
Keywords
All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisor for this Collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.
Please submit your manuscript on our website, quoting the promo code 04D4D to indicate that your submission is for consideration in this Article Collection. Please note that normal Article Processing Charges will apply.
The deadline for submitting manuscripts is 28 February 2026.
Please contact Zhiyuan Zhang at [email protected] with any queries regarding this Article Collection.
Guest Advisors
Peter W de Leeuw, Maastricht University Medical Center, The Netherlands
Peter W de Leeuw is emeritus professor of Medicine at Maastricht University and has a life-long history of research in hypertension. He has been a member of the Council of the ISH and has served as an Editorial Board member of several hypertension journals. His present research interest is in vascular calcification and in fibromuscular dysplasia.
Leon Schurgers, Maastricht University, The Netherlands
Leon Schurgers is chair and professor of Biochemistry at Maastricht University and has a life-long history of research in vascular remodeling. His present research interest is in vascular calcification and vascular smooth muscle cell phenotype switching.